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“A dreamer is one who can only find his way by moonlight, and his 
punishment is that he sees the dawn before the rest of the world.” 
Oscar Wilde






Currently, the only cure for liver failure is orthotopic liver transplantation. However, there 
are insufficient donor organs available to treat every patient on the transplant list and many 
die before they are able to receive a liver transplant. The bioartificial liver (BAL) device is 
a potential extracorporeal treatment strategy utilising hepatocytes or hepatocyte-like cells 
(HLCs) within a bioreactor to recapitulate normal liver function and therefore ‘bridge’ a 
patient with liver failure until they receive a transplant. The work in this thesis utilised 
tissue engineering methods to develop novel approaches to BAL device design through 
development and characterisation of a polymer membrane scaffold (“PX”) for hollow fibre 
bioreactor (HFB) culture and a HLC source generated from the transdifferentiation of 
pancreatic AR42J-B13 (B13) cells. A flat sheet membrane model was used for the 
development of asymmetrical, hydrophobic polystyrene (PS) phase inversion membranes. 
Oxygen plasma significantly increased PS membrane surface wettability through addition 
of oxygen functional groups to create an environment conducive for cell culture. The 
treated membrane was henceforth referred to as “PX”. The culture medium HepatoZYME+ 
was investigated for its ability to induce transdifferentiation of B13 cells to HLCs and 
maintain the hepatic phenotype. Overall, HepatoZYME+-cultured cells experienced 
viability loss. A diluted version, “50:50”, showed induction of the hepatic markers 
carbamoylphosphate synthetase-1 (CPS-1) and HNF4α, as well as a change towards a HLC 
morphology. When using 50:50 as a maintenance medium, transdifferentiated HLCs 
retained loss of pancreatic amylase and also induction of hepatic markers, with comparable 
serum albumin secretion to the established Dex + OSM treatment. However, culture 
viability in 50:50 was still compromised. Therefore, HepatoZYME+ based media were 
deemed unsuitable for induction and maintenance compared to Dex-based protocols. PX 
flat sheet membranes were able to support culture of B13 cells and also the human 
osteosarcoma cell line, MG63, demonstrating improved cell attachment over non-surface 
treated PS membranes. PX membranes supported transdifferentiation of B13 cells to 
HLCs, presenting with loss of pancreatic amylase, induction of the hepatic markers 
transferrin, GS and CPS-1 and serum albumin secretion. Furthermore, PX showed no 
change in mass or loss of culture surface area over 15 days in culture conditions.  Together, 
the novel membrane material and the media formulation and feeding regime developed 
have strong potential to be translated to a HFB setting and guide future BAL device design. 
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The liver is the largest internal organ of the human body and is responsible for a number of 
essential physiological functions. These include regulation of carbohydrate, fat and protein 
metabolism, storage, synthesis of proteins and detoxification of xeno- and endobiotics. 
Although the liver is a highly regenerative organ and is able to restore full organ mass 
where damage has occurred, if there is over 70% loss of liver function due to acute injury 
or chronic disease, the regenerative capability of the liver is impaired and it is unable to 
regain a physiological capacity of functions. This is classed as liver failure, which will 
cause severe deterioration in health and eventual death if not treated. However, the only 
cure for liver failure is an orthotopic liver transplant to replace lost liver function. 
Unfortunately, patients on the transplant waiting list often die before they are able to have 
a transplant due to lack of available donor livers. The number of deaths from liver failure is 
also increasing year upon year. Therefore, new therapeutic strategies are required to reduce 
patient mortality. 
The bioartificial liver (BAL) device is a potential interim treatment for patients with liver 
failure. The principle behind the BAL device is to act as an extracorporeal support through 
replication of the normal physiological functions of the liver. This is done via the use of 
hepatocytes or hepatocyte-like cells (HLCs), housed in a bioreactor, thus allowing the 
patient to be bridged to transplantation or to allow the ailing liver to regenerate. Although 
there have been BAL devices in clinical trials, there are presently none in clinical usage as 
the trials do not show conclusively improved survival rates. This is namely due to a lack of 
a plentiful cell source that can fully function like liver cells and providing an optimum 
environment for these cells to function and thrive. 
To address these issues, the work contained within this thesis presents a novel polystyrene 
membrane biomaterial (PX) for hollow fibre membrane bioreactor (HFB) design and a 
novel source of functional hepatocytes – transdifferentiated HLCs – to provide hepatic 
function, through the use of tissue engineering methods – a combination of molecular cell 
biology, regenerative medicine and chemical engineering theories and techniques. 





This thesis can broadly be divided into two parts – Part I comprises the present Chapter, 
which gives a summary and background to the work. Chapter 2 reviews the literature to 
date, describing liver biology, liver failure, the current status of BAL device designs and 
potential solutions. The aims and objectives of this thesis are detailed at the end of this 
chapter. The materials and methods utilised in the experimental work are then presented in 
Chapter 3. 
Part II comprises the main body of the thesis and is divided into four Chapters. Chapter 4 
involves the development of a polystyrene phase inversion membrane suitable for hollow 
fibre bioreactor cell culture. Chapter 5 investigates a potentially novel induction and 
maintenance culture medium for the hepatic transdifferentiation of the rat pancreatic cell 
line, AR42J-B13 (B13) in comparison with established transdifferentiation protocols. 
Chapter 6 brings the results from Chapters 4 and 5 together and examines the 
biocompatibility of PX flat sheet membranes with regards to its capacity to support cell 
culture, and most importantly, transdifferentiated HLCS, in comparison to other 
established biomaterials. Finally, Chapter 7 provides overall conclusions and suggestions 
for future work, along with the implications of how these results and conclusions could be 
used for the development of a clinically viable next-generation BAL device. 
 
  







2.1 The human liver 
2.1.1 Anatomy of the liver 
The liver is the second largest organ of the human body and the largest gland. It is located 
in the right hypochondrium within the intraperitoneal space. The superior border of the 
liver extends from the 5th intercostal space and reaches below the costal margin on its 
inferior border. The liver has a dual blood supply, with 70% coming from the hepatic 
portal vein and the remaining 30% from the hepatic artery. In the adult human, the mean 
mass of the liver is 1800 g for men and 1400 g for women [1,2].  
 
Figure 2.1 Anterior and posterior views of the liver. Image reproduced with permission from 
[3]. 
The anatomical division of the liver into lobes – left, right, caudate and quadrate (Figure 
2.1) does not correlate to a division of liver functions. The lobes are further subdivided into 
lobules. Each lobule consists of a central vein that is surrounded by hepatocytes in a 
roughly hexagonal shape [4]. Sinusoids supplied by the hepatic artery separate the 
hepatocytes from each other, providing oxygen and nutrients, before draining into the 
central vein. Blood then leaves the liver via the hepatic vein. 





There are over 100 billion cells in the liver, wherein 80% of the lobular parenchyma 
consists of hepatocytes [1]. The remaining non-parenchymal cell population includes 
ductal cells (cholangiocytes), sinusoidal endothelial cells, Kupffer cells, stellate cells and 
pit cells [2,5]. 
 
2.1.2 Liver physiology 
The liver possesses multiple functions that are essential in ensuring that the normal 
physiological state of the human body is maintained. A summary of hepatic cell functions 
is described in Table 2.1. It is a metabolic organ, able to modulate glucose levels to 
prevent the body becoming hyper- or hypoglycaemic. This is done by storing glucose as 
glycogen (glycogenesis) or breaking down glycogen (glycogenolysis) in response to the 
pancreatic hormones insulin and glucagon respectively. The liver can also produce glucose 
(gluconeogenesis), particularly in severe starvation [6]. The liver is also involved in the 
oxidation of fatty acids, production of triglycerides and synthesising cholesterol and 
lipoproteins. 
Table 2.1 Cells of the liver and their functions. 
Cell Function References 
Hepatocyte 
Metabolism, synthesis, storage, 
xenobiotic and ammonia 
detoxification 
[1,2] 
Cholangiocyte Bile transportation, bicarbonate 
and water secretion  
[7] 
Sinusoidal endothelial cell 
Fenestrated barrier between 
sinusoidal blood and hepatocytes 
[5] 
Kupffer cell 
Liver macrophages, cytokine 




Liver regeneration, myofibroblast 




Liver lymphocytes (natural killer 









As well as storing glycogen, the liver acts as a storage organ for vitamins A, B12 and D and 
dietary iron. It removes toxins from the body, an example being the removal of ammonia 
through conversion to urea, as well as drug detoxification. The production of bile by 
hepatocytes signifies an excretory role as well as an aid in digesting fats through 
emulsification. The liver is also able to synthesise blood coagulation factors, plasma 
proteins and amino acids, as well as remove old and damaged erythrocytes via 
phagocytosis [2]. 
 
2.1.3 The hepatocyte 
The hepatocyte is the main functional unit of the liver. Hepatocytes make up the cellular 
majority of the liver parenchyma [1,2]. Morphologically, hepatocytes form irregular 
polyhedral shapes ranging between 20-30 μm in size, with the age, location and 
regenerative capability of the cell being the causes of size and shape variability [1]. 25% of 
hepatocytes also exhibit binuclearity [1]. Cellular volume adapts to changes in blood flow 
and osmotic load through the liver sinusoid. Increased cellular volume due to large solute 
quantities such as glucose, amino acids and bile acids consequently stimulates bile flow, 
exocytosis and protein and glycogen synthesis. Conversely, this causes the inhibition of 
proteolysis and glycogenolysis [1]. 
Hepatocytes are polarised cells that possess three functionally specialised membrane 
domains which differ from each other in protein, lipid and receptor compositions. The 
basolateral or sinusoidal domain is orientated towards the sinusoid, consisting of surface 
microvilli within the perisinusoidal space, also known as the space of Disse. The 
canalicular or apical domain forms the bile canaliculi that run between adjacent 
hepatocytes and the lateral domain extends from the edge of the canalicular domain to the 
basolateral domain (Figure 2.1) [1]. 






Figure 2.2 Ultrastructure of the hepatocyte. The basolateral domain contains surface microvilli 
within the space of Disse. Tight junctions (blue) separate the canalicular domain (green) from the 
lateral domain. 
The fenestrated endothelium allows for efficient transfer of molecules from sinusoidal 
blood to the microvilli of the basolateral domain within the space of Disse, where they are 
taken up by the hepatocytes. The canalicular domain facilitates the movement of bile via 
transporter proteins into the bile canaliculus where it is transported to the bile ducts of the 
portal triad to be stored in the gall bladder, before eventual exit to the small intestine [1]. 
The distribution of hepatocytes in the liver lobule displays functional heterogeneity 
through metabolic gradients along the porto-venous axis. The porto-venous axis runs from 
the portal triad, which includes the hepatic artery, portal vein and bile duct, to the central 
vein. Hepatocytes that lie closer to the portal triad are classified as being in the periportal 
region whereas hepatocytes nearer to the central vein are located in the perivenous region. 
This phenomenon of functional heterogeneity is known as metabolic zonation and applies 
mainly to hepatocyte activity related to glucose metabolism, ammonia detoxification and 
xenobiotic metabolism (Figure 2.3) [4,11]. Other functions, such as the synthesis of serum 
transferrin (TFN), transthyretin (TTR) and albumin, are not zonally distributed and occur 
in all hepatocytes [11]. 





By reversing the flow of blood and therefore the concentration gradients of oxygen, 
nutrients and hormones, zonation can be altered. This is observed in glucose metabolism 
where zonal behaviours of gluconeogenesis and glycolysis are also reversed [12]. 
However, this behaviour is not a universal occurrence. For example, in the case of the 
ammonia detoxifying enzymes, carbamoylphosphate synthetase-1 (CPS-1) and glutamine 
synthetase (GS), reversing the flow of blood has no effect with regards to altering 
distribution of these enzymes along the porto-venous axis. Zonation of these enzymes is 
instead modulated by the Wnt/β-catenin signalling pathway [13,14]. 
 
Figure 2.3 Metabolic zonation down the porto-venous axis of the liver. Hepatocytes radiate out 
from the central vein in ‘plates’ along with the portal triad. The portal triad consists of the bile duct 
(BD), hepatic artery (HA) and portal vein (PV). Blood enters the liver sinusoid via the hepatic 
artery and portal vein and drains into the central vein. Metabolic gradients alter functional 
expression in hepatocytes [4,11]. 
 
2.1.4 Liver failure 
Liver failure is defined as over 70% loss of functional mass [1]. The liver is a highly 
regenerative organ and has the capability of functioning as normal and restoring full organ 
mass providing the damage does not exceed 70%. Beyond this limit, the liver is unable to 
regenerate significantly enough to overcome the damage and can no longer function at 
normal physiological levels and if left untreated, the outlook is poor [15]. Damage to the 
liver leads to life threatening complications that can cause pathophysiological problems in 





other body systems due to the wide ranging functions of the liver, including kidney failure, 
hepatic encephalopathy, immune derangement, circulatory problems and coagulopathy. 
Liver failure can be classed as one of three types – acute, chronic and acute-on-chronic. 
Acute liver failure is where there is no previous history of liver disease but a sudden loss of 
liver function occurs, resulting in coagulopathies and encephalopathies [16]. The major 
causative factor of acute liver failure in the UK and USA is drug-induced, particularly by 
paracetamol overdose. In developing countries, the predominant cause is due to viral 
aetiologies [16]. Chronic liver failure consists of deterioration in liver function due to the 
result of ongoing liver disease. Acute-on-chronic liver failure is a sudden deterioration in 
chronic liver disease over a period of four weeks due to a direct event (e.g. hepatoxicity) or 
an indirect event (e.g. infection) [17]. 
 
Figure 2.4 Standardised mortality rate percentage change of various diseases in the UK 
between 1970 and 2010. Data were normalised to 100% in 1970. Mortality from liver disease has 
increased to over 400% in 2010 since 1970, compared to other diseases which demonstrate an 
overall decline. Image reproduced with permission from [18]. 
Deaths from liver disease in the UK have been on the increase, despite other causes of 
mortality such as diabetes, cancer and respiratory conditions showing a decline between 
1971 and 2010 (Figure 2.4) [18,19]. In England alone, deaths from liver disease steadily 
increased from 9,231 to 11,575 between 2001 and 2009. 37% of these deaths were 
primarily attributable to alcoholic liver disease. The remaining causes of liver failure 





mortality were accounted for by liver cancer and other non-alcoholic liver diseases [20]. 
Notably, due to the extent of obesity, 25% of the general population of the UK is estimated 
to have non-alcoholic fatty liver disease [18]. The burden on the National Health Service 
(NHS) of the UK has been estimated at £3.5 billion per year for alcohol-related health 
problems and £5.5 billion for obesity related diseases [18]. This is likely to increase further 
if the current trend for liver disease mortality continues. 
Orthotopic liver transplantation is currently the only cure for liver failure. As a result of 
this treatment, the patient is required to take immunosuppressive medication to prevent 
their body rejecting the donor organ. Although orthotopic liver transplantation is successful 
in restoring liver functionality in liver failure patients, there are not enough suitable donor 
organs available for the number of patients on the transplant waiting list that require them. 
Furthermore, the numbers of patients requiring transplantation in the UK has also been 
increasing year upon year as of 2015 [21]. Unfortunately, as a result of this mismatch in 
numbers, many patients deteriorate in condition and die before they can receive a 
transplant. 
The increasing rate of mortality from liver disease has driven interest in developing 
alternative methods of treatment to ameliorate this rise. One approach for the preservation 
of remaining liver function and prevention of further organ deterioration is the 
development of an extracorporeal liver support device. The purpose of the liver support 
device is to recapitulate the physiological functions of the normal liver and therefore 
bridge the patient to transplantation. This interim approach of replacing lost liver function 
and preventing further liver deterioration would also be particularly useful in cases of acute 
liver failure that have demonstrated regeneration of the liver over time with no subsequent 
requirement for transplantation [15,22]. 
 
2.2 Liver support devices 
There are two main approaches to liver support device design – artificial (non-biological) 
liver support systems and bioartificial (containing a biological component) liver devices. 
Both of these approaches are reviewed here. 
 





2.2.1 Artificial liver devices 
Due to deterioration of physiological liver functionality during liver failure, there is a 
subsequent increase of water soluble and protein bound toxic substances including 
ammonia, bilirubin and bile salts within the body. Under normal physiological 
circumstances, these would be detoxified and removed by the liver. Accumulation of these 
substances without treatment will eventually lead to pathophysiologies in multiple organ 
systems, including hepatic encephalopathy, immune impairment with subsequent 
susceptibility to infections and renal and circulatory dysfunction [23]. The result of these 
events can eventually lead to multiple organ failure and death if left untreated. Therefore, 
approaches utilising an artificial liver support device design have sought to take on the 
detoxification role of the physiological liver with the goal of reducing these pathological 
events within the body. Approaches to artificial liver device design include haemodialysis, 
haemofiltration, dilution, charcoal adsorption and blood plasma replacement for the 
removal of toxins from patient whole blood and plasma [24]. 
 
Figure 2.5 Structure of the Molecular Adsorbent Recirculating System (MARS) artificial 
liver device. The MARS system removes water soluble and protein bound toxins by haemodialysis 
through a semipermeable membrane into an albumin dialysate, which is further detoxified by 
activated charcoal and resin adsorption and secondary dialysis prior to recirculation. Image 
reproduced with permission from [17]. 
 





One of the most widely tested artificial liver devices is the Molecular Adsorbent 
Recirculating System (MARS) (Figure 2.5). MARS was originally developed in 1993 and 
takes the approach of removing water soluble and protein bound toxins from patient blood 
via haemodialysis using membrane separation techniques [23,25]. 
Semipermeable, albumin coated high flux polysulfone hollow fibre membranes 
(MARSFlux) facilitate diffusion of toxins through to a secondary circuit containing an 
albumin dialysate. The albumin dialysate is circulated through a separate, secondary 
system, where it is perfused over activated charcoal and anion exchange resin columns to 
remove albumin bound toxins, and undergoes low flux dialysis prior to recirculation of the 
regenerated dialysate through the device [23]. 
The efficacy of using MARS on patients with liver failure to reduce the effects of liver 
dysfunction has been assessed in several studies. Initial clinical results with a small group 
of 13 patients suggested that the device was well tolerated by patients and also 
demonstrated significant decreases in bilirubin, ammonia, serum creatinine and urea [26]. 
Further studies and a subsequent systematic review have also noted that MARS 
demonstrates improvement in hepatic encephalopathy [27–29], including a larger 
multicentre randomised controlled trial in 2007 [30]. 
However, there have been mixed reports as to whether MARS significantly improves 
patient survival when compared to standard medical treatment in the long term, 
particularly with regards to acute-on-chronic liver failure. A large clinical trial in 2013 
noted that despite showing significant reductions in serum bilirubin, serum creatinine and 
improvement of hepatic encephalopathy after treatment with MARS, there was no overall 
improvement in patient survival coupling MARS with standard medical treatment versus 
using standard medical treatment alone for acute-on-chronic liver failure patients [31]. 
Furthermore, neither does it appear to restore the functional capability of native patient 
albumin [32]. Due to the conflicting reports on patient survival, these findings demonstrate 
the necessity of further investigations into whether this system is an overall safe benefit 
compared to current treatments for liver failure and therefore whether it should be utilised 
as routine therapy. 
Single pass albumin dialysis (SPAD) utilises a similar system to MARS but does not 
involve recirculation of the albumin dialysate; it is constantly replenished with fresh 





albumin dialysate. An in vitro study comparing the two methods suggested that SPAD was 
more effective than MARS in reducing ammonia and bilirubin levels whilst having 
comparable reductions in bile acid [33]. However, an in vivo study involving patients with 
liver failure suggested that MARS was able to eliminate bile acids at greater efficiency 
than SPAD [34]. This contrast highlights discrepancies between in vitro and in vivo 
studies, as the in vitro study did not take into account potential ongoing bile acid 
production and diffusion from tissues experienced in the in vivo study [34]. In light of this, 
further studies using an in vivo clinical setting would need to be performed to determine 
the efficacy of SPAD as a liver failure therapy. 
 
Figure 2.6 Structure of the Fractionated Plasma Separation and Adsorption 
(PROMETHEUS) artificial liver device. PROMETHEUS utilises plasmaphaeresis to initially 
filter albumin and low molecular weight plasma proteins. This fraction is purified using resin 
adsorbers before re-entering the bloodstream. Haemodialysis is then used to remove water soluble 
toxins from the blood. Image reproduced with permission from [17]. 
The Fractionated Plasma Separation and Adsorption (PROMETHEUS) artificial liver 
device offers a different approach to detoxification than that demonstrated by MARS or 
SPAD. The mechanism of PROMETHEUS utilises plasmaphaeresis, which functions by 
filtration of patient blood through an albumin permeable membrane (AlbuFlow) (Figure 





2.6). This filtered fraction is passed through a secondary circuit containing a resin 
adsorbing agent and anion exchanger prior to re-entering the primary circuit which 
contains the rest of the patient’s blood. To remove water soluble toxins, the blood, with the 
purified albumin fraction, undergoes haemodialysis prior to re-entering the patient [35]. 
PROMETHEUS has demonstrated patient safety and has shown utility in reducing total 
bilirubin, bile acid and ammonia concentrations along with elimination of water soluble 
toxins [36–41]. However, similarly to MARS, PROMETHEUS was able to clear serum 
cytokines but neither device significantly reduced the levels of serum cytokines in acute-
on-chronic liver failure [42]. Similarly to MARS, when PROMETHEUS was utilised in 
combination with standard medical treatment in a randomised controlled trial for treatment 
of acute-on-chronic liver failure, no overall improvement in long term patient survival was 
found when using this device compared to using standard medical treatment alone [43]. 
Various meta-analyses assessing artificial liver devices have conflicting conclusions as to 
whether their therapeutic usage has an overall benefit on patient survival from liver failure. 
A study in 2004 suggested that there was no improvement in liver failure survival at all 
after treatment with artificial liver devices [44], although this study did not differentiate 
between the different types of liver failure and examined only 4 randomised controlled 
trials. A study from 2011 examined 8 randomised controlled trials where they noted 
improvement in acute liver failure but not acute-on-chronic liver failure [45], whereas the 
contrary was reported in a further study in 2013 looking at the results of 19 randomised 
controlled trials, suggesting improved patient survival in acute-on-chronic liver failure but 
not acute liver failure [46]. A study in 2015 of 10 randomised controlled trials again found 
no overall improvement in survival [29]. The mixed reports here are possibly affected by 
an insufficient number of suitable clinical trials for extensive comparison. Secondly, 
variance in the specific aetiological events and extent of liver deterioration leading to a 
patient’s liver failure may impact upon the utility of the artificial liver device [47]. 
Therefore, these factors suggest that there is a great need for additional long term clinical 
trial data to determine if these devices are effective in improving overall patient survival 
beyond current medical therapies or only under specific circumstances. 
Although artificial liver devices have shown some promise in toxin elimination in liver 
failure patients, a major limitation with their design is that they focus solely on 
detoxification and toxin removal. Artificial liver devices therefore do not replicate the full 





functionality of the liver and are unable to recapitulate other functions such as synthesis of 
proteins and metabolism. These factors may contribute to the lack of overall improvement 
in patient survival when used therapeutically, with regards to reports of additional 
coagulopathies and metabolic disturbances associated with liver failure affecting overall 
device efficacy and patient survival [34,48,49]. 
In the normal physiological liver, such synthetic and metabolic functions are carried out by 
hepatocytes [50]. The importance of being able to replicate these aspects is demonstrated 
through the restoration of function in transplanted livers and improved survival. Therefore, 
to solve this issue, there has been great interest in the development of liver support devices 
known as bioartificial liver (BAL) devices. These systems incorporate a biological 
component in the way of hepatocytes or hepatocyte-like cells (HLCs), with the intention of 
recapitulating lost liver functions to prevent further patient deterioration. 
 
2.2.2 Bioartificial liver devices 
BAL devices are hybrid extracorporeal systems that incorporate hepatocytes or HLCs in a 
synthetically designed bioreactor within a flow system. The whole blood or plasma of the 
patient with liver failure is perfused through the BAL device, either coming into direct 
contact with the isolated hepatocytes or allowing a diffusion gradient to be formed between 
the plasma and hepatocytes separated from the plasma by virtue of being cultured on a 
semipermeable membrane. 
The overarching goal of the BAL device is identical to that of the artificial liver device – to 
support a patient to transplantation and reduce the effects of liver dysfunction. Where 
artificial liver devices rely upon detoxification and removal using methods such as 
adsorption, filtration and dialysis, the BAL device seeks to utilise biological methods via 
functioning hepatocytes or HLCs to detoxify ammonia and xeno- and endobiotics. 
Furthermore, the incorporated cells would potentially provide additional liver functionality 
that is not performed by artificial liver devices, such as protein synthesis and metabolism 
of carbohydrates and lipids [51]. By recapitulation of these additional liver functions as 
well as taking on a detoxification and removal role, it is presumed that there will be an 
improvement in overall patient mortality from using a BAL device. Notably, use of smaller 





scale BAL devices has been suggested as potential in vitro drug toxicity models, 
potentially reducing the need for animal models [51]. 
Various BAL device designs have entered clinical trials, but none are currently in active 
clinical usage [52,53]. A summary of five BAL devices with their design characteristics is 
shown in Table 2.2. Notably, the majority of these BAL devices utilise hollow fibre 
membranes as cell scaffolds within a bioreactor. 
Table 2.2 Characteristics of five BAL devices that have undergone clinical trials. 
BAL device Bioreactor design Cell source Perfusion 
HepaMate (previously 
HepatAssist 2000) 






Assist Device (ELAD) 
Hollow fibre 







system with hollow 
fibre bioreactor, SPAD 
and filtration 
Primary human liver 













bioreactor with hollow 






HepaRG human liver 





The HepaMate (formerly HepatAssist 2000) BAL device utilises cryopreserved primary 
porcine hepatocytes as the cell source attached to collagen coated dextran microcarriers 
[54]. These cells are housed within a hollow fibre bioreactor (HFB) and cultured on the 
extraluminal surfaces of semipermeable hollow fibre membranes. Plasma flows through 
the fibre lumen and is kept separated from the hepatocytes by the hollow fibre membranes, 
only allowing diffusion of specifically sized molecules across the membrane wall. 
Additional detoxification is supplied through the presence of a charcoal adsorption column 
within the system (Figure 2.7). 






Figure 2.7 Structure of the HepatAssist 2000 BAL device (now HepaMate). This system 
utilises a hollow fibre bioreactor with primary porcine hepatocytes alongside a charcoal adsorption 
column. Image reproduced with permission from [55]. 
As HepatAssist, this BAL device has shown promising results in clinical trials for acute 
liver failure, demonstrating improvement of neurological symptoms and liver function 
enzymes, coupled with reduction of plasma ammonia and bilirubin [56,57]. However, a 
larger multicentre trial in 2004 involving 171 patients with acute liver failure and primary 
nonfunction following orthotopic liver transplantation failed to show any overall 
improvement in patient survival after 30 days within the BAL treated group compared to 
the control group [55]. Only on removal of the primary nonfunction patients from the 
statistical analysis was HepatAssist deemed to show improvement of survival in acute liver 





failure patients, although no such similar analysis appeared to be performed for primary 
nonfunction patients by removal of acute liver failure patients. The overall efficacy of 
HepatAssist still remains unclear. Furthermore, the US Food and Drug Association (FDA) 
deemed that the trial did not demonstrate the efficacy of HepatAssist. Therefore, further 
clinical trials will be necessary to further clarify whether this device has a positive effect 
on liver failure patient survival [58]. 
The Extracorporeal Liver Assist Device (ELAD) utilises a similar HFB system to 
HepaMate. In contrast to HepaMate, the cells used are the human hepatoma cell line, C3A. 
The use of an established cell line provides an unlimited resource of HLCs that survive 
well when cultured in vitro. The cells are seeded within four cartridges containing hollow 
fibre membranes and patient plasma undergoes filtration and treatment with the cell 
inoculated cartridges prior to re-joining the bloodstream (Figure 2.8)  [50,59,60]. 
 
Figure 2.8 Structure of the Extracorporeal Liver Assist Device (ELAD). Plasma is filtered and 
circulated through the system. The four ELAD cartridges contain hollow fibres seeded with human 
C3A hepatoma cells. Image reproduced with permission from [60]. 
However, evidence on whether ELAD improves patient survival is mixed. A pilot study 
using ELAD to treat patients with acute liver failure suggested that there was some 
improvement in hepatic encephalopathy and ammonia levels but no significant changes in 





blood lactate or serum albumin were found. Overall, survival was no different to that of the 
control group [61]. A second study examined the performance of ELAD with standard 
medical treatment in patients with acute-on-chronic liver failure suggesting no 
improvement at 30 days, but improvement at 90 days compared to standard medical 
treatment alone [62]. In a study involving patients with severe alcoholic hepatitis, no 
significant difference was found, although it was noted that patient age, level of renal 
function and extent of coagulopathies may impact upon the efficacy and overall specificity 
of this treatment toward a certain patient demographic [63,64]. 
The Modular Extracorporeal Liver System (MELS) utilises a woven network of 3 hollow 
fibre bundles (CellModule) for plasma inflow, outflow and gas exchange of oxygen and 
CO2 respectively [58]. In addition to the HFB system, MELS can utilise two other modules 
that are added depending upon patient requirements. MELS incorporates SPAD 
(DetoxModule) and continuous haemofiltration (DialysisModule) for additional 
detoxification [65,66]. Therefore, MELS is considered to be a ‘hybrid’ of artificial and 
BAL configurations (Figure 2.9). 
Currently, MELS utilises primary human liver cells sourced from donor livers unsuitable 
for transplantation comprising a population of parenchymal and nonparenchymal cells 
[66]. These donor livers include livers discarded due to presence of steatosis, cirrhosis or 
traumatic injury [66,67]. 
A Phase 1 clinical study in 2002 demonstrated the safety of MELS and was successful in 
bridging two patients to transplantation [67]. However, as the sample size was 8 patients, it 
is not possible to definitively comment on the overall efficacy of the system and 
comparative patient survival without further clinical studies to confirm the results from this 
study. 






Figure 2.9 Structure of the Modular Extracorporeal Liver Support (MELS) device. The 
system comprises up to three modules containing primary human liver cells from discarded donor 
livers (the HFB CellModule), SPAD (DetoxModule) and continuous filtration (DialysisModule) for 
treatment of liver failure. Image reproduced with permission from [66]. 
In contrast to the other systems which are primarily perfused by the plasma fraction of 
patient whole blood, the Bioartificial Liver Support System (BLSS) utilises primary 
porcine hepatocytes and whole blood within a HFB system, with no separation of plasma 
(Figure 2.10) [68]. A Phase 1 clinical trial looking at the safety of the BLSS noted good 
tolerance with patients, although the sample size was only 4 [69]. To guide future 
development of the system, potential issues were highlighted, such as fluid overload due to 
lack of a haemodialysis or haemofiltration system, as well as potential clot formation 
within the system due to use of whole blood [69]. However, there is no further data 
referring to the comparative efficacy of BLSS against standard medical treatment. 






Figure 2.10 Structure of the Biological Liver Support System (BLSS). This system uses a HFB 
with primary porcine hepatocytes, perfused with the whole blood of the patient. Dotted lines 
represent the flow of whole blood through the system. Dashed lines represent the path of nutrient 
media in the system. Solid lines represent direction of gas flow. Image reproduced with permission 
from [68]. 
The Amsterdam Medical Centre-Bioartificial Liver Device (AMC-BAL) utilises a different 
approach to the overall bioreactor design. Unlike the other systems described in this 
review, which are primarily based upon a HFB system, the AMC-BAL involves direct 
contact between patient plasma and cells from use of a perfused bed bioreactor in a flow 
system. Instead of providing a scaffold for cell attachment, the hollow fibres in this device 
provide oxygenation of the system and removal of CO2 (Figure 2.11) [70–72]. 
The initial Phase 1 clinical trial in 2002 with acute liver failure patients utilised primary 
porcine hepatocytes. The trial reported that no severe adverse effects were detected. 
Reduction of bilirubin and ammonia along with improved neurological symptoms were 
also found. Furthermore, 6 out of the 7 patients treated were bridged to transplantation, 
with the seventh not requiring orthotopic liver transplantation [73]. To comply with 
European Union (EU) standards disallowing use of porcine hepatocytes [70], a more recent 
iteration of the AMC-BAL utilises the human liver progenitor cell line HepaRG [74]. 
Although this version of the AMC-BAL has not been tested under a clinical setting, animal 
studies involving rats with acute liver failure have demonstrated reductions in hepatic 
encephalopathy progression, kidney failure and ammonia build-up [75]. 
 






Figure 2.11 Structure of the Amsterdam Medical Centre-Bioartificial Liver (AMC-BAL). 
Polysulfone housing (A) surrounds a non-woven polyester matrix (B) for cell culture. 
Polypropylene hollow fibres (C) are utilised for gas exchange with gas perfusion entering via (E). 
Patient plasma enters the system through sideports (F) and is perfused through the extracapillary 
space between the hollow fibres (D). Image reproduced with permission from [72]. 
Notably, there is little data involving direct comparative experimental studies between the 
different BAL device designs. Comparative clinical studies between BAL devices are 
difficult due to large variations in overall bioreactor setup and cell source, patient 
population and data collection methods hampering study design. A study in 2007 
compared the AMC-BAL with MELS under in vitro conditions utilising primary porcine 
hepatocytes and found that the devices were essentially comparable in hepatic functions 
after 7 days, although the AMC-BAL displayed higher ammonia elimination over 7 days 
[76]. However, MELS demonstrated reduced lactate dehydrogenase (LDH) release over 
the same time period. LDH release is a marker for reduced cell viability. The LDH 
reduction in MELS is possibly due to comparatively reduced shear stress on the cells from 
perfusion due to the presence of the semipermeable hollow fibre membranes separating 
them from the perfusion compartment in MELS, compared to the direct contact between 
cells and plasma in the AMC-BAL. Interestingly, this study did not utilise the full modular 
capability of MELS and only involved the CellModule rather than the additional SPAD 





and filtration modules. Therefore, the full capability of the MELS unit was not portrayed in 
this study. An in vivo study utilising a full setup of MELS would provide a more direct 
comparison between the units. 
The data reported from these BAL device designs, although showing the safety of the 
systems, suffer from lack of comprehensive clinical trial data with regards to determining 
overall efficacy and improvement to patient survival. The majority of studies are Phase 1 
clinical trials, which are primarily to establish device safety under a clinical setting [77]. 
Similar to the findings with artificial liver devices, subsequent systematic reviews and 
meta-analyses on extracorporeal BAL device research with regards to overall patient 
survival are mixed in whether they offer an improvement upon standard medical treatment. 
A study by Gu et al in 2012 found that after analysis of 31 BAL device studies, of which 
only two were randomised controlled trials, neurological improvements were found along 
with improved elimination of ammonia and bilirubin. However, no significant 
improvement on patient survival was observed [78]. A further systematic review in 2013 
suggested that BAL devices only reduced patient mortality with regards to acute liver 
failure, and not acute-on-chronic liver failure, with the reverse true for artificial liver 
devices [79]. Again, these conflicting reports highlight the necessity for suitably powered 
clinical testing of these devices to determine their overall effectiveness as clinical therapy. 
BAL devices require further development to ensure greater efficacy, safety and 
improvement in patient survival before they can be regularly utilised in clinical situations. 
There are two major challenges to BAL device design that will affect the overall efficacy 
of the system and its entrance into the clinical setting. Firstly, it is necessary to select a cell 
source that can recapitulate the physiological functions of human hepatocytes as displayed 
in vivo and as such, can also be obtained in sufficient numbers for safe clinical usage. 
Secondly, it is important to ensure that the bioreactor can provide a suitable environment 
for the selected cells to thrive in and therefore function effectively as hepatocytes or HLCs 
[23,77,80]. As BAL device design is of primary interest in this thesis, further review of the 
literature will focus on this method of therapeutic liver support. 
 





2.3 Cell sources for bioartificial liver devices 
The extent of function of a BAL device is highly dependent on whether the selected cell 
source is able to behave similarly to the physiological liver. Certainly, orthotopic liver 
transplantation results in restoration of liver function through replacement of the damaged 
organ. However, as previously mentioned, suitable donors are scarce. This problem is the 
driving force behind the search for alternative sources of hepatocytes or cells that are able 
to function as in vivo hepatocytes. As summarised in Section 2.2.2, the various BAL 
devices that have undergone clinical trials utilise different types of hepatocytes or HLCs to 
replace lost liver functionality. The functional replicability of these cells will impact on 
how well they perform as a native hepatocyte substitute. 
It is similarly imperative to consider as part of the hepatocyte cell source selection criteria 
the utility of sourcing sufficient quantities of cells. Along with the basic functional 
capabilities of the chosen cell source, the total number of hepatocytes within the BAL 
device will heavily impact upon the efficacy of the device. Based on animal studies, 
Tsiaoussis et al estimated that to provide sufficient support with a BAL device, the 
quantity of cells required in the system must represent 20% to 40% of the original liver 
mass [51,81], whereas on data based on surgical resections, this range was lowered to 10% 
to 30% [82]. Calculations based on theoretical analyses and data from human liver 
resections suggested a minimum number of approximately 1-2 x 1010 viable hepatocytes in 
the BAL device system for maintenance of normal liver function in a human [65,82,83]. 
As cells can be affected by the environment they are cultivated in, the overall efficacy of 
the hepatocyte or HLC efficacy should be, at minimum, equivalent to this cell number. In 
addition, there is a requirement that a cell source should be easily replenished and thus 
meet the demands of widespread clinical usage. 
A third aspect to consider is the level of risk associated with the cell source. Use of non-
human cell sources such as porcine hepatocytes increase the potential for zoonotic 
transmission of diseases to the patient. The potential for immunological responses from the 
patient from using non-autologous cells should also be considered, as well as the potential 
for metastatic formation from usage of cancer cell lines [77]. 
  





In summary, an ideal cell source would combine: 
1. Replicable human hepatic function. 
2. Sufficient supply for clinical requirements. 
3. No risk in clinical usage. 
 
2.3.1 Primary human hepatocytes 
Primary human hepatocytes would be the gold standard cell line with regards to 
functionality. However, they suffer from similar issues to donor livers used for 
transplantation in that they are limited in supply and have low proliferative capacity [51]. 
Another hindrance with using primary human hepatocytes is that they undergo progressive 
dedifferentiation with loss of phenotype and functionality when cultured in vitro, a 
significant issue due to the in vitro nature of the BAL device [84,85]. Studies addressing 
this limitation have examined different approaches to countering dedifferentiation. These 
approaches include addition of differentiating promoting growth factors to the culture 
medium [85,86]; restoration of extracellular matrix (ECM) interactions through culture 
with ECM proteins [87,88]; or co-culture with other non-parenchymal hepatic cells such as 
stellate cells to recapitulate physiological cell-to-cell interactions and improve primary 
hepatocyte functionality [89,90]. Although these methods have reported improved primary 
hepatocyte functionality compared to culturing primary hepatocytes alone, no single 
standard method of solving the dedifferentiation issue is currently utilised. Determination 
of the optimum strategy is hindered due to issues comparing between systems involving 
varying lengths of culture time, methods of functional analyses and the differences in the 
ratio of non-parenchymal cells to hepatocytes utilised [91]. 
Primary human hepatocytes have been sourced from donor livers rejected for 
transplantation, notably in MELS [66,67]. However, as these cells are from livers 
presenting with pathological features such as steatosis and cirrhosis, their overall yield, 
functionality and viability between batches compared to suitable donor livers are likely to 
vary in quality [92,93]. 
The ability to store primary hepatocytes without adversely affecting viability and function 
is similarly questionable. The method of isolation, cryopreservation and thawing utilised 





can also negatively affect the overall usable cell yield as well as their functional capability. 
Bhogal et al suggested that the critical time point for decreases in quality as part of the 
isolation process was between initial hepatectomy and subsequent perfusion of the liver 
slice prior to digestion and should not be longer than 3 hr [92]. A study in 2005 by Terry et 
al compared the effects of cryopreservation on hepatocytes from suitable and rejected 
donor livers. The findings from this study were that viability and functional capability with 
regards to CYP1A1/2 and albumin secretion was significantly reduced in cryopreserved 
hepatocytes of both sources when compared to freshly isolated hepatocytes [94]. 
Furthermore, freshly isolated hepatocytes from steatotic liver tissue showed reduced 
hepatic functionality and viability compared to freshly isolated hepatocytes from non-
steatotic tissue [94]. Given these issues, development of a standardised isolation, 
cryopreservation and thawing protocol that preserves viability and function, and 
furthermore, preservation of the differentiated hepatocyte state, will be necessary before 
primary human hepatocytes can see widespread clinical use. 
 
2.3.2 Primary porcine hepatocytes 
The increased availability of primary porcine hepatocytes over their human counterpart has 
made them an attractive source of cells for BAL devices [57]. As described previously, 
these cells have been utilised in clinical trials for BAL devices with the HepatAssist, BLSS 
and AMC-BAL devices. Porcine hepatocytes are described as possessing a metabolic 
capability and efficacy similar to that of humans [80], of which examples include 
testosterone metabolism [95], albumin secretion and CYP1A activity [96,97]. However, a 
cross-species incompatibility with regards to activation of parts of the coagulation process 
in humans has been reported [67,80,98]. In addition, primary porcine hepatocytes display 
dedifferentiation in vitro, similar to primary human hepatocytes, which may affect their 
overall effectiveness as a cell source [99].  
There is a risk of transmissible zoonosis by way of the porcine endogenous retrovirus 
(PERV) from porcine hepatocytes, particularly if patient blood or plasma comes in direct 
contact with the cells or if the retrovirus can pass through the separation membrane. There 
have been studies involving HepatAssist, BLSS and AMC-BAL regarding the potential 
transmission of PERV within these BAL device designs, although no transmission was 





displayed [100–103]. In addition, use of primary porcine hepatocytes in clinical treatment 
is hampered by regulations banning xenotransplantation in many EU countries, meaning 
this cell source is not suitable for widespread clinical applications  [24]. 
 
2.3.3 Hepatocyte cell lines 
Hepatocyte cell lines, in contrast to primary hepatocytes, have an unlimited proliferative 
capacity. This feature solves the issue of producing enough cells for clinical usage. The 
human hepatoma cell line HepG2 and its subclone, C3A, are readily utilised in laboratory 
based BAL device studies due to their ease of proliferation and range of hepatic functions 
[104–107]. However, despite possessing a wide hepatic functionality, the HepG2 cell line 
has been shown to have reduced metabolic activity in comparison to primary hepatocytes 
[108,109]. C3A is the cell line of choice for the ELAD system and was selected for its 
improved capacity for albumin synthesis and metabolic capability over the parent HepG2 
line [108]. However, a major issue with both HepG2 and C3A as BAL device cell sources 
is that they do not possess the full capability of ammonia detoxification displayed by 
primary hepatocytes. This issue may hinder the efficacy of the BAL device to eliminate 
toxins from the patient. In studies by Mavri-Damelin et al, it was found that both HepG2 
and C3A do not have a functional urea cycle, with absence of the enzymes ornithine 
transcarbamylase and arginase-1 [110,111]. 
The AMC-BAL system is now currently utilising the HepaRG human liver progenitor cell 
line, which demonstrates cytochrome P450 (CYP) activity, ammonia elimination and 
protein synthesis [112,113]. Comparison with primary human hepatocytes showed that the 
HepaRG line has a similar level of functionality with regards to ammonia elimination and 
apolipoprotein A1 production [74]. It has been successfully tested using an in vivo rat acute 
liver failure rat model showing reduction of hepatic encephalopathy, kidney failure and 
ammonia levels compared to untreated controls [75]. Survival rates were noted to be 
approximately 50% higher although this was in comparison to untreated rats with acute 
liver failure rather than a comparison with standard treatment. Therefore, although these 
findings demonstrate the hepatic activity of the cell line within the system, it is not yet 
possible to predict survival improvement over current strategies with this experimental 
model. Clinical trials will be required to characterise the system further. 





Notably, an in vitro comparison between HepaRG and C3A using this BAL device noted 
that the HepaRG cell line displayed comparatively improved xenobiotic metabolism, 
ammonia and lactate elimination over the C3A cell line [114]. However, it has also been 
reported that the HepaRG cell line possesses a slow growth rate and potentially loses its 
phenotype at higher cell passage numbers  [51]. This may be problematic when producing 
sufficiently differentiated quantities of cells for use. Furthermore, HepRG has 
demonstrated greater resilience to hepatotoxic agents in comparison to primary human 
hepatocytes, suggesting that they may not be fully comparable as a model in drug 
hepatotoxicity testing [115]. 
 
2.3.4 Stem cells 
A stem cell is broadly defined as an undifferentiated cell that upon division, either 
produces a similarly undifferentiated cell or undergoes differentiation to one or more cell 
types [116]. By utilising methods based upon liver development, human embryonic stem 
cells (hESCs) and induced pluripotent stem cells (iPSCs) have both been induced to 
differentiate into HLCs with a range of hepatocyte functions including ammonia 
elimination, albumin and urea synthesis and CYP activity [117–121]. However, 
differentiated yields from hESCs and iPSCs are currently not sufficient in numbers to be 
utilised in a clinical setting, particularly due to the loss of proliferative capacity upon 
differentiation. hESCs and iPSCs appear to possess a less mature functional phenotype 
when compared to adult primary hepatocytes, with the overall metabolic profile 
reminiscent of foetal hepatocytes in the case of albumin secretion and CYP activity 
[122,123]. Therefore, further work looking into protocols for improvement of phenotype 
maturation is required to improve comparability of these HLC sources. Furthermore, 
tumorigenicity and possible metastatic transfer to the patient is a major risk factor with 
using hESCs and iPSCs within a BAL device [124]. 
HLCs have also been derived from human mesenchymal stem cells (hMSCs). A study by 
Aurich et al has shown differentiation to HLCs from hMSCs harvested from bone marrow 
that displayed urea synthesis and increased glycogen deposition as well as expression of 
hepatocyte transcripts such as albumin, TFN and CPS-1 [125]. A further study successfully 
differentiated adipose tissue hMSCs to HLCs [126]. Despite these results, hMSC-derived 





HLCs are not fully comparable to primary hepatocytes as there is currently no single 
protocol that offers a wide range of hepatic functionality [127]. hMSCs have also been 
reported to display heterogeneity in phenotype, not only dependent upon the tissue of 
origin, but also within the same tissue type [128]. This heterogeneity may impact on 
overall effectiveness of these cells. Furthermore, these issues limit potential usage of HLCs 
from hMSCs due to the requirement for standardisation and reduction of phenotypic 
variability. 
 
2.3.5 Transdifferentiated hepatocyte-like cells 
The use of transdifferentiated HLCs provides an alternative approach to obtaining HLCs 
suitable for use in a BAL device. Transdifferentiation constitutes the permanent 
conversion, or cellular reprogramming of one differentiated cell type to another 
differentiated cell type [129]. In the case of HLCs, an in vitro model of pancreatic cell 
transdifferentiation to HLCs has been developed utilising a rat pancreatic acinar cell line, 
AR42J-B13 (B13). Under treatment with the synthetic glucocorticoid hormone 
Dexamethasone (Dex), B13 cells lose their pancreatic phenotype, displaying loss of 
amylase expression. They eventually display hepatocyte-like morphology and functionality 
including expression of albumin, CCAAT/enhancer-binding protein beta  (C/EBPβ), 
hepatocyte nuclear factor alpha (HNF4α), GS, CPS-1, glucokinase, production of acute 
phase proteins and replication of hepatitis B virus within 14 days of culture [130–133]. 
Use of this glucocorticoid treatment has also been replicated with mouse embryonic 
pancreas and human foetal and adult pancreatic cells to induce transdifferentiation of 
pancreatic cells to HLCs, thus demonstrating that it is not a species specific phenomenon 
[134–136]. Comparative gene expression analysis of markers such as CYP2E1, albumin, 
C/EBPβ and CPS-1 was similar between adult primary human hepatocytes and adult 
human pancreatic cells transdifferentiated to HLCs [135]. However, a small percentage of 
cells display resistance to Dex-based transdifferentiation and do not lose the pancreatic 
phenotype, producing a heterogeneous population of cells, and the maturity of 
transdifferentiated HLCs with regards to their metabolic behaviour in comparison to 
mature primary hepatocytes is not clear [129]. Further examination of the mechanisms 
involved in transdifferentiation, such as the growth factors and pathways involved will aid 





understanding of the developmental background between the two tissue types. In addition, 
this information can be used to guide optimisation of current transdifferentiation protocols 
and improve upon the subsequent transdifferentiated HLC phenotype. 
The range of hepatocyte functions displayed in transdifferentiated HLCs make them an 
attractive prospect for supplying a BAL device. Use of the B13 cell line in particular may 
provide a potentially limitless source of HLCs. 
 
2.4 Bioreactor design for bioartificial liver devices 
The bioreactor design and operating parameters can affect the quality of the BAL device 
due to the relationship the selected cell source has with the environment it is being cultured 
in [137]. The ideal bioreactor for a BAL device would be able to maintain a suitable 
growth and metabolic environment for the hepatocytes; allow bidirectional and efficient 
mass transport between the hepatocytes and blood or plasma; and prevent immunogenicity 
between the hepatocytes and the patient. The majority of BAL devices that have entered 
clinical trials utilise the hollow fibre bioreactor (HFB) configuration as their primary 
design. Other bioreactor designs that have been tested include perfused bed, fluidised bed, 
and flat membrane [65]. A summary of bioreactor characteristics is shown in Table 2.3. 
Table 2.3 Characteristics of bioreactors used for hepatocyte culture. 
Bioreactor design Features References 
Perfused bed 
Cells are cultured within a 
porous scaffold, in direct 
contact with medium flow 
[138,139] 
Fluidised bed 
Cells are encapsulated and 
fluidised by vertical medium 
flow against gravity 
[107,140,141] 
Hollow fibre 
Cells are cultured on porous 
fibre membrane scaffolds, 




Sandwich cell culture within a 
gel, or flat monolayer culture 
[145,146] 
 
HFBs provide a three dimensional (3D) culture system and are composed of 
semipermeable hollow fibre membranes that form a dual compartment system comprising 





the intraluminal and extracapillary spaces. An example configuration for HFB cell culture 
is shown in Figure 2.12. One of the major advantages of using HFBs for cell culture is that 
they are an improved method of bioprocessing over other culture methods. HFBs have a 
greatly increased surface area for cell attachment and proliferation, thus allowing for 
higher density hepatocyte culture within a BAL device. In comparison with a tissue culture 
flask and stirred tank bioreactor to grow equivalent numbers of cells, HFBs only require 
0.1% and 0.5% of their respective volumes [147]. In addition, a 3D culture system 
provides a more in vivo environment for cells to two dimensional (2D) culture as 
demonstrated by comparison of 2D and 3D scaffolds [148,149]. 
Common HFB configurations for cell culture involve culturing cells on the internal 
surface, which exposes the cells directly to perfusion within the lumen; on the outer 
surface, where the cells are protected from shear stress damage as they are not directly 
exposed to active perfusion (Figure 2.12); or suspension of cells within a gel in the 
extracapillary space (ECS) [150]. Perfusion may be intra- or extraluminal. Direct exposure 
of the cells to intraluminal perfusion, similar to perfused bed bioreactor systems, can 
provide enhanced bidirectional mass transfer between cell and perfusate due to lack of a 
separating barrier. However, overall cell viability may be compromised due to damage 
from shear stresses from the active flow [151]. It has been suggested that by cultivating 
cells internally within a semipermeable biocompatible polymer fibre, the seeded construct 
can be implanted within a patient and also avoids immune rejection due to control over the 
molecular weight cut off point of the membrane [152]. For the purposes of BAL device 
design, seeding internally within the fibre effectively leads to a 2D monolayer culture 
system. 3D intraluminal cell culture would require additional cell encapsulation [153]. 






Figure 2.12 An example configuration for a hollow fibre bioreactor used for cell culture. (a) 
Longitudinal view; (b) cross sectional view with a close up of a single fibre. In this configuration, 
cells are seeded directly on to the outer surface (shell) of the hollow fibre membrane. Culture 
medium is perfused through the lumen of the hollow fibre and kept separate from the cultured cells. 
The semipermeable nature of the membrane can be tailored to a specific molecular weight cut off 
point for selective diffusion of nutrients and waste products between the intraluminal and 
extracapillary compartments. 
A 3D culture system structured similarly to that of the physiological liver is provided by 
HFBs by the culture of cells on the exterior surface of a hollow fibre, within a bundle of 
similarly seeded fibres within the bioreactor cartridge. By culturing on the fibre outer 
surface, the cells are separated from the flow of media flowing through the fibre lumen. 
Shear stress damage on the cells from direct flow is therefore avoided due to the presence 
of the membrane [154]. The separation of cells from the perfusate is similar to the 
relationship between blood and hepatocytes within the liver sinusoid. Anatomically, a 
fenestrated endothelium separates the hepatocytes from sinusoidal blood flow (Figure 2.2). 
Immobilisation or encapsulation of the cells within a biocompatible ECM-like gel, such as 
collagen, sodium alginate or chitosan, has been shown to promote hepatic phenotype and 
function in hepatocyte culture [155–157] and could be contained within the ECS of the 
hollow fibre, thus retaining the dual compartment system described here [158]. 





The biomaterial utilised for the hollow fibre membranes can directly impact upon the 
hepatocyte phenotype quality and functionality as well as the replicability of the 
physiological environment within the system. As part of developmental consideration, 
these factors must be balanced out with a culture scaffold that is mechanically stable, 
semipermeable, supplies efficient mass transfer between cell and perfusate and is 
biocompatible. Hepatocytes are anchorage dependent cells, and for direct scaffold 
adherence, require a biomaterial that is not cytotoxic and is conducive to allowing 
sufficient densities of cells to attach and subsequently spread. 
Hollow fibre membranes can be fabricated utilising a phase inversion method involving the 
immersion precipitation of a polymer-solvent dope solution in a suitable nonsolvent 
(ternary system) via dry-wet or wet-wet spinning to fabricate a polymer fibre membrane 
with a hollow lumen [154,159]. The precipitate may be porous, nonporous or 
asymmetrical, with a nonporous top layer and porous substructure [159]. The immersion 
precipitation technique can also be used to cast flat sheet membranes that can be used as a 
model system for determining hollow fibre structure. Control over polymer, solvent and 
nonsolvent selection allows for customisation and tailoring of hollow fibre membrane 
characteristics for the required purpose. Ideally, with a porous hollow fibre membrane 
scaffold, the size of the pores should be no larger than 5 μm to ensure that the attached 
cells do not enter the scaffold substructure [154]. Further tailoring of the molecular weight 
cut off (MWCO) of the porous membrane would allow selectivity in transfer of molecules 
across the membrane wall. Previous studies into hollow fibre bioreactor BAL device 
design have focused upon this method of molecular selection and have demonstrated that a 
MWCO of between 150 – 400 kDa is sufficient to prevent transfer of larger complement 
factors and immunoglobulins across the membrane by acting as an immuno-isolation 
barrier [160]. As the liver protein albumin, which has a molecular weight of 65 – 70 kDa, 
binds to several waste molecules such as bilirubin, an even lower MWCO of 100 kDa has 
been shown as sufficient for membrane separation within a HFB system [161]. 
Cell density within the bioreactor system must be balanced between hepatocyte metabolic 
capability and the fixed volume limitation of the HFB system. It has been previously 
reported that a high hepatocyte density within the BAL device is necessary to provide the 
required functional support for patients with acute liver failure [162]. A study using 
porcine hepatocytes demonstrated increased and thereafter consistently high urea 





production and [3H]-leucine incorporation at higher cell density levels, but conversely 
showed reduction in glucose-6-phosphatase activity [162]. It has also been observed that a 
higher hepatocyte density results in a reduction in oxygen consumption rate, potentially 
due to limitations in oxygen diffusivity, or approximation towards the density within the 
normal physiological liver leading to reduction in cellular stress [163]. These results show 
the need for further tailoring of the system to discover optimum hepatocyte functionality. 
In particular, mathematical modelling of HFB culture systems to determine experimental 
operating parameters is especially important for tailoring the system to the cell type [164]. 
Modelling of oxygen transport through the system is one particular example, as different 
cells types have different oxygen requirements. In the case of hepatocytes, zonation of 
some hepatic functions is oxygen and nutrient gradient dependent so parameters must be 
tightly controlled and understood to develop a truly replicable in vitro BAL system 
[53,83,163].  
A hydrophobic surface is not considered conducive for hepatocyte cell culture [165], so 
methods have been developed to improve surface wettability for cell culture, such as 
surface modification by oxygen plasma treatment or surface grafting of bioactive 
molecules to promote cell attachment [166,167]. Using a polymer blend incorporating 
hydrophilic additives such as polyvinyl alcohol or polyethylene glycol can also reduce 
membrane hydrophobicity [168]. Comparative analysis between rat hepatocytes cultured 
on polycarbonate, polysulfone, cellulose acetate and polypropylene membranes determined 
that their metabolic behaviour improved upon more hydrophilic surfaces such as 
polycarbonate and cellulose acetate. This study demonstrates the importance of 
characterising the selected polymer membrane for overall biocompatibility and cell 
function [169]. 
Depending upon the overall purpose of the hollow fibre, the polymer utilised to fabricate 
the fibres may be biodegradable or non-biodegradable. The former characteristic is useful 
for implantation of therapeutic tissue constructs, where the scaffold degrades and leaves 
behind the cultured cells, such as with poly(D,L-lactide-co-glycolide) (PLGA) scaffolds 
[154,170,171]. For situations where scaffold degradation is unwanted, such as in a BAL 
device, or where long term culture is required, such as in cell expansion and 
differentiation, a non-biodegradable scaffold is ideal. Common polymers utilised for HFB 
cell culture include PLGA, polysulfone, polyethersulfone, cellulose acetate and 





polypropylene [105,154,172–174]. Notably, polystyrene (PS), whilst widely established as 
the traditional biomaterial used in 2D cell culture, has yet to be reported as part of a phase 
inversion hollow fibre membrane system for cell culture purposes and thus warrants further 
research in this area. 
 
2.5 Conclusion 
The liver is responsible for multiple functions that contribute to the overall normal 
physiological state of the human body, such as metabolism, detoxification, synthesis of 
proteins, storage and removal. In the case where the liver is no longer able to perform these 
functions, such as in liver failure, systemic pathologies can develop, such as kidney failure, 
hepatic encephalopathy and coagulopathies. The only cure for liver failure is orthotopic 
liver transplantation, but there are not enough donor organs for the patients that require 
them. Therefore, many patients die before receiving a transplant. As the number of deaths 
from liver failure is increasing yearly, it is important to develop new therapeutic strategies 
to prevent liver failure mortality. 
One such strategy is the BAL device. The BAL device intends to bridge patients to 
transplantation through the recapitulation and maintenance of normal physiological liver 
functions within the device. The HFB system provides a physical configuration that is 
similar to liver microanatomy. However, current BAL device designs have not gained 
clinical acceptance, as currently there is no overall improvement in patient survival over 
standard treatment procedures from their use. Notably, the two main issues with BAL 
device design are sourcing hepatocytes or HLCs that can function similarly to that of the 
normal liver; and secondly, providing a suitable culture environment for the cells so they 
can perform liver functions effectively. 
 
2.6 Aims and objectives 
The primary aim of the research in this thesis is to address the above BAL device design 
issues through the development of a novel polymer scaffold for HFB cell culture and 
functional hepatocyte source. Polystyrene has been proposed as a potential candidate for 
developing phase inversion hollow fibre membranes to be used in a BAL device due to its 





known biocompatibility, cost-effectiveness and well documented use as a biomaterial for 
2D cell culture. However, its usage to develop phase inversion membranes for cell culture 
has yet to be reported. A potential cell source for use in a BAL device is transdifferentiated 
HLCs generated from pancreatic cells. These cells display a wide range of hepatocyte 
functions and can be generated from an unlimited source through transdifferentiation of the 
pancreatic B13 cell line. However, further optimisation of the transdifferentiation protocol 
is required to improve the hepatic phenotype and remove heterogeneity within the culture 
population. 
In summary, the objectives of the work in this thesis are as follows: 
 Develop a ternary system for the fabrication of polystyrene phase inversion hollow 
fibre membranes using a flat sheet membrane model. 
 Characterise the resultant membrane through morphology, surface wettability and 
surface chemistry. 
 Investigate and characterise the utility of surface modifying polystyrene 
membranes with oxygen plasma to increase surface wettability for cell culture. 
 Characterise the utility of the culture medium ‘HepatoZYME+’ for inducing 
transdifferentiation of the rat pancreatic B13 cell line to HLCs. 
 Investigate and characterise the utility of ‘HepatoZYME+’ as a maintenance 
medium for transdifferentiated HLCs compared to established Dex-based 
transdifferentiation media. 
 Investigate the utility of oxygen plasma surface modification to affect cell 
attachment on polystyrene membranes. 
 Characterise the biocompatibility of oxygen plasma surface modified polystyrene 
membranes (PX) with regards to cell attachment and viability of the B13 and 
MG63 cell lines, relative to tissue culture polystyrene and PLGA. 
 Investigate the utility of the B13 cell line to undergo transdifferentiation to HLCs 
on PX membranes. 
 Investigate structural changes to PX membranes kept under culture conditions. 
  






Materials and Methods 
This Chapter describes the Materials and Methods utilised throughout this thesis. Specific 




3.1.1 Membrane preparation 
Table 3.1 Polymers, solvents, cell culture substrates and membrane sterilisation reagents. 
Material Supplier 
Product 
Number Working Concentration 




70% (v/v) in deionised 
water 
N-methyl 2-pyrrolidinone (NMP) 
Acros 
Organics 127630025 




Evonik RESOMER RG 
756 S 
20% (w/w) with NMP 
Polystyrene (PS) Sigma-
Aldrich 
182427-500G 20% (w/w) with NMP 
Tissue culture polystyrene 




Tissue culture polystyrene 






Aldrich A5955 1% (v/v) in PBS 





3.1.2 AR42J-B13 cell culture 
Section 3.1.2 describes the culture conditions and additional supplementation for the 
AR42J-B13 (B13) cell line. B13 cells are a subclone of the parent rat pancreatic cell line 
AR42J and were provided by Itaru Kojima (Tokyo, Japan). 
Table 3.2 AR42J-B13 complete maintenance and proliferation medium. 





Sigma-Aldrich D5546 1X 
Foetal bovine serum 
(FBS) Gibco 10270-106 10% (v/v) 
L-glutamine Sigma-Aldrich G7513 1% (v/v) 
Penicillin-
streptomycin Sigma-Aldrich P4333 1% (v/v) 
 
Table 3.3 AR42J-B13 additional complete medium supplements for transdifferentiation to 
HLCs. 















10 μg/ml with 


















HepatoZYME-SFM Gibco 11570536 1X 1X 
L-glutamine Sigma-Aldrich G7513 100% (v/v) 
0.5% (v/v) L-





10 μg/ml with 
0.1% BSA in 
PBS 
10 ng/ml 
Hydrocortisone Sigma-Aldrich H0888 1 mM in PBS 10 μM 
2-mercaptoethanol 
(2-Me) 
Sigma-Aldrich M3148 1X 






10 μg/ml with 





Sigma-Aldrich P4333 100% (v/v) 1% (v/v) 
 
Table 3.5 Additional complete medium supplements and cell culture reagents. 








Sigma-Aldrich D8418 100% (v/v) 






Sigma-Aldrich D5652-50L 1X 1X 
Trypsin-EDTA Gibco 25300-054 0.05% (v/v) Stock concentration 
 
  





3.1.3 MG63 cell culture 
Section 3.1.3 describes the culture conditions for the MG63 cell line. The MG63 cell line 
is a human osteosarcoma cell line obtained from ECACC. 
Table 3.6 MG63 complete maintenance and proliferation medium. 




Eagle’s Medium with 
GlutaMAX (DMEM+) 
Gibco 61965-026 1X 
Foetal bovine serum 
(subsequently heat 
inactivated at 56°C for 30 
min) (FBS) 
Gibco 10270-106 10% (v/v) in DMEM+ 





Gibco 11140-035 1% (v/v) in DMEM+ 
Penicillin-streptomycin Gibco 15140-122 1% (v/v) in DMEM+ 
 
Table 3.7 Additional cell culture reagents. 





Sigma-Aldrich D8537 1X 
Trypan blue Gibco 15250-061 









3.1.4 Immunofluorescence characterisation 
Table 3.8 Fixation reagents. 
Material Supplier Product Number Working 
Concentration 
Methanol Sigma-Aldrich 34860 100% (v/v) 
Paraformaldehyde 
(PFA) 
Fisher P/0840/53 4% (v/v) in PBS 
 
Table 3.9 Immunofluorescence reagents. 
Material Supplier Product 
Number 
Working Concentration 
Blocking buffer Roche 11096176001 2% (w/v) in PBS 
Normal goat serum (NGS) 
Sigma-
Aldrich 
G9023 10% (v/v) in PBS 
Bovine serum albumin (BSA) 
Sigma-
Aldrich 












0.1% (v/v) or 1% (v/v) in 
PBS 
Mowiol mounting medium Calbiochem 475904 n/a 
 
  





Table 3.10 Primary antibodies. 
Primary 
Antibody 





Albumin Mouse Sigma-Aldrich 1 in 100 4% PFA Roche n/a 
Amylase Rabbit Sigma-Aldrich 1 in 100 4% PFA Roche n/a 










1 in 300 




HNF4α Rabbit Santa Cruz 1 in 100 4% PFA Roche n/a 
PH3 Rabbit Milipore 1 in 100 4% PFA Roche n/a 
TFN Rabbit Dako 1 in 100 4% PFA Roche n/a 
 
Table 3.11 Secondary antibodies. 
Secondary Antibody Species Supplier Dilution 
Alexa Fluor 546 Rabbit conjugated Invitrogen 1 in 500 
Alexa Fluor 594 Rabbit conjugated Invitrogen 1 in 1000 
Fluorescein 
isothiocyanate (FITC) 
Mouse conjugated Vector Laboratories 1 in 100 
Fluorescein 
isothiocyanate (FITC) 
Rabbit conjugated Vector Laboratories 1 in 100 
 





3.1.5 RT-PCR characterisation 
Table 3.12 RNA extraction and cDNA synthesis reagents. 
Material Supplier Product Number 
10X DNase I buffer Ambion 8170G 
Chloroform Sigma-Aldrich 132950 
Diethyl pyrocarbonate (DEPC) Sigma-Aldrich D5758 
rDNase I Ambion AM2235 
Ethylene glycol-bis(2-
aminoethylether)-N,N,N′,N′-
tetraacetic acid (EGTA) 
Sigma-Aldrich E3889 
Ethanol (absolute) VWR 20821.330 
Isopropanol Fisher P/7490/17 
Oligo Dt 15 primer Promega C110A 
Omniscript RT Kit Qiagen 205113 
ReddyMix PCR MasterMix Thermo Scientific AB-0575 
RNAsin plus Promega N261A 
Tri-Reagent Sigma-Aldrich T9424 
 
  





Table 3.13 Rat PCR primers. 

























































Table 3.14 Gel electrophoresis reagents. 




National Diagnostics EC-872 1X 
Agarose Sigma-Aldrich A9539 
2% (w/v) in TAE 
buffer 
100 bp ladder Norgen 11300 1X 
Gel Red Biotium 41003 









3.1.6 Quantitative cell culture assays 
Table 3.15 Quantitative assays and additional reagents. 




Pierce BCA Protein Assay Kit Thermo Scientific 23225 
Pierce LDH Cytotoxicity Kit Thermo Scientific 88953 
Quant-iT Picogreen dsDNA Assay 
Kit 
Invitrogen P11496 
Rat Albumin ELISA Quantitation 
Set 
Bethyl Labs E110-125 
Protease inhibitor cocktail Sigma-Aldrich P8340 
 
  





3.2 Membrane fabrication 
3.2.1 Solution preparation 
Solutions were prepared at a concentration of 20% (w/w) polymer. Polystyrene (PS) or 
poly(D,L-lactide-co-glycolide) (PLGA) were added to NMP in airtight containers and left 
overnight at room temperature on a roller mixer to ensure complete dissolution. 
 
3.2.2 Flat sheet membrane fabrication 
Membranes were cast using the phase inversion process as previously described [154]. 
Approximately 5 ml of dope was spread out onto a glass plate using a 1 cm diameter glass 
rod. A membrane thickness of 200 μm was established by wrapping 200 µm wires either 
side of the rod where it was in contact with the solution. The coated glass sheet was then 
submerged in 2 L of either deionised water or 70% (v/v) IMS at 18°C as a nonsolvent. The 
nonsolvent was replaced at 6 and 24 hr intervals after the initial immersion to remove any 
residual solvent. The precipitated membrane was removed from the coagulation bath after 
3 days and allowed to air dry overnight. 
 
3.2.3 PS membrane surface modification by oxygen plasma to create PX 
membranes 
PX membranes were generated by surface modification of PS membranes by oxygen 
plasma. Surface modification was performed in a custom built vacuum chamber using 
inductively coupled plasma generation or a capacitively coupled plasma chamber (Zepto-
Diener), both at radio frequencies (RF) of 13.56 MHz. Oxygen gas was used to generate 
the plasma under vacuum. The membranes were secured to a plastic well plate lid using 
double-sided tape to ensure that the membrane surface would be completely exposed to the 
plasma when in the chamber. The membranes were plasma treated for 1 min, 2 min and 5 
min respectively in the custom built chamber at a power supply of 30 W or by using the 
capacitively coupled plasma chamber at a power supply of 25 W for 30 s. 
 





3.3 Membrane characterisation 
3.3.1 Membrane morphology 
Membrane morphology was examined on both top surface and cross section of untreated 
and treated PS membranes by scanning electron microscopy (SEM) (JEOL JSM480LV). 
For surface analysis, the membranes were cut into approximately 5 x 5 mm squares using a 
scalpel blade and secured to an aluminium stub using double-sided conductive carbon tape. 
For cross sectional analysis, the membranes were immersed in liquid nitrogen for 5 min 
using forceps and freeze fractured using a razor blade. The sample was secured to a slanted 
aluminium stub with the fractured edge of interest exposed on top. After overnight storage 
in a desiccator, samples were coated in gold using a sputter coater (Edwards S150B) and 
viewed under vacuum at an accelerating voltage of 10 kV. 
 
3.3.2 Surface wettability 
Surface wettability of untreated and plasma treated PS membranes was analysed by 
measuring water contact angles using the sessile drop method. 2 μl deionised water was 
pipetted on to the membrane surface using the Dataphysics Contact Angle System OCA 
goniometer and the contact angle imaged and measured using the integrated camera and 
program. Measurements were taken from three randomly selected areas of each membrane 
surface and the means and respective standard errors (SEs) calculated. 
 
3.3.3 Surface chemistry 
Detection of additional oxygen functional groups on untreated and treated membrane 
surfaces was performed using attenuated total reflectance Fourier transform infrared (ATR-
FTIR) spectroscopy (Perkin Elmer Frontier FTIR) and X-ray photoelectron spectroscopy 
(XPS) (Theta Probe). ATR-FTIR spectra were collected through the accumulation of 20 
scans at a resolution of 2 cm-1 and a data interval of 0.25 cm-1. X-ray photoelectron spectra 
were obtained at the National EPSRC XPS Users' Service (NEXUS) at Newcastle 
University, an EPSRC Mid-Range Facility. CasaXPS Version 2.3.16 software was used to 
determine elemental compositions. 





3.4 General cell culture methods 
3.4.1 AR42J-B13 (B13) cell line maintenance and passaging 
Reagents for rat pancreatic B13 cell culture and experiments are described in Section 
3.4.1. B13 cells were maintained in complete medium as previously described [130]. 
Complete B13 medium composition is described in Table 3.2. Cells were cultured in a T75 
flask. At approximately 70% confluence, the culture medium was aspirated off and the 
cells washed with 10 ml sterile PBS. The PBS was then removed and 5 ml 0.05% trypsin-
EDTA solution added. The flask was incubated at 37°C for 5 min to encourage detachment 
from the culture surface prior to the addition of 5 ml complete B13 medium to neutralise 
trypsin-EDTA activity. The cell suspension was then centrifuged at 1000 rpm (151 g) for 3 
min (ALC PK110 Centrifuge). The supernatant was removed and the resulting pellet re-
suspended in 1 ml fresh complete medium. 30 μl cell suspension was added to a fresh T75 
flask containing 12 ml fresh complete medium. Cells were incubated at 37°C at 5% (v/v) 
CO2 in a humidified incubator. Medium was changed every 2 days. 
 
3.4.2 MG63 cell line maintenance and passaging 
Reagents for human osteosarcoma MG63 cell culture and experiments are described in 
Section 3.1.3. MG63 cells were maintained in complete medium as described in Table 3.6. 
Cells were cultured in a T75 flask. Passaging protocol for MG63 cells was the same as that 
described in Section 3.4.1 with the following amendments: MG63 cell suspension was 
centrifuged at 1000 rpm (179 g) for 5 min (ALC PK120 Centrifuge). Cells were incubated 
at 37°C at 5% (v/v) CO2 in a humidified incubator. Medium was changed every 2 days. 
 
3.4.3 Cell line storage and revival 
Liquid nitrogen was used for long term storage of cell lines. Cells were passaged as 
previously described until after the centrifugation step. After centrifugation and removal of 
the supernatant, the cell pellet was re-suspended in 1 ml freezing medium (10% (v/v) 
DMSO, 90% (v/v) FBS). The resulting suspension was transferred to a cryovial and stored 
overnight at -80°C in a Mr Frosty Freezing Container (Thermo Scientific) before 
transferring to liquid nitrogen storage. 





Cells were revived from liquid nitrogen by the addition of 1 ml respective complete 
medium pre-warmed to 37°C to the cryovial and rapid thawing at 37°C. The cell 
suspension was added to 10 ml complete medium and centrifuged at 1000 rpm for 3 min. 
The supernatant was aspirated off and the resulting cell pellet re-suspended in 12 ml 
complete medium. The cell suspension was then transferred to a T75 flask and incubated at 
37°C at 5% (v/v) CO2 overnight in a humidified incubator. The medium was replaced with 
fresh complete medium the following day with subsequent medium changes occurring 
every 2 days as per cell line maintenance protocols. 
 
3.4.4 Cell seeding 
For seeding cells at a specific density, cells were visualised using a 1:1 dilution of cell 
suspension and trypan blue and counted using a haemocytometer or a Fast Read cell 
counter as per manufacturer’s instructions. The seeding volume per well for the required 
density was subsequently calculated as follows: 
 
3.4.4.1 Haemocytometer cell count 
Cells were counted in 4 grids of the haemocytometer and the cell number per grid noted. 
The mean cell number per grid was calculated by adding the cell counts per grid together 
and dividing this total by 4. The seeding volume was then calculated using the following 
formula: 
ܵ݁݁݀݅݊݃ ݒ݋݈ݑ݉݁ (ߤ݈/ݓ݈݈݁) =  
ܥ݈݈݁ ݀݁݊ݏ݅ݐݕ × ܵݑݎ݂ܽܿ݁ ܽݎ݁ܽ ݋݂ ܿݑ݈ݐݑݎ݁ ݏݑܾݏݐݎܽݐ݁
ܯ݁ܽ݊ ݈݈ܿ݁ ݊ݑܾ݉݁ݎ ݌݁ݎ ݃ݎ݅݀ × 10 × 2
 
 
3.4.4.2 Fast Read cell counter cell count 
The total number of cells contained within the 10 grids of a single counter chamber were 
counted and a mean cell number per grid calculated by dividing the total cell count by 10. 
The seeding volume was then calculated using the following formula: 
ܵ݁݁݀݅݊݃ ݒ݋݈ݑ݉݁ (݈݉/ݓ݈݈݁) =  
ܥ݈݈݁ ݀݁݊ݏ݅ݐݕ × ܵݑݎ݂ܽܿ݁ ܽݎ݁ܽ ݋݂ ܿݑ݈ݐݑݎ݁ ݏݑܾݏݐݎܽݐ݁
ܯ݁ܽ݊ ݈݈ܿ݁ ݊ݑܾ݉݁ݎ ݌݁ݎ ݃ݎ݅݀ × 1000 × 2
 





3.4.5 Inducing transdifferentiation of B13 cells to hepatocyte-like cells 
B13 cells were cultured as previously described in Section 3.4.1. Cells were seeded on to 
either TCPS, PS or PLGA membranes or 22 x 22 mm glass coverslips at a density of 3,125 
cells/cm2 (30000 cells in a single well of a 6-well plate) and incubated at 37°C at 95% 
air/5% CO2 in a humidified incubator overnight in complete medium. The following day, 
medium was removed and complete medium supplemented with either 1 μM Dex only or 1 
μM Dex and 10 ng/ml OSM (Table 3.3) was added to the cells. Cells were treated with the 
transdifferentiation medium for a minimum of 14 days as previously described [130] 
unless otherwise specified in the experimental method. Medium was changed every 2 days. 
 
3.5 Treatment of B13 cells with different media 
3.5.1 Treatment of B13 cells with HepatoZYME+ complete culture medium 
B13 cells were cultured as previously described in Section 3.4.1. Cells were seeded in 6-
well plates at a density of 3,125 cells/cm2 either directly on to TCPS or on 22 x 22 mm 
glass coverslips. Cells were incubated at 37°C at 5% (v/v) CO2 in a humidified incubator 
overnight. The following day, medium was removed and complete medium supplemented 
with either 1 μM Dex only, 1 μM Dex and 10 ng/ml OSM, HepatoZYME+ differentiation 
medium (Table 3.4) or a 50:50 dilution of HepatoZYME+ with complete medium 
(henceforth referred to as “50:50”) was added to the cells. Detailed experimental 
conditions can be found in Chapter 5. 
 
3.6 Membrane biocompatibility characterisation 
3.6.1 Bioreactor construction 
PS and PLGA flat sheet membranes were fabricated as described in Section 3.2 with 
minimum dimensions of 85 x 128 mm, comparable with the dimensions of a well plate. PS 
membranes were oxygen plasma treated using a Zepto Diener plasma chamber as 
described in Section 3.2.3. Membranes were tightly screwed into autoclaved custom 
designed 24-well plate polycarbonate bioreactor modules with silicon gaskets. This left a 
membrane surface area of 1.9 cm2 per well exposed for cell culture which is comparable to 
a single well of a commercial 24-well plate (Figure 3.1). Membranes were sterilised as 





previously described [175]. Membranes were incubated in 1% (v/v) antibiotic-antimycotic 
solution in PBS at 4°C for 24 hr then rinsed 3 times with PBS. Module construction and 
membrane sterilisation was performed inside a Class II laminar flow biohood. Specific 
membrane compositions for biocompatibility experiments are described in more detail in 
Chapter 6. 
 
Figure 3.1 Custom 24-well plate polycarbonate bioreactor module for flat sheet membrane 
cell culture. Exposed membrane surface area per well = 1.9 cm2. Scale bar = 2 cm. 
 
3.6.2 Cell attachment 
Cell attachment on different biomaterial surfaces was quantified by measuring cellular 
dsDNA content relative to cell density using the Quant-iT Picogreen dsDNA Assay Kit 
(Invitrogen). Membranes were fixed into custom 24-well plate modules as described in 
Section 3.6.1. TCPS was used as a control culture substrate. Cells were seeded onto the 
different culture substrates at a density of 20,000 cells/cm2 using the method described in 
Section 3.4.4.2. Cells were incubated for 6 hr in a humidified incubator at 37°C at 95% 
air/5% (v/v) CO2 then removed. The culture medium was removed and the cells were 
gently washed in PBS. 500 μl 1X TE buffer provided by the assay was added to each well 
and the plate was incubated at room temperature for 30 min before undergoing 2 freeze-
thaw cycles at -80°C. The working Picogreen solution was a 1:200 dilution in 1X TE 





buffer from the provided stock solution. The provided λ DNA standard was diluted 
according to the manufacturer’s instructions to create a standard curve correlating mean 
fluorescence values to dsDNA content (ng).  The diluted λ DNA standards and lysed cell 
samples were added in triplicate 75 μl aliquots to a 96-well plate suitable for 
fluorospectroscopy. 75 μl of the working Picogreen solution was added to each sample 
well and the plate gently agitated for 5 min. Fluorescence was measured at an excitation of 
485 nm and emission of 528 nm using a Fluorospectrometer BioTek Synergy HT 
(NorthStar Scientific). dsDNA content in the experimental samples was deduced from the 
λ DNA standard curve and correlated to cell density (cells/cm2). 
 
3.6.3 Cell viability 
The LIVE/DEAD Viability/Cytotoxicity Kit (Invitrogen) was used to determine the 
presence of live and dead cells cultured on different biomaterial surfaces. Membrane 
samples were cut into 22 x 22 mm squares and placed into a well of a 6-well plate. The cut 
membranes were held down in the well by sterilised cloning rings and sterilised as 
described in Section 3.6.1. Cells were seeded at a density of 20,000 cells/cm2 using the 
method mentioned in Section 3.4.4.1 then incubated for 48 hr in a humidified incubator at 
37°C in 5% (v/v) CO2. After incubation, the cells were washed gently in PBS and 2 ml 
working live/dead stain solution added, consisting of 1 μM calcein AM and 1 μM ethidium 
homodimer-1 in PBS. The cells were incubated in the solution at room temperature for 30 
min. 100 μl of the working solution was pipetted on to a glass microscope slide and the 
membrane placed cell side down on the droplet. Green fluorescence of live cells and red 
fluorescence of dead cells was visualised on an inverted microscope (Olympus IX51, 
Olympus) and imaged using the CellP software. The number of cells showing green or red 
fluorescence was counted for 6 random fields of view (FOV) per replicate and normalised 
against the total number of cells counted in the FOV using ImageJ to determine the 
percentage number of live and dead cells. 
 
3.6.4 Cytoxicity 
The percentage cytotoxicity was analysed by determining lactate dehydrogenase (LDH) 
activity in the culture medium of cells cultured on different biomaterial surfaces using the 





Pierce LDH Cytotoxicity Kit. Membranes were fixed and sterilised in custom 24-well plate 
modules as previously described (Section 3.6.1). TCPS was used as a control culture 
substrate. Cells were seeded at a density of 3000 cells/well in 3 sets of triplicate wells and 
incubated at 37°C in 5% (v/v) CO2 in a humidified incubator for 48 hr. After incubation, 
30 μl ultrapure water was added to 1 well per set to form the Spontaneous LDH Activity 
Control, 30 μl 10x Lysis Buffer was added to the 2nd well per set to form the Maximum 
LDH Activity Control and 30 μl complete medium were added to the 3rd well per set to 
form the LDH Activity Sample. LDH activity was measured in the culture medium at 
absorbances 490 nm and 680 nm using a Fluorospectrometer BioTek Synergy HT 
(NorthStar Scientific). The percentage cytotoxicity was calculated using the following 
formula as per manufacturer’s instructions: 
% ܥݕݐ݋ݐ݋ݔ݅ܿ݅ݐݕ =
ܥ݋݉݌݋ݑ݊݀ ݐݎ݁ܽݐ݁݀ ܮܦܪ ܽܿݐ݅ݒ݅ݐݕ − ܵ݌݋݊ݐܽ݊݁݋ݑݏ ܮܦܪ ܽܿݐ݅ݒ݅ݐݕ
ܯܽݔ݅݉ݑ݉ ܮܦܪ ܽܿݐ݅ݒ݅ݐݕ − ܵ݌݋݊ݐܽ݊݁݋ݑݏ ܮܦܪ ܽܿݐ݅ݒ݅ݐݕ
× 100 
 
3.6.5 Membrane bulk changes under cell culture conditions 
Membrane bulk changes under cell culture conditions was quantified by percentage weight 
change and percentage surface area change of membranes after 3, 8 and 15 days under cell 
culture conditions.  
PX and PLGA membranes were fabricated as described in Section 3.2. The membranes 
were then cut into squares approximating 20 mm x 20 mm and their length and width 
measured using a micrometer with a resolution of 0.01 mm to determine their pre-
incubation available culture surface areas. The squares were then weighed on an electronic 
balance with a resolution of 0.001 g to determine their pre-incubation masses. Following 
this, the membranes were then transferred to a 6-well plate, held down with cloning rings 
and sterilised as described in Section 3.6.1. After 24 hr incubation at 4°C, the membranes 
were washed in PBS and 2 ml of complete B13 maintenance medium (Section 3.1.2) was 
added to each well. The membranes were incubated at 37°C at 5% (v/v) CO2 in a 
humidified incubator. After 3, 8 or 15 days, the membranes were removed from the 
incubator and the culture medium aspirated away. The membranes were washed 3 times in 
PBS then dried in a desiccator overnight. The membranes were then measured again to 
determine their post-incubation surface areas and masses. 





Means for percentage mass change and percentage surface area change and their standard 
errors (SEs) were calculated for 3 different membranes per time point. Statistical analyses 
were performed using a paired samples Student’s t-test for membranes cast from the same 
polymer and an independent samples Student’s t-test to compare between PX and PLGA 
membranes. 
 
3.7 Immunofluorescent staining of cell cultures 
3.7.1 Cell fixation 
B13 cells were cultured for the time as stated in the relevant chapters. At the experimental 
endpoint, the culture media was removed and the cells washed in PBS. The fixative was 
selected based upon the target antigen of interest (Table 3.8 and Table 3.10). For 4% PFA 
fixation, after washing the cells in PBS, 4% PFA solution was added to the cells and 
incubated at room temperature for 25 min. For methanol fixation, after washing the cells in 
PBS, methanol chilled to -20°C was added to the cells and incubated at room temperature 
for 5 min. After fixation, the fixative was then removed and the cells washed 3 times in 
PBS. The cells were stored in PBS at 4°C prior to immunofluorescent staining. 
 
3.7.2 Immunofluorescent staining 
The staining method was dependent on the fixation method.  The PBS was first removed 
from fixed cell cultures. Cells fixed with 4% PFA were permeabilised using 0.1% (v/v) 
Triton X-100 in PBS and incubated for 20 min at room temperature. Cells fixed with 
methanol did not require permeabilisation or antigen retrieval. 
Following this, blocking buffer was added to the fixed cultures. 2% Roche Blocking Buffer 
(Roche) was added to cells fixed with 4% PFA. Cells fixed with methanol were blocked 
using 10% (v/v) normal goat serum, 1% (v/v) BSA and 0.3 M glycine in PBS (NGS-BSA-
Gly Buffer). The cells were incubated with their respective blocking buffers at room 
temperature for 30 min. Primary antibodies were diluted in blocking buffers as described in 
Table 3.10 and added to the cells on the culture substrate. Cells were incubated overnight 
with the antibody-blocking buffer solution at 4°C. 





The following day, cells were washed 3 times with PBS and incubated at room temperature 
in PBS on a rocker for 30 min to remove residual primary antibody. Secondary 
fluorescently-conjugated antibodies were diluted in blocking buffers as per primary 
antibodies and added to the cells on the culture substrate (Table 3.11). Cells were 
incubated at room temperature with the antibody-blocking buffer solution, protected from 
light. Following this, the cells were washed twice with PBS and then incubated in PBS at 
room temperature on a rocker for 20 min. The PBS was removed and a 1:1000 dilution of 
DAPI in PBS solution added to the cells. The cells were incubated with this solution on a 
rocker for 10 min at room temperature, protected from light, before removing the solution 
and washing the cells in deionised water. Coverslips and membranes were mounted using 
Mowiol mounting medium on to glass microscope slides. An additional glass coverslip 
was added to the top of stained membranes to hold the membrane in place. Slides were 
incubated overnight at room temperature and then stored at 4°C. 
For double staining of cells with two primary antibodies, it was ensured that the primary 
antibodies used had been developed in different species to prevent cross-reactivity. 
Cells were visualised on an Olympus IX51 microscope and imaged using CellP software. 
Post-processing of images was performed using the GNU Image Manipulation Program 
(GIMP) 2. 
 
3.7.3 Percentage expression quantification 
Percentage expression of a marker of interest was calculated by counting the number of 
cells showing both positive immunofluorescent staining for the marker of interest as well 
as the DAPI nuclear stain. These cells were counted in 3 random FOVs per replicate and 
normalised against the total number of DAPI-positive cells counted in the FOV using 
ImageJ to determine the percentage expression of the marker of interest. 
 





3.8 RT-PCR analysis of gene expression 
3.8.1 Total cellular RNA extraction 
RNA was extracted from cells at the stated experimental endpoint using the following 
method. Culture medium was removed and the cells were washed twice in PBS. 500 μl of 
Tri-Reagent (Sigma-Aldrich) was added per well in 6-well plate cultures; 100 μl per well 
in 24-well plate cultures. The solution was allowed to incubate for 5 min at room 
temperature. The lysate was repeatedly pipetted up and down the culture surface to ensure 
a homogenous solution before it was transferred to an RNase-free Eppendorf tube. 
Solutions were able to be stored at -80°C until required. 
After thawing (if required), 200 μl 100% (v/v) chloroform was added to the solution and 
the tube gently shaken for 20 s before incubating for 15 min at room temperature. The 
solutions were then centrifuged at a relative centrifugal force (RCF) of 12,000 g  at 4°C for 
15 min (Eppendorf Centrifuge 5417R). The top aqueous layer was then transferred to a 
fresh RNase-free Eppendorf tube and 500 μl 100% (v/v) isopropanol added to the tube. 
The tube was mixed briefly using a vortex mixer and incubated for 10 min at room 
temperature before centrifugation at a RCF of 12,000 g at 4°C for 10 min. The supernatant 
was removed and 1 ml 75% (v/v) absolute ethanol in DEPC-H2O cooled to 4°C was added 
to the tube before centrifuging at a RCF of 7,600 g at 4°C for 5 min. The supernatant was 
removed and the resultant RNA pellet allowed to dry on a heat block at 37°C. The pellet 
was re-suspended in 20 μl DEPC-H2O and heated at 60°C on a heat block for 10 min then 
placed on ice. Extracted RNA concentration (μl/ml) and purity (A260/A280) was measured 
using the GeneFlow NanoPhotometer. 
 
3.8.2 DNase treatment of extracted RNA 
To remove contamination of extracted RNA samples by genomic DNA, the working mass 
of RNA in solution and volume required for DNase treatment was calculated to be between 
50 ng and 2 μg, based on the sensitivity of the Omniscript RT Kit (Qiagen). The maximum 
volume of RNA sample was 7.5 μl. DNase treatment reagents can be found in Table 3.12 
with required volumes in Table 3.16. 





Table 3.16 Reagents for DNase treatment of one extracted RNA sample. 
Reagent Volume (μl) 
Extracted RNA in solution Dependent on working mass of RNA in solution 
10x DNase I buffer 1.0 
rDNase I 1.0 
RNAsin plus 0.5 
DEPC-H2O 7.5 – Volume of extracted RNA in solution 
TOTAL 10.0 
 
Samples were briefly spun in a centrifuge then incubated at 37°C for 30 min. The DNase 
reaction was stopped by the addition of 1 μl 20 mM EGTA and samples incubated at 65°C 
for 10 min. For long-term storage, DNase-treated RNA samples were then stored at -80°C 
until required. 
 
3.8.3 Reverse transcription (RT) 
cDNA synthesis from DNase-treated RNA was done using the Omniscript RT Kit 
(Qiagen). The reagent components are stated in Table 3.12  with quantities in Table 3.17. 
The reaction mixture was briefly spun in a centrifuge then incubated at 37°C for 1 hr. 
Samples were then kept on ice for 1 min. For long-term storage, cDNA was frozen 
at -20°C until required. 
 
Table 3.17 Reaction mixture reagents for reverse transcription of RNA to cDNA. 
Reagent Volume (μl) 
DNase-treated RNA 11.0 
10X RT buffer (Omniscript RT Kit) 2.0 
5 mM dNTP (Omniscript RT Kit) 2.0 
Oligo dT 1.0 
RNAsin plus 0.2 
RT omniscript (Omniscript RT Kit) 1.0 









3.8.4 Polymerase chain reaction (PCR) and gel electrophoresis 
Expression of specific genes was determined using the polymerase chain reaction (PCR) 
and visualised using gel electrophoresis. For PCR, species specific forward and reverse 
primers were used to highlight specific genes of interest. Primers, sequences and annealing 
temperatures are listed in Table 3.13.  The PCR reaction mixture and quantities per sample 
are stated in Table 3.18. 
Table 3.18 PCR reaction mixture for one cDNA sample. 
Reagent Volume (μl) 
cDNA 1.0 
Forward primer (10 μM) 0.4 
Reverse primer (10 μM) 0.4 




The samples were spun down briefly in a centrifuge and the PCR reaction was performed 
in a TC-412 Techne Thermal Cycler (Jencons Pls) under the following conditions: 
initialisation at 95°C for 2 min, denaturation at 95°C for 25 s, amplification at the specified 
primer annealing temperature for 35 s and extension at 72°C for 1 min. The number of 
cycles of denaturation to extension was 25 for β-actin and 30 for all other primers, 
followed by a final extension step at 72°C for 5 min on the final cycle. All PCR reactions 
included a cDNA-negative control. 
PCR products were analysed using gel electrophoresis. Products were run on a 2% agarose 
gel in 1X TAE buffer alongside a 100 bp ladder. Samples were run at 90 V for 30 min. 
Gels were subsequently stained with Gel Red and visualised under ultraviolet light. Images 
were captured using a Chemi-DocIt2 Imager. 
 
3.9 Quantitative cell assays 
B13 cells were quantified for serum albumin production in culture media (Section 3.9.2). 
Data were normalised against total cell number or total cellular protein content for serum 





albumin production. Total cellular protein quantification is detailed in Section 3.9.1. Total 
cell number quantification is detailed in Section 3.6.2. 
 
3.9.1 Total cellular protein quantification 
Total cellular protein content was quantified using the Pierce BCA Protein Assay Kit 
(Thermo Fisher). The Working Reagent was prepared as per manufacturer’s instructions. 
25 μl of cellular protein lysate from 1% (v/v) Triton X-100 treated B13 cells were added in 
duplicate to a 96-well plate. 200 μl of the Working Reagent was added to each well and the 
contents mixed thoroughly on a shaker for 30 seconds. The plate was protected from light 
and incubated at 37°C for 30 min before being cooled to room temperature. Absorbance 
was measured at 562 nm using a Synergy Plate Reader (Biotek). 
 
3.9.2 Serum albumin production 
Serum albumin in culture media used in the treatment of B13 cells was quantified using the 
Rat Albumin ELISA Quantitation Set (Bethyl Labs). B13 cells were seeded on a specified 
culture substrate at 3,125 cells/cm2 and treated with a specified culture medium for 13 or 
20 days. On day 13 or 20 of treatment, the medium was removed and the cells gently 
washed in PBS. For the cultures in Chapter 5 utilising TCPS 6-well plates, the cells were 
then treated with 1 ml serum-free treatment medium for 1 day. The cultures utilising the 
custom 24-well plate bioreactor in Chapter 6 were treated with 500 μl serum-free 
treatment medium for 1 day. Following this, the culture medium was then removed from 
the cells and stored at -20°C. For protein quantification, the cells were washed in PBS and 
500 μl 1% (v/v) Triton X-100 in PBS containing a 1:100 dilution of protease inhibitor 
cocktail added to the cells to extract cellular protein. The subsequent lysate was collected 
and stored at -80°C. For cell number quantification, the cells were washed in PBS and 500 
μl 1X TE buffer added to the cells and incubated at room temperature for 30 min before 
following the protocol stated in Section 3.6.2 for cell lysis and analysis. 
Serum albumin was then quantified in the removed culture medium. The rat albumin 
ELISA was performed using Nunc F96 Maxisorp plates. Plates were coated and washed in 
preparation for standards and samples as per the manufacturer’s guidelines. All standards 





and samples were transferred to the ELISA plate in volumes of 100 μl and incubated at 
room temperature for 60 min before washing. 
The HRP Detection Antibody was diluted 1:20,000 in Sample/Conjugate Diluent and 100 
μl added per well, before incubation for 60 min at room temperature prior to washing. 100 
μl TMB substrate solution was then added to each well and incubated at room temperature 
for 15 min before adding 100 μl 0.18 M H2SO4 to each well to stop the solution.  
Absorbance was measured at 450 nm using a Synergy Plate Reader (Biotek). 
Normalisation was either done versus total protein content using the Pierce BCA Protein 
Assay Kit (Thermo Scientific) or per million cells via the Quant-iT Picogreen dsDNA 
Assay Kit (Invitrogen). 
 
3.10 Microscopy and image processing 
Flat sheet membrane morphology was analysed using a JEOL JSM480LV scanning 
electron microscope at an accelerating voltage of 10 kV and imaged using the installed 
software. 
Transmitted light images of cells in culture were visualised using a Leica DM IRB 
microscope and imaged using NIS Elements software or GXCapture 7 software. 
Fluorescently stained cells were visualised using a Leica DMRB microscope with images 
taken using an Olympus XM10 or visualised using an Olympus IX51 microscope with 
images taken using CellP software. 
Image-based quantification, including relative proportions of integrated intensity of 
fluorescence, image-based cell counts and measurements of cell diameter was done using 
Image J. 
Post-processing of images for brightness and contrast and figure labelling were performed 
using GIMP 2 and Microsoft PowerPoint. 
 





3.11 Statistical analysis 
For statistical analysis, experiments were performed a minimum of 3 times independently 
of each other (n = 3) and where applicable, a mean and respective standard error (SE) was 
calculated. Further statistical analyses were performed using SPSS 22 for Windows. 
Statistical tests were selected based on whether the data were determined to be parametric 
or non-parametric following a Shapiro-Wilk normality test. Where the data was judged to 
be normally distributed, comparison of differences in mean between stated data sets was 
performed either using an independent samples Student’s t-test for comparison of 2 
independent samples, a paired samples Student’s t-test where samples were compared 
before and after treatments or via a one-way ANOVA with Tukey’s post-hoc tests for a 
minimum of 3 samples. Differences between means in compared data sets were considered 
to be statistically significant where p < 0.05. 
  






Development of polystyrene flat sheet 
membranes for cell culture 
4.1 Introduction 
4.1.1 Phase inversion membranes as a cell culture substrate 
To replicate a physiological environment in an in vitro setting such as a bioartificial liver 
(BAL) device, it is necessary to tailor the culture system to the specific cell type to ensure 
that functionality is maintained as closely to in vivo as possible. Two BAL devices that 
have reached clinical trials have utilised a hollow fibre bioreactor (HFB) system in 
different configurations, such as culturing the cells on the outer surface of the fibre 
(ELAD) or by culturing the cells on collagen-coated dextran microcarriers in the 
extracapillary space of the hollow fibre cartridge (HepatAssist) [23,52]. In both systems, 
the cells are separated from the flow of medium through the fibre lumen by the wall of a 
semipermeable hollow fibre membrane. This set-up bears great similarity to the anatomy 
of the liver sinusoid, where the microvilli of the hepatocyte in the space of Disse are 
separated from sinusoidal blood flow by a fenestrated endothelium. 
Based on the normal liver anatomy, the construction of suitable hollow fibres requires the 
development of semipermeable membranes. These scaffolds are selective barriers that 
allow nutrients in medium flowing intraluminally to diffuse across the membrane to cells 
cultured upon the extraluminal surface, limited by molecular weight. The membrane must 
be constructed from a mechanically stable, biocompatible material, where the cells are able 
to attach, thrive and function as normal; and also must be porous, to facilitate sufficient 
mass transfer to cells whilst preventing transfer of larger molecules and cells themselves 
into the membrane substructure and lumen. 
Phase inversion membranes have previously been used in HFBs for cell culture [154,171–
173] and are favoured for their efficient mass transfer capabilities and potentially porous 
nature. Membranes are cast via a ternary, immersion precipitation method [159,176]. Here, 





a polymer is dissolved in a solvent, and the resulting dope solution introduced to a 
secondary solvent, termed the nonsolvent. The solvent dissolves in the nonsolvent, creating 
a binary liquid phase and therefore precipitating a membrane in the solid phase. Membrane 
characteristics including structure, MWCO, surface chemistry and wettability will vary 
depending upon the mutual affinity and miscibility between the chosen polymer, solvent 
and nonsolvent [159]. Phase inversion membranes can be porous or nonporous in structure, 
or form an asymmetrical structure where a nonporous top skin layer forms on top of a 
porous sublayer [159,177,178]. This is dependent upon the rate of liquid-liquid demixing 
that occurs in a polymer-solvent-nonsolvent system [159]. Flat sheet membranes fabricated 
using the immersion precipitation method of phase inversion are a suitable model system 
to identify potential hollow fibre membrane structural attributes. In the case of flat sheet 
membrane casting, the demixing occurs at the interface between the dope solution and 
nonsolvent through immersion. During hollow fibre membrane formation, demixing occurs 
from both the shell (fibre exterior) and bore (spinneret needle bore) side where the dope 
solution is exposed to nonsolvent from the coagulation bath (fibre exterior) and also the 
spinneret needle bore (fibre interior) [159,179]. As the nonsolvents examined in this 
Chapter via the flat sheet membrane model would also be used in the coagulation bath and 
the spinneret needle under hollow fibre conditions respectively, the structural features 
observed from flat sheet membrane casting could be translated to a hollow fibre membrane 
setting. This translation is due to similar dope solution-nonsolvent interfaces occurring at 
the demixing stage during hollow fibre membrane fabrication. 
 
4.1.2 Polystyrene as a potential biomaterial for hollow fibre bioreactor cell 
culture 
A novel candidate polymer for the development of hollow fibre membranes for 3D 
bioreactor cell culture is polystyrene (PS). PS is a non-biodegradable thermoplastic 
(Figure 4.1). It is highly resistant to photodegradation [180] and does not lose structural 
integrity at 37°C as it possesses a glass transition temperature of approximately 100°C  
[181] and a melting point of 240°C [182]. The durable and long lasting nature of PS means 
that it is an ideal candidate for use in BAL devices. A polymer such as PLGA, whilst 
useful for tissue graft implantation and removal of the graft scaffold by biodegradation, 
would not be suited for long term maintenance of adherent cells that require a constant 





scaffold presence. Outside of BAL device design, this biomaterial could also be utilised for 
long term cell expansion in a HFB setting to produce a large quantity of therapeutically 
useful cells. 
 
Figure 4.1 Chemical structure of polystyrene. Polystyrene is the result of the polymerisation of 
styrene monomers and consists of a repeating unit of a phenyl group attached to a hydrocarbon 
chain. 
PS is biocompatible, inexpensive to mass produce and readily utilised as a culture scaffold 
[183] in the form of tissue culture plastic-ware. 3D porous PS scaffolds have also been 
used to culture the HepG2 human hepatocellular carcinoma cell line [149] and research 
into electrospun PS fibres has also shown good cell attachment of human bladder smooth 
muscle cells [184]. However, the use of phase inversion PS flat sheet or hollow fibre 
membranes for cell culture or BAL device design has not been previously reported in the 
literature. 
 
4.1.3 Selecting a suitable ternary system for casting phase inversion 
membranes 
As previously described in Section 4.1.1, the ternary system chosen for casting phase 
inversion membranes can affect the characteristics of the resultant product. This is 
particularly dependent upon the mutual affinities between the system components.  
N-methyl-pyrrolidinone (NMP) is an FDA-approved solvent that has previously been used 
in the manufacture process of pharmaceutical agents and also as part of solutions in 
controlled release drug delivery devices [185]. NMP is of particular interest in bone tissue 





engineering as it has been shown to enhance the effects of bone morphogenetic protein-2 
(BMP-2) in bone cell maturation [186]. It has been previously used in casting PLGA phase 
inversion flat sheet and hollow fibre membranes, which were able to support human bone 
cell culture [154,171,172], and also in phase inversion cast polysulfone membranes for the 
culture of human hepatocytes [187]. Furthermore, given its miscibility with water, relative 
safety and history of usage in medical device design, NMP was therefore chosen as the 
polymer dissolution solvent for this study. 
The selected polymer concentration in the casting dope is vital to successful hollow fibre 
membrane fabrication. Insufficient polymer concentration can prevent precipitation of a 
mechanically stable membrane. A 1987 study by Eenink and Feijen using poly(L-lactide) 
stated that polymer concentrations below 10% (w/w) would not be sufficient for casting 
hollow fibres [188]. However, a polymer concentration that is too high will result in 
decreased membrane porosity, particularly at the surface interface between dope and 
nonsolvent [159]. Other polymer-NMP concentrations previously utilised for casting 
hollow fibre membranes have included poly(ε-caprolactone) at 15% (w/w) [189], PLGA at 
20% (w/w) [175] and 25% (w/w) [154,189] and polyethersulfone at 30% (w/w) and 35% 
(w/w) [190]. Previous work in this laboratory has utilised a 20% (w/w) concentration 
(Personal communication from Marianne Ellis). From this, a 20% (w/w) PS-NMP solution 
was selected as the initial experimental concentration for a hollow fibre membrane casting 
dope and thus the concentration used for casting flat sheet membranes. 
As the demixing process during phase inversion casting can determine whether a porous 
membrane is formed, deionised water and a solution of 70% (v/v) industrial methylated 
spirits in water (70% (v/v) IMS) were chosen as candidate nonsolvents for the ternary 
system due to their miscibility with NMP, immiscibility with PS and relative safety. In 
addition, 70% (v/v) IMS is already utilised as a common sterilising agent to ensure aseptic 
conditions for tissue culture. 
 
4.1.4 Developing membrane surface treatments to produce a suitable cell 
culture surface 
Adherent cell culture in a HFB system requires the hollow fibre membrane surface to be 
conducive to cell attachment and also porous, to allow for the diffusion of nutrients and 





waste products between intraluminal medium flow and cells cultured upon the outer 
membrane surface. However, it is difficult to find a material that possesses all of these 
characteristics for optimum effect. Efficacy of cell attachment to biomaterial surfaces is 
affected by the membrane surface chemistry, and given that phase inversion cast 
membranes can be porous or nonporous, it may be the case that additional surface 
treatments post-casting must be applied to create a more compatible biomaterial for the 
required purpose. 
Surface modification via plasma treatment allows for versatile alteration of surface 
chemistry depending on the gas utilised. The sample is contained within a vacuum 
chamber and exposed to plasma at a specific power for a certain length of time. This 
allows for additional functional groups to be added to the sample surface and can also 
change the surface topography as the surface is modified by reactive species present in the 
plasma. PS is a hydrophobic material, thus making it less conducive for cell attachment. 
Therefore, oxygen plasma treatment was selected as a potential method for altering the 
culture surface wettability and surface topography. The effectiveness of increasing 
hydrophilicity was then analysed and membrane morphology assessed. 
 
4.1.5 Experimental aims and objectives 
The experimental research described in this Chapter focuses on the development of phase 
inversion cast PS flat sheet membranes and subsequent morphological and chemical 
characterisation. Membranes were cast either by using water or 70% (v/v) IMS as the 
nonsolvent. Initially, the effects of inductively coupled oxygen plasma and subsequently, 
capacitively coupled oxygen plasma as membrane surface treatments were then 
investigated to determine parameters for the subsequent development of a novel substrate 
(PX) that could potentially be utilised for the fabrication of cell culture hollow fibre 
membranes. 
Characterisation of untreated and treated membranes was achieved through analyses of: (i) 
surface and cross sectional morphologies using scanning electron microscopy (SEM); (ii) 
surface wettability via the sessile drop method and finally (iii) surface chemistry via 
attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy and X-
ray photoelectron spectroscopy (XPS). 







4.2.1 Polystyrene flat sheet membrane morphology 
Phase inversion cast flat sheet membranes were used as a model experimental setup to 
determine a suitable polymer-solvent-nonsolvent ternary system for spinning hollow fibre 
membranes and subsequent parameters for surface treatments. Flat sheet membranes can 
be cast using comparatively smaller volumes of polymer dope and nonsolvent and require 
less preparation time than spinning hollow fibre membranes. They form two surface 
interfaces during the casting process – one that is directly exposed to the nonsolvent, which 
is representative of surfaces formed during spinning of hollow fibre membranes, which 
would be the surface that the cells would be cultured upon, and a second surface that 
interfaces with the glass casting plate. The former surface is the surface of interest for this 
study. 
PS flat sheet membranes were cast as described in Section 3.2, with the 20% (w/w) PS in 
NMP mixture dissolving to form a homogenous dope solution. Two nonsolvents were used 
to fabricate the membranes – deionised water and 70% (v/v) IMS. Both nonsolvent 
conditions generated white precipitates as part of the casting process. Membranes cast in 
deionised water precipitated and lifted off the glass casting plate after 2 seconds following 
immersion of  the dope solution in the nonsolvent. This was in contrast to membranes cast 
in 70% (v/v) IMS, which took over 5 min to coagulate and lift off the glass plate. 
SEM imaging was used to visualise membrane surface and cross sectional morphologies. 
Micrographs of PS membrane morphologies are shown in Figure 4.2. 






Figure 4.2 Morphology of PS flat sheet membrane top surfaces and cross sections. Membranes 
were cast from a solution of 20% (w/w) PS in NMP. (a) Deionised water nonsolvent, surface; (b) 
70% (v/v) IMS nonsolvent, surface; (c) deionised water nonsolvent, cross section; (d) 70% (v/v) 
IMS nonsolvent, cross section. Scale bar = 1 μm (surface) or 50 μm (cross section). 
Regardless of the nonsolvent used, the fabricated PS membranes presented with an 
asymmetrical structure, consisting of a smooth nonporous surface skin layer on top of  a 
highly porous substructure. Long finger like macrovoids running perpendicular to the 
surface layer were present in both membranes. Furthermore, these macrovoids were 
surrounded by a sponge-like layer consisting of smaller pore substructures. 
 
4.2.2 Morphology of inductively coupled oxygen plasma treated PS 
membranes 
Both water and 70% (v/v) IMS cast PS membranes were then exposed to oxygen plasma 
under a vacuum with the intention of modifying the surface to become conducive to 
adherent cell culture. Initially, a custom built vacuum chamber using inductively coupled 
plasma was used to treat the membrane surfaces. These treated PS membranes (PX 





membranes) were exposed to the oxygen plasma treatment for 1 min, 2 min and 5 min 
under experimental conditions as described in Section 3.2.3. The surface morphologies of 
each treatment condition are shown in Figure 4.3 and Figure 4.4. 
 
Figure 4.3 Morphology of untreated PS and inductively coupled oxygen plasma treated PX 
membrane surfaces cast in deionised water. Membranes were cast using a solution of 20% (w/w) 
polymer in NMP with deionised water as the nonsolvent. Membranes were either untreated (PS) (a) 
or treated (PX) through exposure to oxygen plasma at 30 W power for 1 min (b), 2 min (c), or 5 
min (d) in a vacuum. Scale bar = 5 μm. 
PX membranes originally cast using deionised water showed no visible differences in 
surface morphology after surface treatment compared to the untreated control PS 
membrane (Figure 4.3). Surfaces appeared to be smooth and nonporous. In contrast, where 
70% (v/v) IMS was used as the nonsolvent during casting, there was no visible increase in 
surface porosity up to 2 min, but after 5 min of treatment, the membrane presented with a 
highly porous surface with pore diameters measuring less than 1 μm (Figure 4.4d). 
 






Figure 4.4 Morphology of untreated PS and inductively coupled oxygen plasma treated PX 
membrane surfaces cast in 70% (v/v) IMS. Membranes were cast using a solution of 20% (w/w) 
polymer in NMP with 70% (v/v) IMS as the nonsolvent. Membranes were either untreated (PS) (a) 
or treated (PX) through exposure to oxygen plasma at 30 W power for 1 min (b), 2 min (c), or 5 
min (d) in a vacuum. Scale bar = 5 μm. 
Cross sectional analysis 5 min post-treatment is shown in Figure 4.5. Similar to their 
untreated counterparts, the substructure contained macrovoids surrounded by a sponge-like 
porous network. Treated membranes showed no visual deterioration of the porous 
substructure. 






Figure 4.5 Morphology of untreated PS and inductively coupled oxygen plasma treated PX 
membrane cross sections. Membranes were cast using a solution of 20% (w/w) polymer in NMP. 
Deionised water (a & c) or 70% (v/v) IMS (b & d) was used as the nonsolvent. Membranes were 
either untreated (PS) (a & b) or treated (PX) through exposure to oxygen plasma at 30 W power for 
5 min (c & d) in a vacuum. Scale bar = 50 μm. 
 
4.2.3 Surface wettability of PS and PX flat sheet membranes 
To investigate the effect of oxygen plasma treatment upon PS membrane surfaces, it was 
necessary to determine whether the method for surface modification had altered the 
membrane surface wettability. A wettable surface, otherwise termed hydrophilic, is 
conducive for cell attachment to the surfaces of biomaterials, whereas untreated PS is 
hydrophobic, therefore not providing a suitable environment for cell attachment. To assess 
the wettability of PX membranes, the sessile drop method was utilised with experimental 
conditions as described in Section 3.3.2. 






Figure 4.6 Images of water droplets on untreated PS and inductively coupled oxygen plasma 
treated PX membranes. Membranes were cast in either deionised water (a to d) or 70% (v/v) IMS 
(e to h). Analysis was via the sessile drop method measuring static water contact angles against the 
membrane surface. PX membranes were exposed to inductively coupled oxygen plasma at 30 W 
power for 1 min (b & f), 2 min (c & g) or 5 min (d & h). Untreated PS membrane surfaces were 
used as a control (a & e). Scale bar = 1 mm. 
 
Figure 4.7 Mean water contact angles for untreated PS and inductively coupled oxygen 
plasma treated PX membrane surfaces. Statistical analysis was by a one-way ANOVA with 











































Static water contact angles were measured for untreated control PS flat sheet membranes 
cast in either deionised water or 70% (v/v) IMS and treated PX membranes exposed to 
oxygen plasma for 1 min, 2 min or 5 min. All PX membranes visually displayed a decrease 
in water contact angle compared to the untreated control PS membranes (Figure 4.6). 
Comparative statistical analyses via a one-way ANOVA with Tukey’s post-hoc tests were 
then performed to examine whether there were significant differences in mean water 
contact angle between a) untreated and plasma treated surfaces for membranes cast with 
the same nonsolvent for increasing time periods and b) membranes cast using different 
nonsolvents with the same surface treatment applied. 
There were statistically significant differences between all treated surfaces compared to the 
untreated surfaces where membranes were cast with the same nonsolvent. However, there 
was no significant difference upon increasing treatment exposure time beyond 1 min. 
There was also no significant difference in contact angle between the different nonsolvents 
used for membrane fabrication, regardless of treatment exposure time (Figure 4.7). 
 
4.2.4 Surface chemistry of PS and PX flat sheet membranes 
Surface wettability is governed by chemical structures present on the surface of a material. 
In the case of developing a suitable cell culture surface, the side of the membrane exposed 
for cell attachment should not be hydrophobic. Culture media containing FBS or similar 
supplementation to aid cell attachment possess proteins such as fibronectin or vitronectin, 
which deposit upon the culture substrate and aid in cell attachment through cell adhesion 
proteins, known as integrins. A hydrophilic surface has been shown to facilitate this 
protein adsorption [169,191,192]. 
Changes in surface wettability from surface modification may signify differences in 
surface chemistry from untreated surfaces. ATR-FTIR spectroscopy was utilised to assess 
whether exposure to oxygen plasma had physically altered the chemical structure of PS 
membrane surfaces. This was assessed on membranes that had been cast in deionised water 
and also in 70% (v/v) IMS. 
Figure 4.8 and Figure 4.9 show ATR-FTIR spectra of untreated PS and inductively 
coupled oxygen plasma treated PX membranes, cast in deionised water and in 70% (v/v) 





IMS respectively. All membranes regardless of treatment showed a strong absorption peak 
at around 700 cm-1, which is indicative of the presence of C-H bonds within a benzene 
ring. Smaller absorption peaks at approximately 2920 and 3020 cm-1 signified C-H alkane 
bonds, and a small peak at 1600 cm-1 suggested the presence of aromatic C-C bonds. 
However, there was a medium peak at around 1700 cm-1 and a small peak between 3080 
and 3650 cm-1 only in the membranes that had been exposed to oxygen plasma. These 
peaks suggested the presence of C=O bonds in the form of aldehyde and ketone structures 
as well as O-H bonds in the form of carboxylic acid groups respectively. These oxygen 
functional groups were not present in the spectra of the untreated control membranes. 
Furthermore, there was no detectable difference in spectra between membranes cast using 
the two different nonsolvents, nor were there differences where oxygen plasma treatment 
time was extended beyond 1 min. 






Figure 4.8 ATR-FTIR spectra of untreated PS and inductively coupled oxygen plasma 
treated PX membranes cast in deionised water. Membranes were either untreated (a) or treated 
with inductively coupled oxygen plasma for 1 min (b), 2 min (c) or 5 min (d). Arrows in the 
overlay spectra (e) depict presence of oxygen functional groups in the treated membranes only. 






Figure 4.9 ATR-FTIR spectra of untreated PS and inductively coupled oxygen plasma 
treated PX membranes cast in 70% (v/v) IMS. Membranes were either untreated (a) or treated 
with inductively coupled oxygen plasma for 1 min (b), 2 min (c) or 5 min (d). Arrows in the 
overlay spectra (e) depict presence of oxygen functional groups in the treated membranes only. 





4.2.5 Membrane surface treatment with capacitively coupled oxygen plasma 
PS membranes investigated in this part of the study were exposed to oxygen plasma using 
a commercial Zepto Diener capacitively coupled plasma chamber as described in Section 
3.2.3. Therefore, it was necessary to confirm that the increased surface hydrophilicity and 
changes to surface chemistry observed with the inductively coupled plasma chamber were 
replicable and comparable with this system. Further wettability studies with statistical 
analysis were performed. ATR-FTIR spectroscopy and XPS were also performed to 
determine any changes between the membrane surfaces in surface chemistry. Further 
visualisation by SEM was utilised to determine any changes to surface morphology. 
Plasma power was set at 25 W and exposure time at 30 s due to no significant reduction in 
hydrophobicity or changes in surface chemistry or morphology seen beyond these 
parameters (data not shown). 
The surface morphology of capacitively coupled oxygen plasma treated PX membranes 
compared to untreated PS membrane controls is shown in Figure 4.10. All treated 
membranes presented with a smooth, nonporous surface indistinguishable from the 
untreated controls regardless of the nonsolvent used for casting. Further visualisation of 
membranes treated at 50 W power for 10 min also showed no changes in surface 
morphology compared to the untreated controls (data not shown). 
 






Figure 4.10 Morphology of untreated PS and capacitively coupled oxygen plasma treated PX 
membrane top surfaces. Membranes were cast using a solution of 20% (w/w) polymer in NMP. 
Membranes were either untreated (PS) or treated (PX) through exposure to capacitively coupled 
oxygen plasma at 25 W power for 30 s in a vacuum. (a) Deionised water nonsolvent, untreated; (b) 
70% (v/v) IMS nonsolvent, untreated; (c) deionised water nonsolvent, treated; (d) 70% (v/v) IMS 
nonsolvent, treated.  Scale bar = 5 μm. 
Figure 4.11 depicts static water droplets on the surfaces of untreated control PS and 
surfaces treated by exposure to oxygen plasma using the capacitively coupled plasma 
chamber for 30 s. All treated membranes demonstrated a reduction in static water contact 
angle compared to the untreated controls with the water droplet visibly spreading across 
the membrane surface, suggesting an increase in hydrophilicity similar to that observed 
previously in Figure 4.6. 






Figure 4.11 Images of water droplets on untreated PS and capacitively coupled oxygen 
plasma treated PX membranes. Analysis was via the sessile drop method measuring static water 
contact angles against the membrane surface. PX membranes were exposed to capacitively coupled 
oxygen plasma at 25 W power for 30 s. Untreated PS membrane surfaces were used as a control. 
(a) Deionised water nonsolvent, untreated; (b) deionised water nonsolvent, treated; (c) 70% (v/v) 
IMS nonsolvent, untreated; (d) 70% (v/v) IMS nonsolvent, treated. Scale bar = 1 mm. 
In addition, analysis between the untreated and treated membranes samples determined that 
there was a statistically significant difference between the static water contact angles of the 
two treatment conditions regardless of the nonsolvent used to originally cast the 
membranes (Figure 4.12). This behaviour was also demonstrated previously with the 
inductively coupled plasma treatment (Figure 4.7). 
 






Figure 4.12 Mean water contact angles for untreated PS and capacitively coupled oxygen 
plasma treated PX membrane surfaces. Membranes were either untreated or exposed to 
capacitively coupled oxygen plasma at a power of 25 W for 30 s. Statistical analysis was by an 
independent samples Student’s t-test. Error bars = + 1 SE; n = 3; p < 0.001. 
A further statistical comparison between the two oxygen plasma treatment methods is 
shown in Figure 4.13. The capacitively coupled plasma treatment appears to result in a 
reduced mean water contact angle when compared to the inductively coupled plasma 
treatment. However, statistical comparison via an independent samples Student’s t-test 
determined that there was no significant difference between the treatment types for either 
membrane casting method, suggesting that the two methods are comparable in affecting PS 








































Figure 4.13 Comparison between mean water contact angles for inductively coupled and 
capacitively coupled oxygen plasma treated PX membrane surfaces. Membranes were either 
exposed to inductively coupled oxygen plasma at a power of 30 W for 1 min or capacitively 
coupled oxygen plasma at a power of 25 W for 30 s. Statistical analysis was by an independent 
samples Student’s t-test. Error bars = + 1 SE; n = 3; p > 0.05. 
ATIR-FTIR analyses of untreated and treated membrane surfaces are shown in Figure 
4.14 for deionised water cast membranes and Figure 4.15 for 70% (v/v) IMS cast 
membranes. As previously observed in Figure 4.8 and Figure 4.9, all untreated and treated 
membranes showed a strong peak at 700 cm-1 indicative of benzene ring C-H bonds, 
further alkane C-H bonds with peaks at approximately 2900 and 3000 cm-1 and C-C bonds 
with a minor peak at 1600 cm-1. 
Both treated membranes showed a medium peak at approximately 1700 cm-1 and a wide 
peak between 3110 and 3650 cm-1, relating to the presence of C=O and O-H bonds. The 
capacitively coupled oxygen plasma treated spectra showed presence of oxygen functional 
groups similar to that seen in membrane surfaces treated using inductively coupled oxygen 








































Figure 4.14 ATR-FTIR spectra of untreated PS and capacitively coupled oxygen plasma 
treated PX membranes cast in deionised water. Membranes were either untreated (a) or treated 
(b) with capacitively coupled oxygen plasma at a power of 25 W for 30 s. Arrows in the overlay 
spectra (c) depict presence of oxygen functional groups on the treated membrane surface only. 






Figure 4.15 ATR-FTIR spectra of untreated PS and capacitively coupled oxygen plasma 
treated PX membranes cast in 70% (v/v) IMS. Membranes were either untreated (a) or treated 
(b) with capacitively coupled oxygen plasma at a power of 25 W for 30 s. Arrows in the overlay 
spectra (c) depict presence of oxygen functional groups on the treated membrane surface only. 
Further examination of surface chemistry utilised XPS analysis to quantify the elemental 
composition of the untreated and oxygen plasma treated membrane surfaces. XPS is able to 
detect resonance peaks for specific surface atoms dependent on electrons ejected from the 
sample surface upon irradiation by X-rays. As PS is a hydrocarbon polymer and added 
oxygen functional groups were apparent from the ATR-FTIR spectra after plasma 
treatment, the elements particularly of interest were C and O. Figure 4.16 shows the XPS 
survey spectra of untreated PS and oxygen plasma treated PX membranes. 






Figure 4.16 XPS survey spectra of untreated PS and capacitively coupled oxygen plasma 
treated PX membranes. Membranes were either untreated or exposed to capacitively coupled 
oxygen plasma at a power of 25 W for 30 s. Intensity of binding energy (eV) peaks is shown as 
counts per second (CPS). (a) Deionised water nonsolvent, untreated; (b) 70% (v/v) IMS 
nonsolvent, untreated; (c) deionised water nonsolvent, treated; (d) 70% (v/v) IMS nonsolvent, 
treated. 
In all conditions, a high intensity peak at 284 eV was detected, which is indicative of a 
large presence of elemental C. Medium intensity peaks at 533 eV, representative of 
elemental O, were detected in the oxygen plasma treated membrane surfaces. However, 
this peak was negligible in the untreated membrane surfaces. 
  





Table 4.1 Mean elemental C and O compositions of untreated PS and capacitively coupled 
oxygen plasma treated PX membrane surfaces. Statistical analysis was by independent samples 
Student’s t-tests and a one-way ANOVA with Tukey’s posthoc tests. 
Membrane Nonsolvent Treatment Mean [C1s] Atomic % Mean [O1s] Atomic % 
Deionised water 
Untreated PS 95.19 ± 1.32 *** 4.81 ± 1.32 *** 
Treated PX 85.91 ± 1.16 ### +++ 14.09 ± 0.34 ### +++ 
70% (v/v) IMS 
Untreated PS 98.37 ± 0.34 1.63 ± 1.16 
Treated PX 81.84 ± 0.42 +++ 18.17 ± 0.43 +++ 
± 1SE; n = 3; *** = (p = 0.001) (untreated only); ### = (p < 0.001) (treated only); 
+++ = (p < 0.001) (untreated vs treated) 
The mean atomic % of C and O for each membrane condition is shown in Table 4.1, given 
as the ratio of peak intensity to the total intensity of electrons measured. The O atomic % 
was higher for all PX membranes compared to untreated membranes. Statistical analyses 
were then performed to determine whether there were any significant differences between 
untreated membranes only, treated membranes only and also between untreated 
membranes and their treated counterparts. 
An independent samples Student’s t-test was used to compare elemental compositions 
between untreated deionised water cast and 70% (v/v) IMS cast PS membranes. It was 
determined that there was a statistical difference between the two untreated membranes 
with the untreated PS membrane cast in deionised water showing a higher O atomic % than 
the untreated IMS-cast  membrane (p = 0.001). There was also a significant difference in O 
atomic % between treated deionised water cast and 70% (v/v) IMS cast PX membranes (p 
< 0.001). 
Further analysis via a one-way ANOVA with Tukey’s posthoc tests showed that there was 
a strong statistical difference in atomic C and O for both PX membranes versus their 
untreated counterparts (p < 0.001). 
 






The research aims for this Chapter were to characterise a method for the development of 
polystyrene hollow fibre membranes using phase inversion cast flat sheet membranes as a 
model system. Two potential ternary systems and the subsequent membrane surface 
treatments with inductively coupled and capacitively coupled oxygen plasmas were 
examined and characterised to generate a biomaterial suitable for adherent cell culture in a 
hollow fibre membrane bioreactor system. 
 
4.3.1 Selection of ternary system for casting polystyrene membranes 
To successfully cast a membrane, it is necessary to establish polymer dissolution in the 
chosen solvent, and subsequent precipitation in a suitable nonsolvent. The eventual 
membrane characteristics are dependent upon the ternary system utilised. The ternary 
system components analysed in this part of the thesis were selected on the basis of their 
considerably documented usage in tissue culture, previous phase inversion membrane 
casting and safety – PS is currently the most widely used cell culture substrate; NMP is an 
FDA-approved solvent that has previously been utilised to dissolve polymers for 
membrane fabrication and water and 70% (v/v) IMS are relatively safe nonsolvents 
frequently used for cell culture. In particular, 70% (v/v) IMS was selected as a potential 
substitute nonsolvent for water due to its use as a disinfecting agent in aseptic cell culture, 
with the consideration that the potential membrane would be cast within an environment 
less conducive to bacterial infection. It has also been previously shown that ethanol-wetted 
foams can improve wettability upon hydrophobic polymers due to liquid phase mixing 
within the porous structure between water and a surface pre-wet with ethanol due to their 
high mutual affinities [193,194]. Furthermore, the formation of a porous membrane is 
encouraged by a mutual affinity between solvent and nonsolvent as well as the 
concentration of the polymer in the dope solution. 
A 20% (w/w) mixture of PS in NMP dissolved entirely into the liquid phase overnight, 
forming a homogenous solution. Subsequent immersion of the dope into water or 70% 
(v/v) IMS caused a white PS precipitate to form. This is a process termed liquid-liquid 
demixing, occurring due to the addition to the polymer-solvent system of a large volume of 
nonsolvent such that the binodal point of the ternary system is surpassed [159]. This 





generates thermodynamic instability in the polymer-solvent solution, thus causing 
precipitation of the polymer [159]. In the PS-NMP-water/70% (v/v) IMS ternary system, 
this behaviour was aided by the miscibility of NMP and comparative immiscibility of PS 
with both nonsolvents. 
PS membrane precipitation behaviour differed depending upon the nonsolvent used. 
Membranes cast using deionised water precipitated almost immediately and lifted away 
from the coagulation plate easily, whereas immersion of the dope in 70% (v/v) IMS caused 
the membranes to precipitate more slowly before lifting away from the plate. The faster 
precipitation behaviour of water-cast membranes infers a more instantaneous demixing of 
polymer from solvent, whereas 70% (v/v) IMS-cast membranes demonstrated a more 
delayed demixing process due to the slower membrane precipitation. This demixing 
behaviour is linked to the solubility of NMP in the respective nonsolvents – increased 
solubility of the solvent in the nonsolvent is a factor that favours a more instantaneous 
form of demixing, suggesting that water has a greater solubility in NMP than 70% (v/v) 
IMS. 
These initial observations show that both ternary systems are able to produce a polymer 
precipitate. However, the differences in solubility of NMP in deionised water or 70% (v/v) 
IMS and differing rates of demixing will affect the resultant structure of the membrane. To 
replicate the physiological environment of the liver in vitro it is necessary for the 
membrane to possess a porous structure, thus allowing diffusion of molecules of a certain 
molecular weight across the membrane substructure. By adjusting the components of the 
ternary system involved to alter the rate of demixing, such as the solubility of solvent and 
nonsolvent, this can aid the formation of surface and substructure pores during membrane 
fabrication. As cells will be cultured on the membrane surface, it is essential that any pores 
present on the surface cannot be greater in size than 5 μm as cells may migrate into the 
substructure [154]. In this case, the top surfaces of both water-cast flat sheet membranes 
and 70% (v/v) IMS-cast membranes were shown to be very smooth with no visible pores, 
suggesting that these nonsolvents are unable to produce porous membranes as part of this 
system. 
A line of investigation previously explored in this laboratory had examined the effect on 
PS flat sheet membrane morphology where the membranes were cast using 20% (w/w) PS 
in 1, 4-dioxane or dimethylformamide as solvents with deionised water as the nonsolvent. 





Both solvents are miscible with water and membranes cast using these solvents had visible 
surface pores in contrast to the PS-NMP dopes, also with highly porous substructures. 
However, the surface pores were sparsely present and averaged between 20 – 100 μm in 
diameter – considerably larger than the required 5 μm diameter [195].  It was also shown 
that casting of membranes where the PS concentration was reduced to 10% (w/w) in a 
dope solution with NMP, 1,4-dioxane or DMF in water did not produce a membrane with 
surface pores [195]. Although a high polymer concentration can result in a less porous top 
layer, a lower concentration would affect the solution viscosity and therefore the capability 
of the dope solution to form mechanically stable hollow fibres. It is therefore likely that the 
polymer itself is the cause of the lack of pore formation on the membrane surface. 
The cross sectional membrane substructures were highly porous with long finger-like 
macrovoids. In the water-cast membranes, these macrovoids presented in the lower third of 
the substructure, whereas in membranes cast in 70% (v/v) IMS showed macrovoids 
descending perpendicularly from the surface, approximately two-thirds the depth of the 
membrane. In both membrane types, the macrovoids were contained within a spongy layer 
that consisted of smaller porous substructures. 
The presence of macrovoids in both systems suggests that the rate of demixing experienced 
during the phase inversion process is rapid rather than delayed. As previously mentioned, 
the membranes cast in 70% (v/v) IMS took longer to coagulate than the water-cast 
membranes, suggesting it had undergone a more delayed demixing. However, a fully 
delayed demixing process would not generate macrovoids but a spongy layer with small 
pores. This was shown in a previous study comparing NMP and 1,4-dioxane as solvents in 
a PLGA phase inversion membrane system with water as the nonsolvent, it was shown that 
the NMP-cast membranes, which contained macrovoids, tended towards instantaneous 
demixing. This was a feature absent in 1,4-dioxane-cast membranes, which possessed a 
spongy substructure due to delayed demixing [154] from the higher affinity of the solvent 
to the polymer. Therefore, it is likely that although the 70% (v/v) IMS-cast membranes 
took longer to coagulate, the reduced rate of demixing compared to water-cast membranes 
was still rapid enough to allow for a similar macrovoid-containing substructure to develop. 
Macrovoids are considered to be unfavourable as they can lead to mechanical weaknesses 
in the membrane structure [159,196]. This is seen in systems operating at higher pressures; 
for example, in gas separation [159,196]. However, a similar high pressure operating 





system is not required for the intended application. A study by Ellis and Chaudhuri in 2007 
characterised PLGA phase inversion hollow fibre membranes as tissue engineering 
scaffolds and suggested that macrovoids in the membrane structure could be considered a 
positive feature [154]. This is due to reduced flow resistance through the macrovoids, yet 
still providing suitable support for other porous sublayers [154]. Therefore, the presence of 
macrovoids in these PS phase inversion membranes should not considered a negative 
feature. 
 
4.3.2 Surface modification of polystyrene membranes by plasma treatment 
To reduce the surface hydrophobicity of polystyrene membranes, both water-cast and 70% 
(v/v) IMS-cast PS membranes were exposed to oxygen plasma. Plasma treatment allows 
for changes to surface characteristics such as wettability and chemistry whilst leaving the 
properties of the bulk material largely unaltered [166]. Where inductively coupled oxygen 
plasma is generated through an electric field in oxygen gas induced from a magnetic field 
generated from a running an RF current through a coil wrapped around the plasma 
chamber, capacitively coupled plasma is generated from an electrical discharge occurring 
between electrodes in oxygen gas [197]. Both inductively coupled and capacitively 
coupled methods of plasma generation form low pressure plasmas which have been used to 
surface treat the membranes investigated in this chapter. 
The surface morphology of membranes exposed to inductively coupled oxygen plasma 
differed between water-cast and IMS-cast membranes dependent upon exposure length. 
Treated and untreated water-cast membranes all presented with smooth surfaces with no 
pores visible. For IMS-cast membranes, surface pores were visible post-treatment, 
increasing in number with greater exposure time, although for both membranes, there was 
no visual deterioration in the bulk substructure. Increases in surface roughness due to 
oxygen plasma exposure have been previously seen in PS, PLGA and polypropylene films 
[198–201]. Therefore, the change in morphology to a more porous surface is attributable to 
the increased exposure to inductively coupled oxygen plasma. From this, oxygen plasma 
alone could be potentially used to generate a porous surface without considerably altering 
the porous substructure. However, the lack of pores in the treated water-cast membrane 
surfaces and also the capacitively coupled oxygen plasma treated samples even at higher 





power and increasing time of exposure suggests that this method may not be entirely relied 
upon. Previous examples of surface topography change signified by increased surface 
roughness have been shown in microwave oxygen and argon plasma treated PS culture 
dishes whilst maintaining the effect of increased hydrophilicity [202]. These changes have 
also been seen in inductively coupled oxygen plasma treatment of PS films [201,203] so 
both methods can be utilised for functionalisation of PS substrates to produce a surface 
altered, less hydrophobic material. The lack of visual change described in this Chapter in 
PS flat sheet membranes upon exposure to capacitively coupled plasma does not 
necessarily preclude changes in the surface structure due to limitations with SEM being a 
visual medium. Further analysis by atomic force microscopy (AFM) would provide a 
topographic image from which to determine further surface structure differences between 
untreated and treated membranes, therefore guiding future optimisation of the plasma 
treatment method to produce a porous surface. AFM can further be used to determine the 
stiffness of the culture substrate, which is a factor that can affect the behaviour of cultured 
cells [204]. Further analysis into the stiffness of untreated and treated membranes would 
also develop characterisation of the biomaterial further. Culture substrate stiffness is an 
additional factor in determining the ability of cells to attach to the substrate surface and 
undergo normal cellular functions such as proliferation, differentiation and tissue specific 
functions [205]. Furthermore, it should also be noted that excessive exposure to plasma 
etching may penetrate through into the bulk structure and mechanically weaken the 
membrane so this approach may not be optimal if long sample exposure time or high 
power is required to generate the plasma [206]. To determine if the plasma treatment has 
affected the mechanical properties of the biomaterial positively or negatively, further work 
necessitates comparative measurements of tensile strength and also elasticity of untreated 
and treated membranes dependent upon the length of exposure to oxygen plasma. This 
analysis would aid tailoring of the plasma treatment method to ensure that the treated 
membrane will possess the changes in surface wettability and chemistry with little to no 
mechanical weakening of the structure.  Both PS membranes when treated with oxygen 
plasma showed reductions in hydrophobicity compared to untreated membranes from static 
water contact angle measurements. Using inductively coupled plasma, exposure beyond 1 
min did not reduce hydrophobicity further, suggesting that there is no added improvement 
for longer exposure time. Capacitively coupled oxygen plasma showed reduction in 
hydrophobicity after 30 s exposure. A possible reason for the lack of improvement with 





longer exposure times may be due to the method utilised to examine changes in surface 
energy. Although the sessile drop method and subsequent measurement of static water 
contact angles are widely used to determine hydrophobicity of a surface, there are 
limitations with this method that may cause variations in results. Such variations altering 
the reported contact angle include evaporation of the water droplet or infiltration of the 
droplet to exposed sections of porous substructure [207,208]. In the case of these results, 
the contact angle measurement was taken immediately after releasing the droplet, thus 
minimising any evaporation effect. However, water infiltration of the membrane due to 
exposure to the porous membrane substructure may have affected contact angle 
measurement by increasing the difficulty of distinguishing between samples with greatly 
reduced contact angles with the goniometer, particularly as no statistical differences were 
found when increasing initial plasma exposure time. Differences in surface chemistry 
between untreated deionised water-cast and IMS-cast membranes and their treated 
counterpart were observed. Quantification of surface elemental C and O showed a 
statistically significant increase in elemental O in untreated deionised water-cast PS 
membranes compared to untreated IMS-cast membranes. However, this increase did not 
correlate with detectable presence of added oxygen functional groups in the membrane 
surface nor a significant improvement in wettability over untreated IMS-cast membranes. 
Treated membranes were observed to have detectable presence of added oxygen functional 
groups with the increase in surface elemental O deemed statistically significant, and also 
between treated deionised water and 70% (v/v) IMS membranes. Furthermore, these 
changes in surface chemistry in the treated membranes correlate with the reduced water 
contact angles similarly observed in the treated membranes only, although there were no 
further differences in wettability between treated membranes cast from different 
nonsolvents. These alterations in PS surface chemistry have also been observed in previous 
studies examining oxygen plasma treatment of PS films [209] and non-tissue culture PS 
dishes [202,210], where wettability was increased and carbonyl and alcohol structures 
were found to be present upon the treated substrate surface. This therefore suggests that 
fabricating PS membranes via phase inversion are similarly able to have their 
hydrophobicity reduced upon treatment with oxygen plasma. Although both ternary 
systems are suitable for casting hollow fibres, the use of capacitively coupled plasma 
treatment was unable to replicate the results of the inductively coupled plasma treatment to 
produce a porous surface on 70% (v/v) IMS cast membranes, even though both methods 





are used to produce similar low pressure oxygen plasmas. Therefore, both ternary systems 
are considered comparable in the case of increased wettability and lack of surface pores 
when treated with oxygen plasma generated using the capacitively coupled method. 
A future experimental approach to take into consideration is the analysis of potential 
hydrophobic recovery of plasma treated surfaces. Hydrophobic recovery describes the loss 
of modifications to the surface energy of a treated surface over time, although the extent 
that this occurs to treated PS surfaces appears to vary within the literature [211,212]. A 
potential situation that may arise would be an increase in PX membrane hydrophobicity 
and therefore potentiate a risk that the membrane will revert to being non-conducive to 
adherent cell culture. A possible approach would be to perform a long-term time-course 
examination utilising contact angle measurements to determine if wettability is reduced. 
Furthermore, a time-course assessment of cell attachment would determine the overall 
long-term efficacy of the biomaterial. 
 
4.4 Conclusion 
This Chapter has examined the development and characterisation of phase inversion cast 
PS membranes that could be used as a cell culture substrate in a hollow fibre membrane 
setting. Two ternary systems have been developed utilising a 20% (w/w) PS-NMP casting 
solution and either deionised water or 70% (v/v) IMS as a nonsolvent. Both systems were 
able to produce asymmetrical membranes possessing a nonporous top skin over a highly 
porous substructure. The lack of pore structure on the membrane surfaces suggest that the 
membranes are potentially able to support cell culture without the cells entering the 
membrane substructure. However, surface pores of no greater than 5 μm diameter are 
required to ensure the cells do not enter the membrane substructure. Therefore, the phase 
inversion casting method described here is not sufficient on its own for providing 
completely porous membranes from surface to substructure. Further work in this area to 
develop a porous membrane could examine additional surface treatments, such as sodium 
hypochlorite, or the addition of porogens such as sodium chloride to the casting dope. 
Utilising an additional method could tailor the pore size further to a specific MWCO. 
Subsequent surface treatments with inductively coupled and capacitively coupled oxygen 
plasma were able to significantly reduce the hydrophobicity of the untreated membranes by 





the addition of oxygen functional groups. This could create an environment more 
conducive to cell attachment as well as possibly providing a method for generating a 
porous top skin in the case of inductively coupled plasma treatment and 70% (v/v) IMS 
cast membranes. In addition, this would allow for intra- and extraluminal nutrient diffusion 
without the loss of cells into the membrane substructure, although further work will be 
required to optimise a suitable method for developing surface pores. Capacitively coupled 
oxygen plasma treated deionised water and 70% (v/v) IMS membranes were comparable in 
their reduction of surface wettability, important for encouraging cell adhesion to the 
membrane surface. 
Further membrane experimental work in this thesis utilises capacitively coupled oxygen 
plasma treatment to increase surface wettability of membrane surfaces. Although this 
method was unable to replicate the appearance of surface pores seen when treating 70% 
(v/v) IMS membranes using inductively coupled plasma, the PS-NMP-water system and 
PS-NMP-IMS system under capacitively coupled oxygen plasma treatment were 
comparable with regards to changes to surface wettability and addition of oxygen 
functional groups. Bearing the scale up costs in mind, from a process point of view, water 
was selected as a more cost effective nonsolvent to study further with regards to 
developing a suitable membrane. Therefore, further work in this thesis sought to determine 
the suitability of the PS-NMP-water system as a biomaterial for supporting cell culture. 
  






Characterisation of induction and 
maintenance media for the 
transdifferentiation of pancreatic cells 
to hepatocyte-like cells 
5.1 Introduction 
5.1.1 Transdifferentiated hepatocyte-like cells as a cell source for bioartificial 
liver devices 
An orthotopic liver transplant allows for the restoration of physiological liver function to 
patients with liver failure. However, a shortage of suitable donor livers means that many 
patients die whilst waiting on the transplant list. The principle behind the bioartificial liver 
(BAL) device as a therapeutic biotechnology allows a patient with liver failure to maintain 
liver function until an organ transplant becomes available. Furthermore, the ability to 
replicate liver structure and functions is additionally useful as an in vitro liver model. The 
motive behind this would be to use such models as a replacement for animal models which 
are currently used for drug toxicity testing and also in understanding liver development and 
functionality. 
Given the lack of donor livers it is essential to find a suitable functional substitute that can 
be sourced from a regular supply. Transdifferentiated hepatocyte-like cells (HLCs) provide 
a novel approach to sourcing cells for a BAL device. Transdifferentiation (or cellular 
reprogramming) is defined as the conversion of one differentiated cell type to another, and 
is considered a type of metaplasia [213,214]. This process has been documented in rats 
with the appearance of HLCs in the pancreas when fed a copper-deficient diet [215]. 
Human cases of hepatoid carcinomas occurring in the pancreas demonstrate that this is not 
solely an animal phenomenon, nor is it  purely an in vivo occurrence either [216]. An in 





vitro model was developed utilising the rat pancreatic acinar cell line AR42J-B13 (B13), a 
subclone of the AR42J line. The B13 subclone has been shown to be more susceptible to 
differentiation down endocrine lineages than its parent line [130,217]. B13 cells have been 
shown to readily transdifferentiate into HLCs when cultured with Dexamethasone (Dex) 
with loss of the pancreatic phenotype [130] and gain of hepatic markers. This involves  
induction of CCAAT/enhancer binding protein beta (C/EBPβ), considered the ‘master 
switch’ for direct conversion; and hepatocyte nuclear factor 4 alpha (HNF4α), essential for 
hepatic differentiation, within the first 2 days of treatment. This is followed by expression 
of a range of mature liver markers such as transferrin (TFN), glucose-6-phosphatase and 
albumin with continued treatment [130–132,218]. 
Transdifferentiation of pancreatic cells to HLCs using this method has also been 
demonstrated in mouse embryonic pancreas [136] and primary mouse, rat and human 
pancreatic cells [134,135,219–221]. The addition of Oncostatin M (OSM) to the culture 
medium has been shown to enhance the conversion to a hepatic phenotype and upregulate 
the production of acute phase proteins, essential for the inflammatory response of the 
immune system [130–132,218]. As well as transdifferentiating to HLCs, the B13 cell line 
has shown plasticity in its ability to convert to other cell types such as insulin producing β-
cells [217] and ductal cells [222], displaying similar functionalities to their primary 
counterparts. 
Characterisation of transdifferentiated HLCs has shown that they possess a wide range of 
hepatic functions including expression of both ammonia detoxification enzymes glutamine 
synthetase (GS) and carbamoylphosphate synthetase-1 (CPS-1) in different cell 
populations, reflecting their zonation along the porto-venous axis [4,14,218]. They also 
show long term expression of functional cytochrome P450 (CYP) enzymes [223], 
responsiveness to the xenobiotics ciprofibrate and phenobarbitol [131,218] and can support 
replication of Hepatitis B virus [133], displaying functional similarity to primary 
hepatocytes which makes them an ideal candidate for a BAL device cell source. As B13 
cells come from an established cell line that can be readily cultured in vitro, 
transdifferentiated HLCs, with their wide range of hepatic functions, also offer a potential, 
limitless alternative to other cell sources for drug toxicity models. However, an issue with 
this cell source is that not all B13 cells lose their pancreatic phenotype upon treatment 
[129]. Furthermore, the functional maturity of transdifferentiated HLCs when compared to 





mature hepatocytes is unclear, warranting further investigation into improving the 
transdifferentiation protocol. 
Greater understanding of the mechanisms behind transdifferentiation as a whole can help 
guide understanding of the factors involved in normal development. For example, 
transdifferentiated HLCs are also useful as an in vitro model for investigating the 
background behind pancreatic and liver development. The ability of pancreatic cells to 
convert to hepatocytes belies their similar developmental origins as during embryonic 
development they originate from the same region of the endoderm [218]. This knowledge 
can also be translated to guide the development of new cellular therapies utilising stem cell 
reprogramming. In addition, knowledge of transdifferentiation can aid the understanding 
behind certain metaplastic events such as in Barrett’s metaplasia, as metaplasia is often a 
precursor to cancer development [224–226]. 
 
5.1.2 HepatoZYME+ as an induction and maintenance medium for 
transdifferentiated HLCs 
The original method for the transdifferentiation of pancreatic cells to HLCs initially 
utilised supplementation of the complete B13 culture medium with the glucocorticoid 
hormone Dex [130]. Initially, treatment of the B13 cell line with Dex would stimulate an 
upregulation of amylase exocrine function beyond that of naïve cells; similar behaviour to 
that previously reported in the parent AR42J cell line [217]. It was found that with 
prolonged glucocorticoid stimulation, this expression decreased over time along with 
subsequent induction of hepatic markers, displaying a loss of pancreatic phenotype toward 
a hepatic one [130]. As previously mentioned, additional supplementation with OSM 
alongside Dex improved the hepatic phenotype beyond that seen from culturing with Dex 
alone [130–132]. Interestingly, B13 cells express c-Myc, Klf4, Oct4 and Sox2, known as 
the four pluripotency factors [227]. After glucocorticoid treatment, c-Myc remains as the 
only one active, and it has been hypothesised that maintenance of a pluripotent phenotype 
provides the B13 cell line with its ability to transdifferentiate into different cell types 
[129,227]. 
The basal culture medium HepatoZYME-SFM is a proprietary serum-free medium that has 
previously been used for the long term maintenance of hepatic phenotypic expression for 





the culture of isolated primary rat and human hepatocytes [228,229]. From a 
manufacturing process point of view, consistency in the protocol is essential for scale up 
for clinical usage so that there are no variations in the quality of the product. Serum-free 
media are attractive as foetal bovine serum (FBS), although commonly used in tissue 
culture media to aid attachment of adherent cells to culture substrates, suffers from issues 
such as wide batch-to-batch variability that can affect product optimisation as well as 
ethical issues with sourcing [230–232]. 
A protocol supplementing HepatoZYME-SFM with the glucocorticoid Hydrocortisone (10 
μM), the cytokines hepatocyte growth factor (HGF) (10 ng/ml) and OSM (20 ng/ml) 
(HepatoZYME+) reported promising results for improvement of the hepatic phenotype as 
part of the directed differentiation of human embryonic stem cells (hESCs) and induced 
pluripotent stem cells (iPSCs) to HLCs over other specialised hepatocyte media [121,233–
235]. On the basis of this, the hepatic differentiation and maturation qualities of the serum- 
free HepatoZYME+ medium were of interest as a potentially novel culture medium that 
could be translated to the B13 transdifferentiated HLC model as a possible inducing agent 
and maintenance medium. 
 
5.1.3 Experimental aims and objectives 
The experimental research in this Chapter involves the characterisation of two potential 
culture media – HepatoZYME+ and 50:50 – for the induction of transdifferentiation of the 
pancreatic B13 cell line to HLCs in comparison with established Dex-based protocols. The 
50:50 culture medium consisted of HepatoZYME+ diluted 1 in 2 with the complete B13 
culture medium, therefore containing half the supplementation concentrations of 
HepatoZYME+ - Hydrocortisone (5 μM), HGF (5 ng/ml) and OSM (10 ng/ml).  The 
research questions to be answered here were whether HepatoZYME+ could a) induce 
conversion to HLCs in the B13 cell line when compared to Dex-treated cells; and b) 
produce HLCs with an improved hepatic phenotype beyond that already established by 
Dex-induced transdifferentiation. 
The effects of the culture media on the cell line and transdifferentiated HLCs as potentially 
novel methods of inducing and maintaining this state were characterised with regards to 
their morphology and expression of gene and protein markers. The first part of this Chapter 





describes the treatment of the B13 cells with the experimental culture media to induce 
transdifferentiation, and the second part investigates use of the experimental culture media 
to maintain transdifferentiated HLCs. 
Characterisation of untreated and treated cells was done via analyses of (i) morphology by 
transmitted light microscopy; (ii) protein expression by immunofluorescent staining with 
fluorescent microscopy; (iii) protein expression quantification and finally (iv) gene 
expression by RT-PCR. 
 
5.2 Results 
5.2.1 Characterisation of transdifferentiation in B13 cells using 
HepatoZYME+-based media 
Prior to treatment, B13 cell cultures were initially maintained in complete B13 culture 
medium as described in Section 3.4.1. The efficiency of transdifferentiation has previously 
been found to be affected by the initial cell seeding density, where seeding at too high a 
density demonstrated resistance to conversion toward a hepatic phenotype [236,237] and 
seeding too sparsely showed low cell growth and conversion rates [236]. Therefore, an 
initial seeding density of 30,000 cells per well of a standard cell culture 6-well plate (3,125 
cells/cm2) was utilised for the experiments in this Chapter. 
24 hr post seeding, the B13 cell culture medium was supplemented with either 1 μM Dex 
or changed completely to HepatoZYME+ or a 50:50 combination of complete B13 culture 
medium and HepatoZYME+, referred to as “50:50”. B13 cells cultured in complete B13 
culture medium only were used as an untreated control. 






Figure 5.1 Morphology of B13 cells in different induction media over 5 days. Cells were 
treated without (a) or with 1 μM Dex, (b) HepatoZYME+ (c) or 50:50 (d). Areas demarcated by 
dashed lines show cells with an enlarged, flattened, hepatocyte-like morphology (b & d) compared 
to the untreated control (a). Arrows indicate areas of dead or dying cell colonies (c). Scale bar = 50 
μm. 
Morphological changes in the cells over 5 days of treatment were visualised through 
transmitted light microscopy as shown in Figure 5.1. Compared to the untreated control, a 
flattening and enlargement of cell morphology was observed in some cells of the Dex-
treated and the 50:50-treated cultures, a trait seen previously in the transdifferentiation of 
B13 cells to a hepatocyte-like phenotype. However, after 5 days, the cells cultured in the 
HepatoZYME+ medium did not exhibit this behaviour. The colonies initially took on a 
star-shaped morphology after 24 hr of treatment. After 2 days the cells had vacuoles 
present in the cytoplasm, and at 5 days, the cells had shrivelled in shape and were 
detaching from the culture surface, with some dead colonies present. Reducing the 





concentration of Hydrocortisone to 1 μM did not improve cell survival with similar loss of 
colony viability over 24 hr (data not shown). Similar shrivelling, cytoplasmic vacuolation 
and dead colonies were also observed in the 50:50-treated cells, although the rate of 
occurrence was reduced. 
Due to lack of survival of the HepatoZYME+ cultures beyond 5 days, further analysis 
sought to identify whether the thriving cultures containing cells with flattened morphology 
were tending towards a functioning HLC phenotype rather than a pancreatic one. 
Immunofluorescent staining was utilised to identify protein expression of pancreatic and 
liver markers in Dex-treated and 50:50-treated cells after 9 days of culture, with the B13 
cells treated under normal maintenance conditions used as a pancreatic control. 






Figure 5.2 Expression of the pancreatic marker amylase in B13 cells cultured in different 
induction media. Cells were treated without (a – c) or with 1 μM Dex (d – f) or 50:50 (g – i) for 9 
days. Cells were stained for the pancreatic marker amylase (green) and nuclei stained with DAPI 
(blue). Images (c), (f) and (i) are composites of (a & b), (d & e) and (g & h) respectively. Dex and 
50:50 cultures showed a reduction in amylase expression compared to the control. Scale bar = 20 
μm. 
Staining for the pancreatic marker amylase is depicted in Figure 5.2. All cultures showed 
cells positive for amylase expression, although not all the cells in the Dex-treated and 
50:50-treated cultures were positive for amylase, in comparison to the B13 controls where 
all the cells were positive for amylase, suggesting reduced expression in the treated 
cultures. Amylase also appeared to be present in some of the larger, flatter cells in the 
50:50 cultures. 






Figure 5.3 Expression of the hepatic marker CPS-1 in B13 cells cultured in different 
induction media. Cells were treated without (a – c) or with 1 μM Dex (d – f) or 50:50 (g – i) for 9 
days. Cells were stained for the ammonia detoxifying liver enzyme CPS-1 (green) and nuclei 
stained with DAPI (blue). Images (c), (f) and (i) are composites of (a & b), (d & e) and (g & h) 
respectively. Dex and 50:50-treated cultures contained cells that were positive for CPS-1 
expression. Scale bar = 20 μm. 
Figure 5.3 and Figure 5.4 show immunofluorescent staining of the hepatic markers CPS-1 
and HNF4α under the different culture conditions. CPS-1 characteristically displays a 
distinct punctate staining in the cytoplasm and was clearly expressed within some cells in 
the Dex-treated and 50:50-treated cultures. The Dex-treated and 50:50-treated cultures 
showed expression of HNF4α in some nuclei, with reduced expression in the 50:50-treated 
cultures compared to Dex-treated cells. Neither of these liver markers was visible in the 
B13 cell control cultures. 






Figure 5.4 Expression of the transcription factor HNF4α in B13 cells cultured in different 
induction media. Cells were treated without (a – c) or with 1 μM Dex (d – f) or 50:50 (g – i) for 9 
days. Cells were stained for the liver transcription factor HNF4α (red) and nuclei stained with 
DAPI (blue). Images (c), (f) and (i) are composites of (a & b), (d & e) and (g & h) respectively. 
Dex and 50:50-treated cultures contained cells positive for HNF4α expression. Scale bar = 20 μm. 
The presence of hepatocyte markers in the Dex-treated and 50:50-treated cultures with 
reduction of amylase expression as seen in the B13 culture control suggests that the 
treatment had induced some cells to convert to an HLC phenotype. However, the presence 
of vacuolated cells and dead colonies in the 50:50-treated cultures, which were absent in 
the Dex-treated cultures, suggest that although this medium composition alone is able to 
induce transdifferentiation to HLCs, long term survival is less likely compared to the Dex-
treatment alone. 
 





5.2.2 Characterisation of HepatoZYME+-based media as a post-induction of 
transdifferentiation treatment for B13 cells 
Given the loss of cell viability visualised when solely using HepatoZYME+ or 50:50 as 
transdifferentiation induction and maintenance medium, further studies sought to 
determine the characteristics of B13 cultures that had already been induced to 
transdifferentiate to HLCs. These experiments utilised initial supplementation with 1 μM 
Dex and 10 ng/ml Oncostatin M (OSM) (referred to as ‘Dex + OSM’). The combination of 
Dex + OSM in the transdifferentiation culture medium has previously shown enhancement 
of the transdifferentiation process and hepatic phenotype compared to supplementing the 
culture medium with Dex alone [130,132].  
Previously, sole use of 50:50 medium was shown to be able to induce some B13 cells to 
convert to a flattened HLC morphology and express liver markers, whereas culture in 
complete HepatoZYME+ encouraged loss of cell viability. Previous work in the literature 
examining the transdifferentiation of B13 cells to HLCs under treatment with Dex + OSM 
have treated cells for up to 14 days with 80-90% of cells converting to HLCs after 7 days 
[237]. This provided an initial benchmark to compare the effect of the 50:50 culture 
medium on the B13 cultures. 
B13 cells were initially treated for 7 days with complete B13 medium supplemented with 
Dex + OSM. After 7 days, the cultures either continued treatment with Dex + OSM or the 
medium was changed to the 50:50 composition. B13 cells cultured in complete B13 
medium were used as a control. Initial experiments using HepatoZYME+ instead of 50:50 
caused loss of culture viability (data not shown). Therefore, the initial investigation here 
was to assess the capability of the 50:50 composition to maintain conversion of the hepatic 
phenotype on pre-induced cells. 
Morphological assessment of the cultures at 7, 10 and 14 days of treatment is shown in 
Figure 5.5. After 7 days of Dex + OSM treatment, the majority of cells had converted to a 
larger, flattened morphology in contrast to the control culture with the presence of 
binucleate cells indicative of HLCs. At this point, the culture medium was changed to the 
50:50 composition. After 10 days of culture, the cells cultured only in Dex + OSM 
continued to present with flattened morphology with further binucleate development, with 
some cells taking on a more regular ‘polygonal’ shape. 






Figure 5.5 Morphology of B13 cells cultured in different transdifferentiation media for 14 
days. Cells were treated with Dex + OSM only for 14 days (b - d) or initially treated with Dex + 
OSM for 7 days before changing culture medium to 50:50 for the remaining 7 days (e & f). Cell 
morphology is shown at 7 days (b), 10 days (c & e) and 14 days (d & f) of culture. Comparative 
B13 cell morphology control is shown after 4 days of culture (a). Arrows indicate examples of 
polygonal HLC morphology. Scale bar = 50 μm. 





The cells cultured in the 50:50 composition, having been treated for 3 days since the switch 
from Dex + OSM medium, also contained cells with the binucleate trait, but appeared to be 
larger in size and less regular in shape. Distinctly elongated cells and vacuoles appeared to 
take up the majority of cytoplasmic space, similar to that observed in Figure 5.1d. After 14 
days of culture, the Dex + OSM only cultures had retained their flattened, polygonal 
morphology in tight colonies as seen after 10 days, whereas the cells cultured in 50:50 
were not in tight colonies and appeared  more rounded. The cells were also elongated and 
irregularly shaped. Several cells were also observed to be multinucleate, possessing 
numbers of nuclei ranging from 2 to 6, as well as being highly vacuolated within the 
cytoplasm. 
Immunofluorescent staining sought to identify and compare protein expression of 
pancreatic and liver markers within these cultures after 14 days of treatment. After 7 days 
of Dex + OSM treatment a mixed population of cells expressing the pancreatic marker 
amylase that contained both rounded B13 and flattened HLC morphologies was visible, 
although there were some flattened HLCs negative for amylase. By 14 days, expression of 
amylase appeared to be largely absent in Dex + OSM only-treated cells, particularly those 
possessing the enlarged, flattened HLC morphology. There was very sparse positive 
expression distributed in cells that did not display this morphological change. In contrast, 
the cultures where the medium had been changed to the 50:50 composition for the final 7 
days displayed heterogeneity in terms of expression. Several cells showed elevated 
amylase expression compared to the B13 control, similar to that seen after the initial 7 days 
of treatment in Dex + OSM, but there was also a population of cells with reduced or 
negative amylase expression compared to the B13 control. Unlike the Dex + OSM only-
treated cultures, the highly positive amylase expressing cells also displayed a flattened 
morphology rather than the smaller, rounded phenotype of B13 cells. (Figure 5.6). 






Figure 5.6 Expression of the pancreatic marker amylase in B13 cells cultured in different 
transdifferentiation media for 14 days. Cells were treated without (a – c) or with Dex + OSM 
only for 7 days (d – f) or 14 days (g – i); or with Dex + OSM for 7 days and 50:50 for a further 7 
days (j – l). Cells were stained for the pancreatic marker amylase (green) and nuclei stained with 
DAPI (blue). Images (c), (f), (i) and (l) are composites of (a & b), (d & e), (g & h) and (j & k) 
respectively. Changing to the 50:50 composition presented with some cells showing upregulated 
amylase expression compared to the control after 14 days. The Dex + OSM-only condition 
presented with weak to largely absent expression of amylase after 14 days. Scale bar = 20 μm. 
A double immunofluorescent stain for the functional markers GS and CPS-1, both 
enzymes involved in detoxification of ammonia by the liver, is shown in Figure 5.7. 
Expression of these enzymes was present in both Dex + OSM only-treated cultures at 7 
days and 14 days and also where the medium had been changed to the 50:50 composition, 
with no visible increase or decrease in expression compared to the Dex + OSM only 





medium. There was a visible heterogeneity in expression of these markers, with HLCs 
either showing positive for either one of these enzymes rather than simultaneously. As 
production of these liver enzymes is zonated along the porto-venous axis, this observed 
distribution is not unexpected, suggesting populations of periportal and perivenous 
hepatocytes in the culture. 
 
Figure 5.7 Expression of the hepatic markers GS and CPS-1 in B13 cells cultured in different 
transdifferentiation media for 14 days. Cells were treated without (a – d) or with Dex + OSM 
only for 7 days (d - f) or 14 days (i - l); or with Dex + OSM for 7 days and 50:50 for a further 7 
days (m - p). Cells were stained for the ammonia detoxifying liver enzymes CPS-1 (red) and GS 
(green) and nuclei stained with DAPI (blue). Images (d), (h), (l) and (p) are composites of (a - c), 
(e - h), (i - k) and (m - o) respectively. GS and CPS-1 were expressed in the Dex + OSM-only and 
50:50-treated cultures. Scale bar = 20 μm. 
 






Figure 5.8 Mean percentage expression of GS and CPS-1 positive cells cultured in different 
transdifferentiation media for 14 days. Data is representative of three independent experiments. 
Statistical analysis was by a one-way ANOVA with Tukey’s post-hoc tests. Error bars = + 1 SE; n 
= 3. All Dex-treated conditions were significantly different to the control (*** = p < 0.001), but not 
significantly different to each other in GS and CPS-1 expression (p > 0.05). 
The percentages of cells staining positive for GS and CPS-1 after 14 days of culture were 
quantified by counting GS or CPS-1 DAPI-positive cells.  The data were statistically 
compared between the different culture conditions using a one way ANOVA with Tukey’s 
posthoc tests to determine whether there was any difference in expression levels between 
the culture conditions (Figure 5.8). Control cultures did not express either GS or CPS-1. 
Over 70% of cells in both the Dex + OSM only and 50:50 cultures appeared to be 
expressing either GS or CPS-1. No statistically significant differences was found between 
the total percentage of cells expressing both markers in the Dex + OSM treated cultures 
and the cells treated with 50:50, although the total expression in the cells treated with 
50:50 did appear to be slightly lower than that of the Dex + OSM only treatment. 
Expression of GS in the 50:50 treated cells appeared to be slightly increased over Dex + 
OSM only treated cells, and CPS-1 expression appeared to be slightly reduced as well, but 














































Figure 5.9 Expression of the hepatic markers HNF4α and albumin in B13 cells cultured in 
different transdifferentiation media for 14 days. Cells were treated without (a – d) or with Dex 
+ OSM only for 7 days (d - f) or 14 days (i - l); or with Dex + OSM for 7 days and 50:50 for a 
further 7 days (m - p). Cells were stained for the liver transcription factor HNF4α (red), the liver 
plasma protein albumin (green) and nuclei stained with DAPI (blue). Images (d), (h), (l) and (p) 
are composites of (a - c), (e - h), (i - k) and (m - o) respectively. Both the Dex + OSM-only and 
50:50 culture conditions showed dual expression of HNF4α and albumin in HLCs. Scale bar = 20 
μm. 
Figure 5.9 displays a double immunofluorescent stain of the liver enriched transcription 
factor HNF4α and albumin, a protein synthesised by hepatocytes. The Dex + OSM-treated 
cultures showed positive expression of both these liver markers in the same HLCs after 7 
days and also at 14 days. Similarly, both markers were present where the medium had been 
changed to the 50:50 composition. However, albumin expression appeared to be weaker 
overall compared to the cultures treated continuously with Dex + OSM, but not completely 
absent as seen in the B13 cell control.  






Figure 5.10 Mean percentage expression of HNF4α positive cells and HNF4α positive cells co-
expressed with albumin cultured in different transdifferentiation media for 14 days. Data is 
representative of three independent experiments. Statistical analysis was by a one-way ANOVA 
with Tukey’s post-hoc tests. Error bars = + 1 SE; n = 3; * = p = 0.014; *** = p < 0.001. All Dex-
treated conditions were significantly different to the control. HNF4α expression was not 
significantly different between treated conditions, but Dex + OSM only treatment had a 
significantly percentage of cells positive for both HNF4α and albumin. 
Quantification of mean percentage expression of HNF4α-positive cells and cells co-
expressing both HNF4α and albumin is shown in Figure 5.10. In both populations of the 
Dex + OSM treated cells and the 50:50 treated cells, over 90% of cells were positive for 
HNF4α, but not all HNF4α positive cells were positive for albumin. The B13 control was 
negative for both markers. Statistical analysis by a one way ANOVA with Tukey’s posthoc 
tests found that the percentage of cells expressing both HNF4α and albumin was 
significantly lower in the 50:50 treated culture compared to using Dex + OSM only. 
Furthermore, multinucleate cells with 6 nuclei were also visible in the 50:50 cultures only, 













































Figure 5.11 Mononucleate, binucleate and multinucleate cells expressing the hepatic markers 
HNF4α and albumin. B13 cells were treated with Dex + OSM only for 7 days and then 50:50 for 
a further 7 days. Cells were stained for the liver transcription factor HNF4α (red), the liver specific 
protein albumin (green) and nuclei stained with DAPI (blue). Image (d) is a composite of images (a 
- c). The field of view contained mononucleate, binucleate and multinucleate cells. Arrows indicate 
presence of cells possessing 6 nuclei. 
To examine whether the increase in nuclei beyond the binucleate feature seen in cultures 
where the medium was changed to the 50:50 composition could be correlated to possible 
mitotic activity, immunofluorescent staining for the mitotic marker phospho-histone H3 
(PH3) was performed and quantified by the mean percentage expression for each culture 
condition after 14 days of treatment. Figure 5.12 shows positive expression for PH3 in the 





B13 control, whereas expression appeared negative in the Dex + OSM only-treated 
cultures and also in the 50:50-treated cultures. 
 
Figure 5.12 Expression of the mitotic marker PH3 in B13 cells cultured in different 
transdifferentiation media for 14 days. Cells were treated without (a – c) or with Dex + OSM for 
14 days (d – f) or with Dex + OSM for 7 days and 50:50 for a further 7 days (g – i). Cells were 
stained for the mitotic marker PH3 (red) and nuclei stained with DAPI (blue). Images (c), (f) and 
(i) are composites of (a & b), (d & e) and (g & h) respectively. PH3 was expressed in the control 
but absent from the Dex + OSM-only and 50:50 treated cultures. Scale bar = 20 μm. 
Calculation of the mean percentage expression of PH3 showed that on average fewer than 
10% of DAPI positive cells were also positive for PH3 expression in the control (mean = 
6.50%, SE = 1.21), but this was a statistically significant difference compared to the other 
treatment conditions which had no PH3 positive cells (p < 0.001). In addition, there was no 
significant difference between the Dex + OSM only and 50:50 treated cultures (p > 0.05). 
  





5.2.3 Characterisation of transdifferentiated HLCs maintained in 
HepatoZYME+-based media 
It has been shown in previous work that B13 cells can be maintained in transdifferentiation 
media of Dex + OSM-only culture media for at least 14 days [130,131,222,238], and Dex-
only culture media for 21 days [131]. In both of these conditions, the cultures converted to 
the HLC phenotype. In this section, further experiments increased the total culture time to 
21 days, with initial induction and maintenance of transdifferentiation using Dex + OSM 
occurring over 14 days. This was done to ensure the presence of mature liver markers and 
loss of pancreatic expression as previously shown over 14 days in the Dex + OSM-only 
cultures. After 14 days in Dex + OSM-only medium, the cells either continued to be 
maintained in Dex + OSM or the culture medium was changed to HepatoZYME+ medium 
or the 50:50 composition for a further 7 days of culture. The presence of pancreatic and 
liver markers was subsequently characterised. Although previous cultures of non-induced 
B13 cells in HepatoZYME+ had caused a distinct deterioration of cell viability in less than 
5 days (Section 5.2.1), its effect upon stable colonies of transdifferentiated HLCs was 
unknown. 
Figure 5.13 shows that after 14 days of culture in Dex + OSM, the culture largely consists 
of enlarged, flattened regular polygonal cells indicative of HLC morphology, prior to 
changing the culture media to HepatoZYME+ or 50:50. Binucleate cells were also visible. 
At 17 days of culture, this morphology is continued in the Dex + OSM only-treated 
cultures, whereas the cells maintained in HepatoZYME+ have a rounded appearance 3 days 
post-change, losing the tight junctions previously present. Some cells retained a flattened 
appearance but had become even more enlarged and less regular in shape. In contrast, the 
cells maintained in 50:50 appeared to be larger compared to the Dex + OSM only culture 
after 3 days, with a more regular ‘polygonal’ shape, but also retaining clear tight junctions 
between cells (Figure 5.13g). However, there was also a small population of cells that had 
lost the polygonal HLC morphology, tending towards a more rounded, enlarged and 
irregular shape similar to that seen in the HepatoZYME+ culture, with loss of the tight 
junctions between cells. 
 






Figure 5.13 Morphology of transdifferentiated HLCs maintained in different 
transdifferentiation media after 21 days. Cells were treated with Dex + OSM only for 21 days (b 
- d) or initially treated with Dex + OSM for 14 days before changing culture medium to 
HepatoZYME+ (e & f) or 50:50 (g & h) for the following 7 days. Cell morphology is shown at 14 
days (b), 17 days (c - g) and 21 days (d - h) of culture. Comparative B13 cell morphology control 
is shown after 4 days of culture (a). Scale bar = 50 μm. 
 






Figure 5.14 Expression of the pancreatic marker amylase in B13 cells cultured in different 
transdifferentiation media for 21 days. Cells were treated without (a – c) or with Dex + OSM 
only for 14 days (d – f) or 21 days (g – i); or with Dex + OSM for 14 days and HepatoZYME+ (j – 
l) or 50:50 (m – p) for a further 7 days. Cells were stained for the pancreatic marker amylase 
(green) and nuclei stained with DAPI (blue). Images (c), (f), (i), (l) and (p) are composites of (a & 
b), (d & e), (g & h), (j & k) and (m & p) respectively. Expression of amylase after 21 days of 
culture in the treated conditions is largely absent. Scale bar = 20 μm. 





The presence of the pancreatic marker amylase was investigated at 14 days and 21 days. In 
the Dex + OSM only culture at 14 days, there was evidence of sporadic yet weak 
expression in very few cells. In general for all treatment conditions, after 21 days of culture 
amylase expression was largely inhibited (Figure 5.14). 
 
Figure 5.15 Expression of the hepatic markers GS and CPS-1 in B13 cells cultured in 
different transdifferentiation media for 21 days. Cells were treated without (a – d) or with Dex 
+ OSM only for 14 days (d - f) or 21 days (i - l); or with Dex + OSM for 14 days and 
HepatoZYME+ (m - p) or 50:50 (q - t) for a further 7 days. Cells were stained for the ammonia 
detoxifying liver enzymes CPS-1 (red) and GS (green) and nuclei stained with DAPI (blue). 
Images (d), (h), (l), (p) and (t) are composites of (a - c), (e - h), (i - k), (m - o) and (q - t) 
respectively. GS and CPS-1 were expressed in all treated cultures but not the control. Rounded cell 
morphology is visible in the HepatoZYME+ and 50:50-treated cultures. Scale bar = 20 μm. 
Staining for the liver markers GS and CPS-1 demonstrated that after 21 days of culture, the 
Dex + OSM only treated cells retained GS and CPS-1 expression beyond 14 days with 





cells expressing one or the other enzyme. Cells treated with HepatoZYME+ or the 50:50 
composition also presented with positive GS and CPS-1 staining, including the cells that 
had taken on a rounded or irregular morphology. (Figure 5.15).  
 
Figure 5.16 Expression of the hepatic markers HNF4α and albumin in B13 cells cultured in 
different transdifferentiation media for 21 days. Cells were treated without (a – d) or with Dex 
+ OSM only for 14 days (d - f) or 21 days (i - l); or with Dex + OSM for 14 days and 
HepatoZYME+ (m - p) or 50:50 (q - t) for a further 7 days. Cells were stained for the liver 
transcription factor HNF4α (red), the liver specific protein albumin (green) and nuclei stained with 
DAPI (blue). Images (d), (h), (l), (p) and (t) are composites of (a - c), (e - h), (i - k), (m - o) and (q 
- t) respectively. All treatment conditions apart from the control had positive HNF4α and albumin 
expression. 
HNF4α was continually expressed under all transdifferentiation maintenance conditions up 
to 21 days of culture even where the cells had adapted to a rounded irregular appearance. 





However, expression of albumin appeared to be reduced after the culture medium was 
changed to HepatoZYME+ or 50:50 (Figure 5.16). 
 
Figure 5.17 Relative mean secreted serum albumin content over 24 hr from B13 cells cultured 
in different transdifferentiation media for 21 days. Data were normalised per μg total cellular 
protein content and is representative of three independent experiments. Statistical analysis was by a 
one-way ANOVA with Tukey’s post-hoc tests. Error bars = + 1 SE; n = 3; ** = p < 0.01; *** = p < 
0.001. 
To further compare the functional capacity of these cultures, the amount of albumin 
secreted by the cells into the culture medium after 24 hr was quantified using an enzyme-
linked immunosorbent assay (ELISA) specific to rat albumin and normalised per μg total 
cellular protein content (Figure 5.17). Mean total cellular protein content of each culture 
condition is shown in Table 5.1. B13 cells in complete B13 maintenance medium were 
used as a negative control due to their pancreatic phenotype and cultured for 7 days only. 
In addition to the previously analysed medium compositions, B13 cells supplemented with 
1 μM Dex were also measured for albumin secretion levels after 21 days of culture as an 
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Table 5.1 Mean total cellular protein content of B13 cells cultured in different 
transdifferentiation media for 21 days. 
Culture Condition Mean Total Cellular Protein Content (μg) 
Control (7d) 723.36 ± 77.62 
Dex (21d) 585.11 ± 61.32 
Dex + OSM (21d) 407.76 ± 23.48 
Dex + OSM (14d) → HepatoZYME+ (7d) 207.83 ± 31.08 
Dex + OSM (14d) → 50:50 (7d) 444.27 ± 26.16 
± 1 SE; n = 3 
Compared to the other Dex treated samples, switching to HepatoZYME+ after 14 days 
resulted in reduced total cellular protein content at the end of the 21 day culture period. 
The Dex only treated culture had higher total protein content than all the Dex + OSM 
treated cultures. Dex + OSM only and where the culture medium was switched to 50:50 
had similar total cellular protein content after 21 days. 
All treated samples had detectable albumin content within the culture medium after 24 
hours, whereas there was none present in the control. Changing to the 50:50 composition 
for the final 7 days of culture appeared to increase the amount of albumin secreted 
compared to continuing with Dex + OSM for the full 21 days. However, the difference 
between these two conditions was not found to be statistically significant after analysis 
with a one-way ANOVA and Tukey’s post-hoc tests (p > 0.05). The levels of albumin 
secreted from the Dex + OSM only-treatment and from changing to the 50:50 treatment 
were judged to be significantly higher compared to the B13 cell control and Dex-only 
treated culture (Dex + OSM only = p < 0.01; 50:50 = p < 0.001); and also where the Dex + 
OSM treatment was changed to HepatoZYME+ (Dex + OSM only = p < 0.01; 50:50 = p < 
0.001). Treatment with HepatoZYME+ did appear to show marginally greater albumin 
secretion than Dex treatment alone. However, no statistically significant difference was 
found between these two conditions, nor was any difference highlighted when they were 
both compared against the B13 cell control (p > 0.05). 






Figure 5.18 Gene expression of liver markers in transdifferentiated HLCs cultured in 
different transdifferentiation media for 21 days. Cells were treated with Dex only for 21 days, 
Dex + OSM only for 21 days; or with Dex + OSM for 14 days and HepatoZYME+ or 50:50 for a 
further 7 days. Gene expression was analysed using RT-PCR. Liver markers – C/EBPβ, HNF4α, 
CYP2E1, CPS-1, albumin, transthyretin (TTR) and transferrin (TFN). Reference gene – β-actin. 
The negative control contained no cDNA. Adult rat pancreas and liver cDNA were used as positive 
primary controls for their respective tissue markers. B13 cells cultured in complete B13 medium 
only were used as the untreated control. 
RT-PCR was utilised to examine the presence of hepatic markers at the mRNA level. 
(Figure 5.18). Gene expression of liver specific markers was only observed in the 
transdifferentiated cultures and not the B13 cell control, although the relative levels of 
expression for each of the markers was different under the different conditions. Expression 
of the transcription factors C/EBPβ and HNF4α appeared upregulated in the Dex + OSM 
only culture and also where the medium had been changed to HepatoZYME+, in contrast to 
Dex only-treated cells and where the medium was changed to 50:50. Positive expression of 
functional markers CYP2E1 and CPS-1 was similar between the Dex only, Dex + OSM 
only and 50:50 conditions, with weak to absent expression in the HepatoZYME+ condition. 
Albumin was also expressed in a similar fashion in these conditions, although appearing 
slightly upregulated in the 50:50 culture compared to the Dex only and Dex + OSM only 
conditions. In the case of TTR and TFN, the genes for two transport proteins synthesised 





by the liver, gene expression was strongest in the Dex + OSM only culture. In order from 




The research aims for this Chapter were to investigate whether a potentially novel culture 
medium (HepatoZYME+) could be utilised for the induction and maintenance of 
transdifferentiated HLCs from the B13 pancreatic cell line. This was done through 
characterisation of the culture medium on cell behaviour was performed by way of 
examining the effects on cell morphology, protein and gene expression in comparison with 
existing Dex-based transdifferentiation culture media to determine the most suitable 
medium composition for inducing transdifferentiation in the B13 cells and maintaining a 
stable hepatic phenotype. 
 
5.3.1 HepatoZYME+-based media for the induction of B13 cell 
transdifferentiation to HLCs 
Attempts at culturing the B13 cell line in HepatoZYME+ alone were largely unsuccessful, 
as it was clear that the cells were unable to thrive in the culture medium as they were 
visibly shrivelling, highly vacuolated and detaching from the culture surface after the first 
2 days of treatment. The 50:50 cultures were more successful, as although they eventually 
displayed the same loss of colony viability seen in the HepatoZYME+ cultures, the rate of 
cell deterioration, vacuole development and detachment from the culture surface was 
slower. A small population of cells in the 50:50 culture appeared to have developed a 
flatter, enlarged hepatocyte-like morphology distinct from the rounded, smaller control 
B13 cells. This behaviour was also visible in the cultures treated with Dex only. 
Immunofluorescent staining for hepatic markers after 9 days showed that the cultures were 
heterogeneous in expression for cells positive for HNF4α and CPS-1. The change to a 
flatter, enlarged HLC morphology and appearance of these markers have been shown to be 
present at this time point in other transdifferentiation studies where Dex was used as the 
induction factor [130,131,218,236], thus suggesting that the 50:50 culture medium is able 
to induce expression of these hepatic markers within a similar time frame. The presence of 





the pancreatic marker amylase observed in both the Dex only cells as well as the 50:50 
cultures at this time point is not unexpected as amylase expression has been observed to be 
initially upregulated upon glucocorticoid treatment, further than that normally seen in 
untreated B13 cells, before a gradual loss of expression occurs. Amylase expression is 
generally absent by 14 days of culture in the transdifferentiation medium, indicating the 
requirement of loss of the pancreatic phenotype for conversion to the HLC state 
[130,131,218]. 
Although these experiments suggested that the 50:50 culture composition has the potential 
to induce transdifferentiation of B13 cells to a hepatic phenotype, the gradual deterioration 
in cell viability over time means that this culture condition is unsuitable as a method for 
generating transdifferentiated HLCs as they cannot be maintained beyond the short term. 
This is not an improvement over established Dex-based transdifferentiation protocols. As 
the loss of viability was observed in the HepatoZYME+ and 50:50 treated cultures only, it 
is possible to infer that the composition of HepatoZYME+ may be the cause. 
 
5.3.2 HepatoZYME+-based media for the maintenance of transdifferentiated 
HLCs 
Given that the 50:50 composition had shown capacity in causing HLC phenotypic changes 
to the B13 cell line, its effects on B13 cells that had been pre-induced to transdifferentiate 
to HLCs were assessed. 
For B13 cells that had been cultured in the transdifferentiation induction medium Dex + 
OSM for 7 days before changing to 50:50 for a further 7 days, a clear morphological 
change was apparent. Prior to changing the medium, the Dex + OSM treated cells had 
adopted a flatter, enlarged polygonal appearance with some binuclear cells within the 
population for the first 7 days of culture. Where Dex + OSM was utilised for the full 14 
days of culture, a change to a hepatocyte-like morphology was apparent, with the majority 
of B13 cells taking on an enlarged, flattened appearance. This is consistent with previous 
reports utilising these treatment conditions [130,132,133]. Where the medium was changed 
to 50:50 after 7 days of initial culture in Dex + OSM, the morphology was more irregular, 
with some cells increasing in size but losing their polygonal appearance, tending towards a 
more rounded one with vacuoles within the cytoplasm for the following 7 days. The cells 





were also dissociating from each other and also from the culture surface, which was not 
seen in the Dex + OSM only cultures. 
Notably, there was strong amylase expression in a small proportion of cells treated with 
50:50 for 7 days alongside cells that appeared negative. The strong expression is in 
contrast to what was observed in the Dex + OSM only culture, which showed some 
amylase expression at 7 days but was negligible after 14 days. The behaviour seen in the 
50:50 culture is in contrast to what has previously been observed with regards to the 
regulation of amylase expression during the transdifferentiation process with Dex-based 
treatment. As previously mentioned, in the early stages of glucocorticoid culture of B13 
cells, there is enhancement of amylase expression which then decreases over prolonged 
exposure to the glucocorticoid with eventual loss of amylase expression and gain of 
hepatic markers [130,131]. In addition to the glucocorticoid Hydrocortisone, 
HepatoZYME+ contains the cytokine HGF, which has been shown to inhibit amylase 
content in the AR42J parent line [217] and in combination with Dex, significantly reduce 
amylase expression after only 5 days compared to supplementing with Dex alone [131]. 
Hydrocortisone is a less potent glucocorticoid than Dex. Furthermore, the concentration of 
HGF in the 50:50 medium was 5 ng/ml compared to the 10 ng/ml utilised in the study by 
Burke et al in 2006, which reported that HGF and Dex together reduced amylase 
expression significantly [131]. It has been previously shown in the AR42J parent line that 
the extent of amylase secretion upregulation from Dex stimulation is dose-dependent 
[217,239,240]. Secondly, previous investigations by Tosh et al and Fairhall et al note that 
removal of glucocorticoid stimulation does not appear to cause reversal of phenotype in 
transdifferentiating HLCs [218,241]. Thus, a possible explanation for the persistent 
amylase expression is that as Hydrocortisone is a less potent glucocorticoid compared to 
Dex and the HGF concentration is reduced compared to previous studies, this may reduce 
the extent of the eventual downregulatory effect on amylase compared to the combination 
of higher concentration Dex and HGF in the culture medium. It may be that prolonged 
maintenance in 50:50 beyond 7 days would eventually show complete loss of amylase 
expression and therefore the pancreatic phenotype, although further studies may be 
confounded by the increasing loss of viability in the culture. Notably, immunofluorescent 
staining for amylase in cells cultured for 7 days in 50:50 after 14 days of culture in Dex + 
OSM showed negative expression for this marker, suggesting that once the HLC 
phenotype is fully established, the pancreatic phenotype has been lost and changing to 





50:50 does not subsequently upregulate amylase protein. However, a quantitative method 
of determining amylase secretion levels into the culture supernatant, such as the Phadebas 
colorimetric assay, would allow for increased understanding combined with the visual 
methods applied here as to the extent that amylase activity has changed in these cells 
between the different culture media. 
Immunofluorescent staining also established that the change of medium to 50:50 did not 
cause a complete loss of protein expression of hepatocyte specific markers in HLCs. GS 
and CPS-1 staining were not co-expressed within the cell, reflecting the zonated 
distribution of expression seen in the liver where CPS-1 is only expressed in periportal 
hepatocytes and perivenous hepatocytes only express GS as previously reported [4,218]. 
This behaviour was also observed where the cultures were treated with Dex + OSM for 14 
days and cultured for a further 7 days in 50:50 or HepatoZYME+.  
Statistical analysis of percentage cell expression showed that there were no significant 
differences between GS, CPS-1 and total GS and CPS-1 expression between treating cells 
with the Dex + OSM only treatment for 7 days and changing to the 50:50 composition for 
7 more days. Although cell counting based on images is a useful method of determining 
percentage cell expression, given the visible deterioration of the culture in the 50:50 
culture, further work to analyse this could involve combination of a secondary method for 
assessing mean percentage expression, such as fluorescent activated cell sorting, functional 
assays measuring ammonia detoxification and GS and CPS-1 specific ELISAs to provide 
further clarity as to how the culture media has affected expression against function. 
HNF4α expression was also similar between these two treatments, being expressed in the 
majority of cells. However, co-expression with albumin was statistically found to be 
reduced in the 50:50 treated cells compared to Dex + OSM, where nearly all HNF4α 
positive cells were also positive for albumin. A possible reason for this is the loss of 
viability of the culture, as the culture medium was changed at the critical time when 
albumin would normally be upregulated. HNF4α is normally upregulated within the first 2 
days of exposure to Dex treatment, whereas albumin is a marker that appears 
approximately 7-9 days after instigating transdifferentiation [130,131]. 
To further investigate the extent of active function in the different cultures as percentage 
expression only refers to the quantity of cells that are positive for that marker, quantitative 





analysis was sought. The rat albumin ELISA was utilised to compare the amount of serum 
albumin secreted into the culture supernatant from cells treated using two established 
methods of B13 transdifferentiation to HLCs (Dex only and Dex + OSM only for 21 days) 
and from culturing in Dex + OSM for 14 days before changing to HepatoZYME+ or 50:50 
for the following 7 days. From comparing the serum albumin content in the medium of the 
Dex only and Dex + OSM cultures, the Dex + OSM only culture was significantly 
increased compared to the Dex only culture, reflecting the result obtained by Shen et al in 
2000 that showed a higher percentage cell expression of albumin in Dex + OSM treatment 
compared to Dex only treatment over 14 days of culture [130] and other studies reporting 
an increased population of B13 cells undergoing transdifferentiation to HLCs alongside 
enhancement of the hepatic phenotype [132,218]. Serum albumin was detected in the 
culture medium of cells treated with HepatoZYME+, although it was significantly reduced 
compared to the Dex + OSM only culture and not significantly different from the Dex only 
culture. In contrast, the 50:50 medium was found to have the highest albumin content 
compared to the other conditions. However, this was not found to be statistically different 
from that of the Dex + OSM culture. It is possible that albumin secretion was further 
enhanced due to the presence of HGF in the 50:50 culture media, as this effect from HGF 
has previously been observed on addition to primary rat hepatocytes in culture [242] and 
also in the maturation of foetal mouse liver in combination with OSM [243]. This may 
have also affected the albumin secretion measured in the HepatoZYME+-treated cell 
medium.  
As the heterogeneity in population with regards to transdifferentiated hepatocytes is more 
apparent in Dex only-treated cultures compared to Dex + OSM treated cells, the total 
protein content will contain a combination of HLCs and non-transdifferentiated B13 cells 
unaffected by the transdifferentiation treatment which may still be undergoing 
proliferation. Although this normalisation is representative of the effect of Dex only 
treatment on a population of cells, it does not directly reflect the albumin secretion 
capability of only the HLCs within the population. Normalisation to cells expressing a liver 
specific marker would allow for a more direct comparative understanding of the 
functionality of the HLCs within these different cultures. Notably, the mean total cellular 
protein content measured for normalisation of the HepatoZYME+ culture was 
approximately half as much as that of the Dex + OSM culture after 21 days. This infers a 
possible loss of culture viability similar to that seen in earlier experiments, which may 





augment loss of cell function such as reduced albumin secretion capability. In contrast, the 
50:50 culture did not show reduced total cellular protein in comparison, displaying similar 
levels to the Dex + OSM culture. However, being less potent than HepatoZYME+ and 
considering the loss of culture coherency observed in previous experiments, a similar, 
eventual loss of viability is possible, albeit at a reduced rate of deterioration. Therefore, a 
further point of investigation could utilise viability studies such as analysis of caspase-3 
activity and lactate dehydrogenase release alongside metabolic studies using as MTT or the 
colorimetric resazurin assay alamarBlue. This would allow comparison between the 
different culture conditions to determine if HepatoZYME+ based media increases apoptotic 
activity and affects metabolic function in correlation with the reductions in total cellular 
protein and secretory activity seen here. 
RT-PCR was used to look at gene expression of hepatic markers after pre-treatment in Dex 
or Dex + OSM only for 14 days and then treatment with HepatoZYME+ or 50:50 for a 
further 7 days, compared to 21 days in Dex or Dex + OSM only. Notably, extracted RNA 
quantities from the HepatoZYME+ and 50:50 treated cultures were found to be lower 
compared to the other conditions. This may have been affected by overall culture viability. 
The hepatic markers were only detected in the positive liver control and the 
transdifferentiated culture extracts, but not the pancreatic controls, in agreement with 
previous studies [130,131,244]. The transcription factors C/EBPβ and HNF4α were 
upregulated the most under the Dex + OSM only treatment, but the HepatoZYME+ treated 
cells also showed strong expression compared to Dex only treatment and the 50:50 culture. 
The observed increase in C/EBPβ and HNF4α in HepatoZYME+ may be due to the 
increased concentration of HGF and OSM present in the culture medium, which has been 
previously shown to cause increased expression of these two factors in transdifferentiating 
B13 cells [130–132], or further unknown factors present within the proprietary basal 
medium. The weaker expression within the 50:50 culture may be related to only having 
half the concentration of the factors contained with HepatoZYME+ and reduced 
glucocorticoid potency, and the Dex only culture including no additional growth factors. 
Expression of functional markers CYP2E1, CPS-1, albumin, TTR and TFN was the 
weakest within the HepatoZYME+ culture compared to the Dex only and Dex + OSM only 
conditions. The 50:50 sample showed slightly elevated albumin expression, which 
correlates with the observation from serum albumin protein quantification. Although these 
results confirm that hepatic markers remain upregulated after changing culture medium, 





which is in agreement with the protein expression of markers seen from 
immunofluorescent staining, there appear to be relative differences in the level of gene 
expression depending on the culture medium used. Expression of C/EBPβ in the positive 
liver control was reduced in comparison with all the Dex treated cultures. C/EBPβ is 
normally upregulated during early liver development [245] and is induced in B13 cells as 
the ‘master switch’ between a pancreatic and hepatic phenotype during transdifferentiation 
[130]. Therefore, the lower expression in the control may be attributed to primary adult 
liver possessing a more mature phenotype than the transdifferentiated HLCs at this time 
point. Expression of CYP2E1 and CPS-1 were found to be upregulated in the control liver 
compared to the transdifferentiated cultures, although expression of TTR and TFN in the 
control liver was similar to that of the Dex + OSM only culture. This suggests that the 
transdifferentiated HLCs are comparable in presence of expression to control liver. 
However, the variation in expression levels may be related to the relative maturity of the 
transdifferentiated cultures compared to the control liver. Further quantification using 
qRT-PCR would assist further in comparatively confirming mRNA levels with statistical 
analysis to examine the gene level differences between the different conditions. 
A significant point of interest observed in the 50:50 cultures was the presence of not only 
binucleate cells, which are present in Dex-based cultures, but large, multinucleate cells that 
were expressing hepatic markers. A distinguishing feature of hepatocytes is that the 
population is heterogeneous for mononucleate or binucleate cells. In physiology, changes 
in the liver parenchyma during postnatal growth are characterised by increases in 
hepatocyte polyploidisation [246]. It has been suggested that the formation of binucleate 
cells in hepatocytes is due to incomplete cytokinesis [247,248], and that polyploidy is a 
protective measure against cellular stress and damage [249,250]. Given the apparent loss of 
culture viability observed in these experiments, this may have been a stimulatory factor in 
the appearance of these multinucleate cells if the culture medium contained a cytotoxic 
factor, or was absent for a factor essential for survival. Although hepatocytes and 
transdifferentiated HLCs are generally non-proliferative under normal physiological 
conditions, it was found that HGF in the presence of Dex, enhanced by the presence of 
non-essential amino acids, was able to induce a small population of transdifferentiated 
HLCs to proliferate [131]. In liver regeneration, HGF is known as a mitogen, so the 
presence of this growth factor may have influenced the presence of multiple nuclei as it 
was part of the supplementation in the 50:50 medium. Although all treated cultures apart 





from the proliferating B13 cell control were negative for PH3, a marker of mitosis, further 
work could examine other cell cycle phase markers, such as cyclin D1 (G1) and cyclin B1 
(G2/mitosis) to explore whether the culture medium has influenced cells to actively enter 
the cell cycle. Despite this, it is doubtful that the multinucleate cells would be able to 
survive long term. 
To identify the likely causative agent or agents behind the overall loss of viability, further 
understanding of the composition of HepatoZYME+ is required. HGF and OSM are 
cytokines that have previously been used as additional culture supplements in maturation 
media for embryonic liver tissue and in complete B13 DMEM-based transdifferentiation 
media, positively enhancing the hepatic phenotype [130–132,243]. The concentrations 
utilised in HepatoZYME+ and 50:50 are within the range utilised in previous studies. Both 
Dex and Hydrocortisone have been shown to act upon the glucocorticoid receptor to 
induce transdifferentiation [130], but Dex is considered to be 25 times more potent in 
effect than Hydrocortisone [251,252]. Therefore, as the concentration of Hydrocortisone in 
HepatoZYME+ is 10 μM, the concentration of Dex to achieve equivalent glucocorticoid 
activity would be 400 nM; in the 50:50 culture medium, the equivalent concentration is 
200 nM Dex. The 1 μM concentration utilised in the Dex-treated cultures is comparatively 
2.5 times more potent than the Hydrocortisone present in HepatoZYME+, and 5 times more 
potent than that within the 50:50 medium. Transdifferentiation of B13 cells to HLCs has 
been previously achieved using concentrations of Dex as low as 10 nM, a glucocorticoid 
concentration much less potent than that contained in HepatoZYME+ or 50:50 
[130,238,253]. As B13 cells displayed some morphological change and upregulation of 
hepatic markers similar to that observed in HLCs when culturing using 50:50, it is possible 
to infer that as the Hydrocortisone content of the 50:50 medium is within the reported 
range of glucocorticoid concentrations used to induce transdifferentiation, the 
Hydrocortisone, HGF and OSM within the medium are unlikely to be the overarching 
causative factors for the observed loss of cell viability. 
Notably, HepatoZYME+ is serum-free and due to the proprietary nature of the basal 
medium HepatoZYME-SFM, it is unknown what other supplementation is involved 
beyond that stated here. It is possible that the lack of FBS to aid cell adhesion to the culture 
surface affected cell viability, as additional experiments using different serum 
concentrations in DMEM-based Dex-supplemented transdifferentiation media revealed 





low to negligible B13 cell attachment, survival and transdifferentiation where there was no 
serum present. A stable culture with transdifferentiated cells was able to be established 
with a minimum of 5% (v/v) FBS and was able to be cultured for up to 60 days (data not 
shown). The 50:50 culture medium contained 5% (v/v) FBS by virtue of being 
HepatoZYME+ diluted with the complete B13 culture medium. This may have improved 
its survival beyond that of complete HepatoZYME+, due to the presence of adhesion 
proteins from the FBS and dilution of the unknown factors contained within the proprietary 
basal medium. However, as the loss of culture stability was still occurring, this suggests 
that the contents of HepatoZYME-SFM itself are likely to be the issue, be it missing an 
essential factor required for the B13 cells and transdifferentiated HLCs to thrive, or a 
combination of factors at a concentration too toxic for them to survive. From this, 
additional experimental controls to clarify the effects of the HepatoZYME+ and 50:50 
media would aid understanding of which component within the culture media is 
responsible for overall loss of viability when using HepatoZYME+-based media or the 
induction of transdifferentiation observed with the 50:50 culture medium. This approach 
would involve characterisation of the effects of each of the components individually and in 
combination upon the B13 cells and cells pre-induced to transdifferentiate. For example, 
for the 50:50 culture medium, this approach would involve variant cultures of the B13 cells 
solely with Hydrocortisone, HGF or OSM within the combined basal medium of 
HepatoZYME-SFM and complete DMEM, as well as culturing using these additives 
within complete DMEM in the absence of HepatoZYME-SFM. Examining these factors 
using this experimental method would allow for greater specificity as to the causative 
agents involved in inducing transdifferentiation and also the loss of culture viability. 
 
5.4 Conclusion 
The aim of the research described in this Chapter was to investigate and characterise the 
utility of different culture media to induce transdifferentiation in pancreatic B13 cells, and 
also whether the media are able to maintain or enhance the hepatic phenotype in B13 cells 
that have undergone transdifferentiation to HLCs. The focus was on the culture medium 
HepatoZYME+, a hepatocyte maturation medium that has been reported to improve the 
hepatic phenotype of the directed differentiation of hESCs and iPSCs to HLCs and whether 
this could be translated over to the transdifferentiation of pancreatic cells to HLCs. Two 





culture media were examined; complete HepatoZYME+, and 50:50, a 1 in 2 dilution of 
HepatoZYME+ with complete B13 culture medium. These were comparatively 
characterised alongside established Dex-based transdifferentiation media. 
HepatoZYME+ was unable to induce transdifferentiation in B13 cells, and instead, visible 
deterioration of the culture within 48 hr was observed with complete loss of cell viability 
by day 5. The 50:50 culture medium appeared to show morphological changes in the cells 
similar to that of HLCs and simultaneously observed in Dex-treated cells. Protein 
expression of hepatic markers, absent in untreated B13 cells, was also seen. Despite this, 
the 50:50 medium also suffered from a gradual loss of cell viability and morphological 
derangement not seen in the Dex-treated cells, and was unable to support a culture long 
term. Therefore, neither HepatoZYME+ nor 50:50 are better than current 
transdifferentiation methods. 
Subsequent studies showed that the 50:50 culture medium was able to maintain expression 
of hepatic markers in transdifferentiated HLCs initially cultured using Dex + OSM. Firstly, 
at an earlier stage of transdifferentiation, induction of hepatic markers was maintained, 
although amylase expression was also present. Culture viability appeared compromised as 
observed previously. As a maintenance medium for the later stage of transdifferentiation, 
initially, the 50:50 culture medium appeared to show an improved regularity in hepatocyte-
like morphology but eventually, both HepatoZYME+ cultures deteriorated as seen 
previously. Amylase expression was not upregulated in the presence of the HepatoZYME+- 
based cultures once conversion had been established. Both HepatoZYME+ and 50:50 were 
able to show protein expression of hepatic markers, but there was a distinct reduction in 
albumin secretion with HepatoZYME+. In contrast, the 50:50 medium was comparable to 
the Dex + OSM culture medium. Hepatic gene expression was present, but the level of 
regulation for the HepatoZYME+ and 50:50 was variable when compared to Dex-based 
media. Finally, it appeared that the 50:50 culture medium was able to generate 
multinucleate cells beyond the mononucleate and binucleate phenotype normally seen in 
hepatocytes and transdifferentiated hepatocytes. 
To answer the research aims of this Chapter, it is possible to conclude that neither the 
HepatoZYME+ culture medium, nor the 50:50 medium, are suitable for inducing 
transdifferentiation to HLCS, nor are they suitable for maintenance of transdifferentiated 
HLCS. Despite this, several interesting points regarding the biology of transdifferentiation 





have been highlighted through the work in this Chapter. Firstly, the 50:50 culture was 
shown to be able to initiate morphological changes and upregulation of hepatic markers in 
untreated B13 cells similar to that observed in Dex-based induction media, suggesting that 
this formulation is able to induce some cells to convert to an HLC phenotype. Furthermore, 
as a maintenance medium, transdifferentiated HLCs did not show complete reversal of the 
hepatic phenotype, and appeared to be comparable to the established Dex + OSM protocol 
with regards to serum albumin function with 50:50. Finally, the appearance of 
multinucleate cells when culturing using 50:50 may be partially encouraged by a 
combination of glucocorticoid hormone and HGF, although further work in this area to 
examine the cell cycle signalling mechanisms behind this will be required. 
The loss of viability in both HepatoZYME+ based protocols show that they are no 
improvement on current transdifferentiation protocols. However, to examine why the 
cultures would eventually deteriorate in such a manner, future work quantifying cell 
viability, metabolic and cytotoxicity studies could be utilised to investigate the causative 
factor for loss of culture stability in these media, thus informing modifications for a 
potentially improved set of culture conditions beyond that described here. 
The experiments in this Chapter have shown that out of the investigated culture media, the 
established Dex + OSM culture medium is the optimal culture condition for 
transdifferentiation of B13 cells to HLCs, as it can induce and maintain the hepatic 
phenotype within a stable culture. Therefore, further work in this thesis will utilise this 
culture medium with the intention of inducing and maintaining transdifferentiation of B13 
cells to HLCs cultured on the surface-treated phase inversion PX membranes developed in 
Chapter 4. 
  







transdifferentiation of pancreatic cells 
to hepatocyte-like cells on surface 
treated polystyrene flat sheet 
membranes 
6.1 Introduction 
6.1.1 Biocompatibility of PX membranes for bioartificial liver device design 
Developing a suitable in vitro environment for cells that recapitulate normal cellular 
functions is essential for a bioartificial liver (BAL) device, particularly as the primary goal 
is to replace the function of a failing liver effectively. By using tissue engineering 
techniques, the culture scaffold and medium can be tailored specifically to the cell type. 
For example, an ideal scaffold for a BAL device would be nontoxic and support cell 
adhesion and normal hepatocyte function in vitro. 
The results presented in Chapter 4 have described and characterised a method for 
modifying the surface chemistry and wettability of phase inversion cast PS membranes to 
encourage a surface environment more conducive to cell culture (termed here PX 
membranes). Furthermore, the results presented in Chapter 5 determined a suitable 
induction and maintenance cell culture medium for the transdifferentiation of the 
pancreatic B13 cell line to functional HLCs respectively (Dex + OSM). Therefore, it was 
necessary to bring these components together to assess the cell culture capabilities of PX 
membranes with the intention of potentially translating both biomaterial and cell source to 
BAL device design. 





The ideal biomaterial should be able to promote initial cell attachment to the membrane 
surface through deposition of proteins that are adsorbed onto the biomaterial surface and 
subsequently interact with the extracellular matrix. The interaction between cell and 
substrate is termed ‘focal adhesion’ [254], the extent of which eventually leads to 
stimulation of cell spreading and subsequent proliferation or differentiation. Optimal levels 
of initial cell attachment will increase the proliferative and differentiating capacity of the 
cells and overall culture viability due to the presence of sufficient numbers of cells. 
Furthermore, it is not possible to rule out that the utility of PX membranes to support 
transdifferentiation of pancreatic cells to functioning HLCs may also be affected by 
biomaterial characteristics such as surface chemistry and wettability. In the case of 
mesenchymal stem cells, they have been shown to differentiate down various lineages 
based on the stiffness of the gel they are seeded upon [255,256]. 
 
6.1.2 Expanding the scope of biomaterial development for regenerative 
medicine 
A promising step further would be to expand the scope of the biomaterial to be able to 
support culture of a variety of cell types. In comparison with traditional tissue culture 
flasks and stirred tank bioreactors, HFBs are able to expand a large population of cells 
whilst using a fraction of the volume of the former and latter methods [147,150]. 
Combining a biomaterial that can support multiple cell lines with the HFB makes it an 
attractive prospect in regenerative medicine for the scale up of cell therapies to clinical 
quantities, be it the production of cells or producing sufficient quantities of cellular 
products, such as growth factors. For example, one potential use involves the MG63 cell 
line, a human osteosarcoma cell line that is used as a bone tissue model [257,258]. Notably 
for liver tissue engineering, it is also posited as a potentially cost effective and limitless 
source of hepatocyte growth factor (HGF) [259] that could be utilised in various induction 
and maintenance media for hepatic differentiation and also transdifferentiation. The ability 
of PX membranes to support MG63 culture is therefore also of relevance to this Chapter. 
 





6.1.3 Experimental aims and objectives 
The experimental research described in this Chapter sought to investigate the 
biocompatibility of oxygen plasma treated PX phase inversion flat sheet membranes and 
the ability of B13 cells to convert to HLCs on this culture substrate. The research questions 
to be addressed were whether PX phase inversion membranes: a) are biocompatible in 
comparison with other established biomaterials; b) can support the transdifferentiation of 
B13 pancreatic cells to HLCs; and c) can retain bulk physical characteristics under 
transdifferentiation culture conditions. These are important factors in establishing whether 
PX phase inversion membranes can potentially be used as a HFB tissue culture scaffold for 
long term cell culture, such as that in a BAL device. PX membranes were fabricated using 
deionised water as the nonsolvent to initially cast PS membranes and were subsequently 
exposed to oxygen plasma using a capacitively coupled plasma chamber to increase 
surface wettability. 
This Chapter is divided into three parts. Firstly, biocompatibility studies sought to compare 
PX membranes as developed in Chapter 4 as a suitable substrate against established 
biomaterials – tissue culture polystyrene (TCPS) and poly(D,L-lactide-co-glycolide) 
(PLGA)  phase inversion cast membranes. Two cell lines were utilised – rat pancreatic 
cells (B13), which are of great interest in this thesis due to their ability to transdifferentiate 
to functional HLCs [130,131,241,244]; and human osteosarcoma cells (MG63), an 
osteoblast-like cell that is a potentially limitless source of HGF [259]. Biocompatibility 
was characterised through analyses of both cell lines with regards to (i) quantification of 
cell attachment on the different biomaterial surfaces to identify the efficacy of the surface 
treatment used to generate PX membranes; (ii) cell viability by visualisation of a live/dead 
stain followed by quantification of live and dead cells on each culture substrate and (iii) 
assessing the utility of using cellular release of lactate dehydrogenase into the culture 
medium as a measure of viability. 
The second part of the Chapter deals with investigating the utility of B13 cells to 
transdifferentiate to HLCs upon PX membranes, utilising the Dex + OSM treatment as 
investigated in Chapter 5. Transdifferentiation of pancreatic cells to HLCs was 
investigated through (i) determination of pancreatic and hepatic protein expression by 
indirect immunofluorescent staining on PX membranes and (ii) comparison of hepatic 
function of transdifferentiated HLCs on PX membranes against standard TCPS and PLGA 





membranes. Functional characterisation was performed through quantification of serum 
albumin secretion. 
Lastly, a comparative study into whether the transdifferentiation culture conditions exacts 
physical alterations in PX and PLGA membranes without cells present was performed by 
comparative measurements examining differences in membrane mass, culture surface area 
and volume over time. 
 
6.2 Results 
6.2.1 Cell attachment on PX membranes 
Attachment studies were performed over a 6 hr period to compare four culture substrates – 
TCPS, untreated PS membranes, PLGA membranes and treated PS membranes (known as 
PX). Two different cell lines were utilised – rat pancreatic B13 cells and human 
osteosarcoma MG63 cells. 
PS and PLGA membranes were cast as previously described in Section 3.2 using the phase 
inversion immersion precipitation method. To create PX membranes, untreated PS 
membranes were exposed to oxygen plasma generated by a capacitively coupled plasma 
chamber as described in Section 3.2.3. Both PX and PLGA membranes were then prepared 
for cell culture by fixing them in autoclaved polycarbonate bioreactor modules and 
sterilising the membrane culture surface (1.9 cm2) with 1% (v/v) antibiotic-antimycotic 
solution for 24 hours at 4˚C. The membrane culture surfaces were then washed in sterile 
PBS prior to cell inoculation (Section 3.6.1). 
The bioreactors were seeded with B13 cells or MG63 cells at a density of 20,000 cells/cm2. 
This parameter was selected as it has been utilised previously in similar cell attachment 
studies on both PLGA flat sheet and hollow fibre membranes [154,171,260]. The seeded 
bioreactors were then incubated at 37˚C for 6 hr under static conditions. The cells were 
then lysed prior to quantification with the PicoGreen dsDNA quantification assay as 
described in Section 3.6.2. Tissue culture polystyrene (TCPS) for adherent cells was used 
as a control biomaterial and seeded accordingly. 






Figure 6.1 Mean cell densities of B13 cells seeded on different culture substrates after 6 hr 
culture. TCPS, PS, PX and PLGA membrane surfaces were seeded with B13 cells at a density of 
20,000 cells/cm2 each and cultured for 6 hr. Culture density of cells attached to the membrane 
surfaces was quantified by the PicoGreen dsDNA quantification assay. Statistical analysis was by 
way of a one-way ANOVA with Tukey’s post hoc tests. Error bars = + 1 SE; n = 4; ** = p = 0.01; 
*** = p < 0.001. B13 cell attachment to PX was not significantly different to TCPS but was 
significantly higher than PS and PLGA. 
Figure 6.1 shows the mean culture densities of B13 cells attached to the surfaces of 
different biomaterials 6 hr after seeding the bioreactors. Here, PX membranes appeared to 
have the highest mean cell attachment with a density similar to that of the initial seeding 
density, suggesting that the majority of the cells seeded had adhered to the culture substrate 
after 6 hr incubation. This was followed by TCPS, then in order: PLGA and PS. In 
contrast, there were significantly fewer cells attached to untreated PS membranes and 
PLGA membranes after 6 hr. Statistical analysis showed that there was no significant 
difference between TCPS and PX membranes with regards to the number of cells attached 
to the culture substrates, nor between TCPS and PLGA. Similarly, no significant difference 
was found between untreated PS and PLGA membranes. The higher attachment to PX 
membranes was found to be statistically significantly different when compared to cells 































Figure 6.2 Mean cell densities of MG63 cells seeded on different culture substrates after 6 hr 
culture. TCPS, PS, PX and PLGA membrane surfaces were seeded with MG63 cells at a density of 
20,000 cells/cm2 each and cultured for 6 hr. Culture density of cells attached to the membrane 
surfaces was quantified by the PicoGreen dsDNA quantification assay. Statistical analysis was by 
way of a one-way ANOVA with Tukey’s post hoc tests. Error bars = + 1 SE; n = 4; * = p < 0.05; 
*** = p < 0.001. MG63 cell attachment to PX membranes was not significantly different to TCPS 
or PLGA membranes but was significantly higher than PS membranes. 
Figure 6.2 shows the mean cell densities of MG63 cells attached to different culture 
substrates after 6 hr incubation. With this cell line, TCPS was found to have the most cells 
attached to the culture surface, followed by the PX membrane; then in order, PLGA then 
untreated PS. Statistical analysis found no significant differences between TCPS and PX 
with regards to mean cell density, although no significant difference was found in 
attachment of cells between PX and PLGA membranes. PX membranes were found to 
have significantly higher MG63 cell attachment than that on PS membranes, whilst cell 


































Figure 6.3 Comparison of mean cell densities between B13 and MG63 cells seeded on 
different culture substrates after 6 hr culture. TCPS, PS, PX and PLGA membrane surfaces 
were seeded with either B13 cells or MG63 cells at a density of 20,000 cells/cm2 each and cultured 
for 6 hr. Culture density of cells attached to the membrane surfaces was quantified by the 
PicoGreen dsDNA quantification assay. Statistical analysis compared between cell lines per culture 
substrate using an independent samples Student’s t-test for each substrate. Error bars = + 1 SE; n = 
4; ** = p = 0.01; *** = p < 0.05. B13 cell attachment was found to be significantly higher than 
MG63 cell attachment on TCPS, PX and PLGA membranes but there were no significant 
difference between the two cell lines on PS membranes. 
Compared to B13 cell attachment on all culture substrates, fewer MG63 cells overall had 
attached to each biomaterial surface 6 hr post seeding. Statistical analysis suggested that 
there were significant differences between attachment of the two cell lines on TCPS, PX 
and PLGA membranes with higher mean cell densities of B13 cells present than MG63 
cells. Furthermore, there was no significant difference between the attachment capabilities 
of the different cell lines on PS membranes (Figure 6.3). 
 
6.2.2 Cell viability on PX membranes 
To culture cells on a biomaterial, it is essential that there is no loss of cell viability over 

































toxic to cells. Furthermore, the interaction between the cell membrane proteins and the 
surface chemistry of the biomaterial may not be amenable to normal cellular functions and 
may increase apoptotic behaviour. 
Previously, PX membranes demonstrated an overall improvement of cells attaching to the 
membrane surface compared to untreated PS membranes. PX membranes appeared to be 
comparable to TCPS with regards to adhered cell densities of both the B13 and MG63 cell 
lines. Due to the low cell densities present on PS membranes, further studies sought to 
investigate the viability of cells cultured on PX membranes in comparison to TCPS and 
PLGA membranes only. To distinguish between live and dead cells a fluorescent stain 
utilising calcein AM and ethidium homodimer-1 was applied to B13 and MG63 cells that 
had been cultured for 48 hr on the aforementioned substrates, as described in Section 3.6.3. 
Figure 6.4 depicts fluorescent visualisation of B13 cells on TCPS, PX and PLGA 
membranes. All biomaterial surfaces showed the presence of attached cells. There was a 
high proportion of B13 cells showing positive for calcein AM metabolism on all substrates, 
suggesting that the culture populations were metabolically active and therefore viable. 
There was very low incidence of ethidium homodimer-1 binding to nucleic acids with no 
cell colonies showing positive, only single isolated cells. These observations suggested 
negligible cell death within the cultures after 48 hr. 
The cells stained with calcein AM and ethidium homodimer-1 were further quantified and 
analysed by comparing the mean percentage live or dead cells between the different culture 
substrates (Figure 6.5). All culture substrates showed overall mean viable cells of greater 
than 98% of the culture population, with less than 1.5% of cells dead. B13 cells cultured on 
PX membrane surfaces appeared to have the greatest mean percentage of live cells, 
reaching over 99.5%, followed by TCPS and PLGA, both with means over 98.5%. PLGA 
appeared to have a slightly higher percentage of dead cells in certain areas of the 
membrane. This suggested with greater variation in the results, given the larger standard 
error. When taking the standard error into account, the overall culture viability was still 
above 97.5% at the lower bound. Furthermore, statistical analyses found that there were no 
significant differences in B13 cell viability between the different culture substrates. 
 






Figure 6.4 Viability of B13 cells seeded on TCPS, PX and PLGA membranes after 48 hr 
culture. TCPS (a - c), PX (d - f) and PLGA (g - i) membrane surfaces were seeded with B13 cells, 
stained after 48 hr culture and visualised by fluorescent microscopy. Live cells positive for calcein 
AM metabolism are shown in green (a, d, g); dead cells positive for ethidium homodimer-1 are 
shown in red (b, e, h).  Images (c), (f) and (i) are composites of (a & b), (d & e) and (g & h) 
respectively. Scale bar = 200 μm. 






Figure 6.5 Mean percentage live and dead B13 cells seeded on different culture substrates 
after 48 hr culture. Statistical analyses were by way of a one-way ANOVA with Tukey’s post hoc 
tests. (a) Mean percentage live cells; (b) mean percentage dead cells. Error bars = + 1 SE; n = 3; p 
> 0.05. No significant differences in viability were found between the different culture substrates 
after 48 hr of culture. 
Upon similar investigation of the MG63 cell line, cells appeared to be attached to all 
culture substrates after 48 hr, as previously observed with the B13 cell line. The high 
proportion of positive staining for calcein AM metabolism and single, isolated cells 
staining positive in sparse quantities for ethidium homodimer-1 upon the different culture 
substrates as previously mentioned was also observed in the MG63 cell line (Figure 6.6). 






Figure 6.6 Viability of MG63 cells seeded on TCPS, PX and PLGA membranes after 48 hr 
culture. TCPS (a - c), PX (d - f) and PLGA (g - i) membrane surfaces were seeded with MG63 
cells, stained after 48 hr culture and visualised by fluorescent microscopy. Live cells positive for 
calcein AM metabolism are shown in green (a, d, g); dead cells positive for ethidium homodimer-1 
are shown in red (b, e, h).  Images (c), (f) and (i) are composites of (a & b), (d & e) and (g & h) 
respectively. Scale bar = 200 μm. 
Figure 6.7 shows quantification of stained live and dead MG63 cells by mean percentage 
of live and dead cells. Upon all culture substrates, the mean percentage of live cells in the 
culture population was found to be at least 96%. TCPS and PX had similar percentages of 
live cells with both reaching means of over 99%. In contrast, MG63 cultures on PLGA 
appeared to have a greater proportion of dead cells present, with a mean of over 3% dead 
cells within the culture population compared to just over 0.5% in the TCPS and PX 
cultures. 
Statistical analysis comparing the different culture substrates suggested that there was no 
significant difference between the proportions of live and dead cells on TCPS and PX. 
However, both substrates were judged to be significantly different when compared with the 





PLGA cultures. Based on the statistical analyses, the PLGA MG63 culture appeared to be 
less viable in comparison with cells seeded upon TCPS and PX. 
 
Figure 6.7 Mean percentage live and dead MG63 cells seeded on different culture substrates 
after 48 hr culture. Statistical analyses were by way of a one-way ANOVA with Tukey’s post hoc 
tests. (a) Mean percentage live cells; (b) mean percentage dead cells. Error bars = + 1 SE; n = 3; 
*** = p < 0.001. Mean percentage live and dead cells on TCPS and PX were found to be 
statistically significantly different to PLGA (p < 0.001), but were not found to be significantly 
different from each other (p > 0.05). 
A comparative analysis between mean percentage live and dead B13 and MG63 cells on 
the different culture substrates is shown in Figure 6.8. Statistical analysis using an 
independent samples Student’s t-test suggested that there was no significant difference 
between the two cell lines with regards to their mean percentage live and dead cells on 
TCPS and PX membranes. However, a small significant difference was found between the 
two cell lines when culturing on PLGA, suggesting that B13 cells have a greater proportion 
of live cells compared to MG63 cells when both are cultured on PLGA membranes. The 
increased error bars of both PLGA cultures compared to TCPS and PX suggest an 
increased variability in cell viability on the surface of PLGA membranes compared to 











Figure 6.8 Comparison between mean percentage live and dead B13 and MG63 cells seeded 
on different culture substrates after 48 hr culture. Statistical analyses between cell lines were 
by way of independent samples Student t-tests for each substrate. (a) Mean percentage live cells; 
(b) mean percentage dead cells. Error bars = + 1 SE; n = 3; * = p = 0.05. B13 and MG63 cells 
appeared to show a small significant difference between their live and dead cells on PLGA. No 
significant differences were found between live and dead B13 and MG63 cells cultured on TCPS 
and PX. 
A second, quantifiable method for assessing cell death was sought to compare with the 
results previously obtained through visual quantification. Initial experiments looked at the 
utility of measuring the release of the cytosolic enzyme lactate dehydrogenase (LDH) into 
the culture medium. LDH is released upon damage to the cell membrane, a signifier of cell 
death. The assay utilises a colorimetric approach to measure absorbance from the 
formation of a red formazan product in the culture medium. This is directly proportional to 
the LDH content in the culture medium. Percentage cytotoxicity is then reported based on 
comparison of the measured LDH content against the maximum LDH content determined 
from whole culture lysis. 
* 
* 






Figure 6.9 Mean percentage cytotoxicity based on LDH release from MG63 cells seeded on 
different culture substrates after 48 hr culture. Statistical analysis was by a one-way ANOVA 
with Tukey’s post hoc tests. Error bars = + 1 SE; n = 3; p > 0.05. No significant differences in 
cytotoxicity were found between the culture substrates. 
Initial experiments utilising the MG63 cell line for LDH release analysis are shown in 
Figure 6.9. The results obtained here suggested that the cells cultured on the PX 
membrane had the lowest incidence of LDH present in the culture medium, followed by 
PLGA. In contrast to the results obtained from the live/dead stain, TCPS had the highest 
incidence of LDH release. Despite this, statistical analysis found that there was no 
significant difference between LDH release in the cultures on all different substrates as 
expected from the large error bars. 
However, initial experiments utilising this assay on the B13 cell line were unable to 
quantify the mean percentage cytotoxicity in these cultures. This was due to the presence 
of large background interference measured in the culture media, which confounded 
subsequent calculation of the mean percentage cytotoxicity. Further analyses with no-cell 
cultures suggested that the composition of the culture medium may be the causative agent 
(data not shown). In addition, this may also account for the larger standard errors from the 
































6.2.3 Transdifferentiation of pancreatic cells to hepatocyte-like cells on PX 
membranes 
The ideal biomaterial should be able to facilitate good cell adhesion to the biomaterial 
surface and support stable cell viability within the culture. Sections 6.2.1 and 6.2.2 
established the ability of PX membranes to support cell adhesion and promote cell viability 
in two different cell lines at a level comparable to TCPS. 
Furthermore, the ability of a cell to differentiate or transdifferentiate into a different cell 
type can be affected by the characteristics of the scaffold material it is cultured upon. 
Therefore, the aim of this part of the Chapter is to establish whether the B13 cell line can 
be induced to transdifferentiate to HLCs on PX membranes and determine their functional 
capability compared to TCPS and PLGA membranes. 
Immunofluorescent staining for protein expression of pancreatic and hepatic markers was 
used to visualise B13 cells cultured on PX membranes that had been treated with the Dex + 
OSM transdifferentiation medium for 14 days. Cultures on glass coverslips were used as a 
phenotypic control. Figure 6.10 shows immunofluorescent staining for the pancreatic 
marker amylase in B13 cells. Untreated B13 cells cultured on PX membranes presented 
with cells on the culture surface that were positive for amylase expression, similar to the 
untreated B13 cells cultured on glass coverslips. After treatment with Dex + OSM for 14 
days, the cells appeared to have taken on a flattened, enlarged morphology on both 
substrates, similar to that previously reported in B13 transdifferentiation to HLCs. 
Furthermore, amylase expression was largely absent in these treated cells. 






Figure 6.10 Expression of the pancreatic marker amylase in B13 cells cultured on different 
culture substrates for 14 days. Cells were cultured on glass coverslips or PX membranes and 
treated with the Dex + OSM transdifferentiation culture medium for 14 days. Controls were fixed 
after 4 days. Cells were stained for the pancreatic marker amylase (green) and nuclei stained with 
DAPI (blue). (a – b; g - i) Glass; (d – f; j - l) PX. Images (c), (f), (i) and (l) are composites of (a & 
b), (d & e), (g & h) and (j & k) respectively. Scale bar = 200 μm. Untreated B13 controls displayed 
amylase expression on both substrates. Dex + OSM treated cells on both substrates showed 
morphologically flattened cells with comparatively weak to absent amylase expression. 






Figure 6.11 Expression of the hepatic transporter protein TFN in B13 cells cultured on 
different culture substrates for 14 days. Cells were cultured either on glass coverslips or PX 
membranes and treated with the Dex + OSM transdifferentiation culture medium for 14 days. 
Controls were fixed after 4 days. Cells were stained for the hepatic transporter protein TFN (red) 
and nuclei stained with DAPI (blue). (a – b; g - i) Glass; (d – f; j - l) PX. Images (c), (f), (i) and (l) 
are composites of (a & b), (d & e), (g & h) and (j & k) respectively. Scale bar = 200 μm. TFN was 
absent from the control cultures. Dex + OSM treated cells had an enlarged, flattened morphology 
and demonstrated expression of TFN on both substrates. 
To assess the presence of hepatic markers, immunofluorescent staining was used to look at 
expression of the hepatic transporter protein TFN in both cultures (Figure 6.11). 
Expression of TFN was absent in the untreated B13 controls on both glass coverslips and 
the PX membrane. However, after 14 days of Dex + OSM treatment, TFN expression was 
clearly apparent in cells presenting with the flattened, enlarged morphology on both culture 
substrates. 






Figure 6.12 Expression of the ammonia detoxifying enzymes GS and CPS-1 in B13 cells 
cultured on different culture substrates for 14 days. Cells were cultured either on glass 
coverslips or PX membranes and treated with the Dex + OSM transdifferentiation culture medium 
for 14 days. Controls were fixed after 4 days. Cells were stained for the ammonia detoxifying 
enzymes CPS-1 (red) and GS (green). Nuclei were stained with DAPI (blue). (a – d; i - l) Glass; (e 
– h; m - p) PX. Images (d), (h), (l) and (p) are composites of (a - c), (e - g), (i - k) and (m - o) 
respectively. Scale bar = 200 μm. GS and CPS-1 were absent from the control cultures. Dex + 
OSM treated cells had an enlarged, flattened morphology and demonstrated expression of GS and 
CPS-1 on both substrates. 
Protein expression of the ammonia detoxifying enzymes GS and CPS-1 is shown in Figure 
6.12. Similarly to the expression of TFN, GS and CPS-1 expression is only present in the 
Dex + OSM treated cells cultured on both substrates, with staining positive in the flattened 
cells only. The control cultures were both negative for GS and CPS-1 expression, 
regardless of culture substrate. 
As PX membranes appeared to be able to support induction of transdifferentiation of B13 
cells to HLCs, further analysis was performed to gain a better understanding of the 
functional capability of HLCs cultured on PX membranes. Here, the secretion of serum 
albumin was compared between B13 cells induced to transdifferentiate on TCPS, PX and 





PLGA membranes after 14 days of culture. Serum albumin was then quantified over a 24 
hr period using a rat albumin ELISA as previously described (Section 3.9.2) and reported 
as mean serum albumin content per million cells over 24 hr. 
Serum albumin secretion was not detected from B13 cell controls seeded on TCPS, PX and 
PLGA that were not treated with Dex + OSM. In contrast, detectable serum albumin was 
found in the Dex + OSM treated cultures (Figure 6.13). 
 
Figure 6.13 Relative mean secreted serum albumin content over 24 hr from B13 cells treated 
with Dex + OSM on different culture substrates for 14 days. Data were normalised per million 
cells and is representative of three independent experiments. Statistical analysis was by a one-way 
ANOVA with Tukey’s post-hoc tests. Error bars = + 1 SE; n = 3; *** = p < 0.001. 
Figure 6.13 shows the relative mean serum albumin content of Dex + OSM treated B13 















































mean serum albumin secretion, followed by cells treated on PX, which had a secretion 
efficacy of over 75% of the TCPS culture. In contrast, Dex + OSM treated cells on PLGA 
had far lower mean serum albumin content than the other two biomaterial surfaces.  
Statistical analyses comparing the Dex + OSM treated cultures to each other found that the 
content on TCPS was significantly higher than both PX and PLGA (p < 0.001). The 
increased albumin content of PX compared to PLGA was also found to be significantly 
higher (p < 0.001). 
Further analyses comparing untreated B13 cells to their Dex + OSM treated counterparts 
on each substrate was done by independent samples Student’s t-test. The increased serum 
albumin secretion in Dex + OSM treated cells on TCPS and PX was both found to be 
significantly different (p < 0.001) compared to the control cells on those substrates. 
However, the albumin secretion from Dex + OSM treated cells on PLGA was not found to 
be significantly different from the untreated culture on PLGA (p > 0.05). 
 
6.2.4 Characterisation of PX and PLGA membrane bulk under 
transdifferentiation culture conditions 
A structurally stable culture scaffold is a necessity for tissue culture. A culture scaffold that 
is fit for purpose should be able to support a culture for as long as required. Although B13 
cells seeded on PLGA membranes have previously been shown to be able to attach to the 
culture surface after 6 hr and have good viability after 48 hr of culture, it was observed in 
the 14 day transdifferentiation cultures on PLGA that serum albumin secretion from B13 
cells treated with Dex + OSM on PLGA membranes were found to be greatly reduced 
relative to cultures on TCPS and PX membranes and not significantly different from 
untreated B13 cells on PLGA. 
Visually, at the end of the transdifferentiation culture period, PLGA membranes appeared 
to show deformity in structure. Figure 6.14 shows a representative image of a PLGA 
membrane fixed within the bioreactor after 15 days in culture, alongside a PX membrane 
used for culture at the same time. The available culture surface area on the PLGA 
membrane appears to have receded from the edge of the well. In comparison, the PX 





membrane has shown no visible change in size and remains covering the bottom of the 
well. 
 
Figure 6.14 PX and PLGA membrane macrostructures after 14 days under 
transdifferentiation culture conditions. (a) PX membrane; (b) PLGA membrane. Black arrow 
shows receding edge of the PLGA membrane, a feature absent in the PX membrane. Scale bar = 5 
mm. 
Further experiments were performed to examine whether the transdifferentiation culture 
conditions alone could contribute to a change in membrane bulk in both PX and PLGA 
membranes in the absence of cells. To address this, 22 x 22 mm square samples of PX and 
PLGA membranes were sterilised over 24 hr at 4˚C with 1% (v/v) antibiotic-antimycotic as 
previously described (Section 3.6.1) in standard TCPS 6-well plates. After sterilisation, the 
membranes were gently washed with sterile PBS and complete B13 culture medium was 
added, ensuring that the membrane surface was completely covered by the culture medium. 
The samples were then incubated for 24 hr at 37˚C, before the medium was then changed 
to the Dex + OSM culture medium for the following 14 days. Therefore, membranes were 
under culture conditions for a total of 15 days. 
Membranes were measured for dimensions (length, width and depth) using a micrometer 
and weighed before undergoing the sterilisation process and subsequent incubation. 
Measurements were taken at the culture time points of 3 days, 8 days and 15 days after the 
membrane had been removed from the culture medium, washed carefully with PBS and 





dried using a desiccator to eliminate residual moisture mass. Further to this, each time 
point was compared to the pre-culture dimensions and mass of the membrane and the mean 
percentage change calculated. 
 
Figure 6.15 Mean percentage change of mass of PX and PLGA membranes under B13 
transdifferentiation culture conditions without cells at 3, 8 and 15 days. PX and PLGA 
membranes were prepared for undergoing the culture conditions for transdifferentiation of B13 
cells to HLCs and incubated for 3, 8 and 15 days with the transdifferentiation culture medium at 
37˚C in 5% CO2. Membranes were weighed at the specified time point and compared to the 
original membrane mass prior to entering culture conditions and the mean percentage change of 
mass calculated. Statistical analysis was by a one-way ANOVA with Tukey’s post hoc tests for 
comparing within membranes and with independent samples Student’s t-tests for comparing 
between membranes at the same time point. Error bars are for PLGA only as PX membranes 
showed no change in mass at any time point. Error bars ± 1 SE; n = 3; p > 0.05. No significant 
differences in mass were found between membranes or between time points. 
Comparison of PX and PLGA membrane mass demonstrated that there was negligible 
change in mass between the lengths of incubation and also prior to undergoing 
transdifferentiation culture conditions (Figure 6.15). PX membranes in particular showed 





























membranes showed a minor reduction in mass although this was deemed to be not 
statistically significant (p > 0.05). 
 
Figure 6.16 Mean percentage available culture surface area of PX and PLGA membranes 
under B13 transdifferentiation culture conditions without cells at 3, 8 and 15 days. PX and 
PLGA membranes were prepared for undergoing the culture conditions for transdifferentiation of 
B13 cells to HLCs and incubated for 3, 8 and 15 days with the transdifferentiation culture medium 
at 37˚C in 5% CO2. Membrane culture surface area was measured at the specified time point and 
compared to the original membrane surface area prior to entering culture conditions and the mean 
percentage change of surface area calculated. Statistical analysis was by a one-way ANOVA with 
Tukey’s post hoc tests for comparing within membranes and with independent samples Student’s t-
tests for comparing between membranes at the same time point. Error bars = + 1 SE; n = 3; ** = p 
< 0.01; *** = p < 0.001. PLGA membranes displayed a significant reduction in culture surface area 
after 3 days incubation. 
Despite finding no significant changes in mass within the culture conditions for either 
polymer membrane, as mentioned previously it was observed visually that the PLGA 
membranes appeared to have undergone physical deformation, appearing smaller in size 
than what was seen prior to entering culture conditions. Therefore, the available culture 










































culture surface areas at different time points for each membrane type is shown in Figure 
6.16. 
PX membranes did not display a significant variation in culture surface area during any 
time point of the culture period (p > 0.05). PLGA membranes, in contrast, appeared to 
have lost approximately 40% of the original available culture surface area after 3 days in 
culture. Statistical analysis was able to confirm that after 3 days under culture conditions, 
the decrease in PLGA membrane culture surface area was a significant difference (p < 
0.001). However, beyond this time point, there was no further significant change in PLGA 
membrane culture surface area the longer the incubation time (p > 0.05).  
Comparisons between PX and PLGA membranes demonstrated that the reductions in 
PLGA membrane surface area compared to PX membranes at the same time point were 
also statistically significant differences – 3 days (p < 0.01); 8 days (p < 0.01) and 15 days 
(p < 0.001). 
 
6.3 Discussion 
The research aims for this Chapter were to investigate the biocompatibility of PX flat sheet 
membranes developed in Chapter 4, to determine if the biomaterial is suitable for tissue 
culture. Characterisation of PX membranes was studied through comparison with 
established biomaterials – TCPS and PLGA. Cell attachment and viability of two different 
cell lines (B13 and MG63) were assessed as well as the utility of the pancreatic B13 cell 
line to transdifferentiate to HLCs on PX membranes. Furthermore, the effects of 
transdifferentiation culture conditions without cells on the physical structures of PX and 
PLGA membranes were also examined. 
 
6.3.1 Attachment of B13 and MG63 cell lines to PX membranes 
For adherent cell culture, it is important to ensure that the biomaterial of choice provides a 
suitable environment for anchorage dependent interactions to occur. The phase inversion 
PS membranes initially developed in Chapter 4 possessed a hydrophobic surface. 
Hydrophobicity is a trait that has previously been shown to not encourage attachment of 
cells to biomaterial surfaces [168,183,192,193]. Furthermore, in HFB for tissue 





engineering applications, a more hydrophilic surface encourages hydraulic permeability 
and greater transfer of nutrients through the membrane wall [168]. Therefore, additional 
surface treatment by way of oxygen plasma exposure modification to alter the membrane 
surface chemistry was utilised. This was found to reduce hydrophobicity of the membrane 
surface to create a scaffold more conducive for adherent cell culture (PX membranes). In 
addition, different cell lines may favour various combinations of biomaterial characteristics 
over others with regards to attachment, viability and functional capacity. A greater quantity 
of cells adhering to biomaterial surfaces will facilitate cell spreading and subsequent 
proliferation and differentiation. For tissue engineering purposes, this feature is positive for 
producing large batches of cells quickly [171]. 
Both the B13 and MG63 cells attached to both PS and PX membranes after 6 hr. However, 
there were noticeable differences in the overall numbers attached. PX membranes were 
found to have significantly higher cell attachment than PS membranes. This suggested that 
the addition of oxygen functional groups to the membrane surface via the oxygen plasma 
surface treatment was successful in encouraging a greater number of cells to attach through 
the reduction in surface hydrophobicity. This behaviour is consistent with previous cell 
studies on oxygen plasma treated PS films with human foetal osteoblastic cells, mouse 
fibroblast cells and human umbilical vein endothelial cells [203,209,210]. 
With regards to the B13 cell line, the numbers of cells attached to the PX membrane was 
found to be comparable to TCPS with nearly all the seeded cells attached to the membrane 
surface. Notably, cell attachment on phase inversion PLGA membranes was lower than 
both TCPS and PX, and found to be comparable to that of untreated PS membranes. This 
suggests that the PX biomaterial possesses a more favourable attachment surface than 
PLGA membranes in the case of the B13 cell line, particularly as PLGA is a hydrophobic 
polymer [193]. 
The MG63 cell line similarly showed low cell attachment on untreated PS membranes. 
However, PX membranes showed reduced attachment of MG63 cells compared to TCPS, 
although this was not a statistically significant reduction. MG63 cells cultured on PLGA 
membranes also appeared to show attachment comparable to that of PX membranes. This 
observation is in contrast with B13 cell attachment, which overall, had higher attachment 
than MG63 cells on all substrates bar PS membranes. These differences in attachment 
behaviour suggest a degree of variation between cell lines in how suitable a particular 





biomaterial is for purpose. For example, a previous study by Ellis and Chaudhuri utilising 
primary human bone derived cells demonstrated that PLGA flat sheet membranes with a 
similar lactide:glycolide ratio (72:25) had comparable attachment to TCPS within the first 
6 hr [171]. This contrasts the results shown here for both cell lines on PLGA. It is possible 
that additional factors beyond surface chemistry, such as membrane surface roughness, 
may also influence adsorption and folding of adhesion proteins on to the biomaterial 
surface, the result of which may favour one cell type over another [261]. Indeed, phase 
inversion PLGA membranes have previously been shown to possess a rough surface 
morphology visible under SEM [171,175,260,262]. 
These results suggest that the oxygen plasma surface treated PX membranes were 
successful in improving cell attachment of both B13 and MG63 cells compared to 
untreated PS membranes. PX membranes have an attachment capacity comparable to 
TCPS for B13 cells, which is a positive attribute for utilising this biomaterial for 
transdifferentiation to HLCs. Furthermore, this biomaterial is also able to support 
attachment of MG63 cells, albeit at a reduced efficiency. However, to expand and explore 
the scope of PX membranes with regards to other cell lines and aid future development, a 
further point of investigation could be to examine the effects of surface roughness and 
substrate stiffness between the different culture substrates with regards to improving cell 
attachment, as well as the study of other cell lines originating from different tissues. 
Additional surface treatments on the membrane, such as increasing oxygen plasma 
treatment time and power beyond that utilised in this thesis, could be assessed for any 
subsequent changes in surface morphology through SEM and surface roughness and 
substrate stiffness by AFM. Cell attachment of different cell lines originating from 
different tissues could then be assessed in comparison with untreated PX membranes. The 
effect of substrate stiffness on different cell types could be further assessed through 
measurement of cell spreading area on the membrane surface as an indicator of adhesion 
strength and type, particularly as stiffness is a factor involved in efficacy of attachment, 
proliferation and differentiation, especially with regards to how the substrate stiffness 
relates to the environment of native tissue [254]. 
 





6.3.2 Viability of B13 and MG63 cell lines on PX membranes 
Given the low cell attachment of PS membranes compared to PX membranes, further 
studies into B13 and MG63 cell viability were performed only on TCPS, PX and PLGA 
membranes. This was done primarily through comparative analysis of calcein AM 
metabolism of live cells and binding of ethidium homodimer-1 to nucleic acids in dead 
cells. 
After 48 hr of culture both B13 and MG63 cells were shown to be attached to all culture 
substrates. Furthermore, the cells showed excellent viability with metabolically active cells 
and very low numbers of dead cells. No infection was detected on the polymer substrates, 
suggesting that treatment with the antibiotic-antimycotic solution previously recommended 
for sterilising PLGA membranes prior to culture is also a suitable treatment for sterilisation 
of PX membranes [175]. 
Notably, MG63 cells cultured on PLGA membranes appeared to have a significantly 
higher percentage of dead cells than those found on TCPS and PX. B13 cells also showed a 
slight increase in the numbers of dead cells on PLGA although this was not deemed 
statistically significant. The hydrophobic nature of PLGA may have influenced this 
behaviour, as a previous study by Chang et al reported that culturing MG63 cells on a 
hydrophobic surface demonstrated lower proliferative capacity and enhanced apoptotic 
behaviour at 48 hr when compared to a hydrophilic surface. This behaviour was observed 
to be due to reduced cell adhesion and subsequent spreading on the culture surface, causing 
insufficient activation of the Ras pathway by fibroblast growth factor-1 (FGF-1) [263]. The 
Ras pathway is involved in modulating the cell cycle and also rearrangement of the actin 
cytoskeleton [263–265]. In contrast to the PLGA utilised in this Chapter, the study by 
Chang et al utilised hydrophobic PS as an experimental substrate. Although the PLGA 
used in this Chapter is hydrophobic due to the lactide majority within the polymer, the 
glycolide contained within the polymer is hydrophilic [171]. This factor may reduce the 
hydrophobicity of the culture substrate beyond that utilised in the study by Chang et al and 
hence comparatively lessen the detrimental effects of PLGA surface wettability on the 
MG63 cells. Given the reduced PLGA attachment and viability seen with B13 cells, 
examination of these signalling factors with this cell line on PLGA may be a further point 
of investigation by comparing apoptotic behaviour with activation of Ras from initial 
attachment and proliferation over time. 





Further analysis of cell viability was attempted by examining LDH release into the culture 
medium after 48 hr. LDH is released when there is damage to the cell membrane – a 
signifier of cell death. However, although it was possible to calculate release for MG63 
cells, which were found to have low cytotoxicity, this was not possible for B13 cells. It 
was found that experimental sample measurements being measured as lower or identical to 
the spontaneous LDH release control, thus confounding calculation of percentage 
cytotoxicity. Although this may suggest very low or negligible cytotoxicity in B13 cells to 
the extent of being identical to the spontaneous LDH release control, which would agree 
with the results obtained by calcein AM and ethidium homodimer-1 analyses, it was also 
found that the FBS utilised in the cell culture medium gave a very high background which 
may have interfered with the controls. Notably, this effect was reduced in the MG63 
cultures. 
It is posited that as the MG63 culture medium utilised heat inactivated FBS, this factor 
may have reduced the confounding background effect seen in the B13 cells, which used 
non-heat inactivated FBS. A study by Thomas et al in 2015 showed a 50% reduction in 
background when using heat inactivated FBS as part of the culture medium used in the 
LDH assay [266]. A potential solution would be to switch to serum-free medium to 
quantify LDH release over 48 hr to completely avoid the background effect, although this 
may increase loss of viability in B13 cells as previously described in Chapter 5. Reduction 
of FBS may also avoid issues with too much background, although a different solution 
would be to utilise a method that is largely unaffected by the contents of the culture 
medium, such as the colorimetric resazurin assay alamarBlue. 
Therefore, these results have shown that at 48 hr, B13 and MG63 cells cultured on PX 
membranes have good viability that is comparable with TCPS. Cultures on PLGA were 
also found to be viable. Although the studies in this Chapter found high overall viability in 
all cell lines on all substrates, this was only assessed up to 48 hr. Therefore, extending the 
culture period beyond 48 hr for proliferative and viability studies would help establish 
whether there is similar behaviour as reported here for both cell lines. Also, additional 
methods for assessing apoptotic behaviour could help gain a better understanding of 
changes in cell viability, such as staining with annexin V. This method detects 
phosphatidylserines that appear on the membrane surface in early apoptosis. As positive 
staining for ethidium homodimer-1 and release of LDH are factors indicative of loss of 





membrane integrity which occurs later in apoptosis and therefore may not have been fully 
assessed in the time frame examined here, annexin V would be able to detect apoptotic 
behaviour in cells at an earlier time point [267]. 
 
6.3.3 Transdifferentiation of the B13 cell line to HLCs on PX membranes 
Previously, the work in Chapter 5 had demonstrated the greater efficiency of the Dex + 
OSM transdifferentiation culture medium to induce conversion of the B13 cell line to 
HLCs over solely using Dex as the inducing agent. 
Here, treatment of B13 cells with Dex + OSM on PX membranes over 14 days induced 
transdifferentiation towards a hepatic phenotype. There was a distinct loss of the pancreatic 
phenotype shown through loss of expression of the pancreatic marker amylase replicating 
that observed on glass. Furthermore, expression of the hepatic markers TFN, CPS-1 and 
GS were found to be induced in the Dex + OSM treated cultures and not the untreated 
samples on all culture substrates. This is a significant observation as firstly, it shows that 
the loss of pancreatic phenotype coincides with induction of hepatic markers as previously 
described in the literature [130,131]; but secondly, the culturing of B13 cells on PX 
membranes in complete B13 culture medium alone does not induce transdifferentiation of 
B13 cells to HLCs. Therefore, this suggests that PX membranes can be utilised for 
homogenous cell expansion, and with the right treatment conditions, potentially be used to 
support the differentiation of one cell type to another as displayed here. However, it is not 
possible to fully ascertain the degree of transdifferentiation between the two substrates 
from the immunofluorescent staining alone. Examination of induction of hepatic markers 
and quantification of functional markers over time would be able to determine if the 
different cultures reach similar levels of transdifferentiation at the same time points. 
Notably, the transdifferentiated HLCs cultured on PX membranes were also able to 
demonstrate functional capability of secreting serum albumin into the culture medium, 
with none detected from untreated B13 cells on all substrates. However, the amount 
secreted was found to be reduced when compared to transdifferentiated HLCs cultured on 
TCPS. It is possible that this may have been affected by the number of cells attached to the 
membrane surface, as these are relative albumin quantities. PX displayed a higher overall 
attached cell number than TCPS (data not shown). It has previously been reported that too 





high a cell density can slow the rate of transdifferentiation and expression of hepatic 
markers [236,237]. Therefore, there is the possibility that there were fewer 
transdifferentiated HLCs at the right stage of maturity to express and secrete albumin on 
PX membranes at this time point. Further work will need to examine the 
transdifferentiation efficacy on PX membranes utilising different initial seeding densities. 
Although it is apparent that there are HLCs actively secreting albumin on PX membranes, 
the culture viability at this stage on all substrates is not known. Although the PicoGreen 
assay is widely utilised in the literature as a method of calculating cell number, a limitation 
is that it does not discriminate between live or dead cells and therefore quantifies all 
dsDNA present. Additional comparison with a metabolic assay to quantify viable cell 
number, such as the MTT assay, would be more informative to equate the albumin 
secretion results to living cells only. 
Notably, relative to reported serum albumin secretion from primary rat hepatocytes 
cultured on TCPS, the amount secreted from the transdifferentiated HLCs cultured on 
TCPS is lower by at least 10-fold [96,268,269]. This difference suggests that although 
transdifferentiated HLCs as previously reported have a similar range of functions to 
primary rat hepatocytes, the lower level of secretion may reflect a less mature hepatic 
phenotype in the transdifferentiated HLCs. A comparative culture with primary rat 
hepatocytes on the different substrates with functional quantification would inform this 
assessment further. To add further clinical applicability, as the B13 model of 
transdifferentiation to HLCs can be translated to human pancreatic cells, further study into 
whether this reduction in albumin secretion would similarly occur when compared to adult 
primary human hepatocytes would also be useful. 
Interestingly, B13 cells induced to transdifferentiate on PLGA membranes showed 
presence of serum albumin in the culture medium but this was greatly reduced in 
comparison with the serum albumin secretion of cells cultured on TCPS and PX. This was 
also accompanied by low overall calculated cell number compared to TCPS and PX. It is 
possible that the low cell number calculated is due to fewer cells surviving culture on 
PLGA. As mentioned previously, the measured dsDNA content from the PicoGreen assay 
does not distinguish between live or dead cells. Measurement of metabolic activity on all 
culture substrates, such as by the MTT assay, in combination with the calculated cell 
number would be able to confirm whether cells on PLGA had reduced metabolic activity. 





Another possibility is that the reduced serum albumin secretion from cells cultured on 
PLGA is due to fewer cells undergoing transdifferentiation. Detection of the pancreatic 
marker amylase through visualisation by immunofluorescence after 14 days of 
transdifferentiation treatment combined with a quantitative method such as the Phadebas 
colorimetic assay would confirm whether the pancreatic phenotype is still prevalent in the 
cells. An additional quantitative hepatic marker assay, such as measurement of cytochrome 
P450 activity would also further determine the presence of hepatic transdifferentiation 
alongside the results obtained from serum albumin secretion. Although the serum albumin 
result here suggests that some cells on PLGA may be able to transdifferentiate to HLCs, 
the low attachment and functional secretion means that for translating to hollow fibre 
membrane culture, it is unsuitable. The PX biomaterial would be more suitable as it has 
displayed improved attachment and functionality compared to PLGA. 
Furthermore, PLGA membranes displayed a deformation in structure after the full 15 days 
of treatment, which was further replicated under no-cell culture conditions. In comparison, 
PX membranes showed no change in structure. Although PLGA is a biodegradable 
polymer, no significant change in overall mass was found as significant degradation is 
reported to occur beyond the time point of these experiments [270]. However, it has been 
noted in the literature that wetting of PLGA, such as by culture medium, can cause the 
polymer to plasticise through lowering of its glass transition temperature and effectively 
shrink [271]. A study by Kim et al showed differences in glass transition temperatures 
between dry versus wet PLGA (75:25 lactide:glycolide) membranes, ranging from 45.2˚C 
dry to 37.3˚C wet [262]. As culture conditions are at 37˚C, it is possible that the change in 
morphology is due to reduction in glass transition temperature. Further viability studies 
would be useful in determining whether there is a gradual increase in cell death concurrent 
with changes in topography, contributing to the low overall cell number and function. 
Changes in culture surface area and topography during the culture period are potentially 
going to affect the proliferative and differentiation capacities of the cells and produce 
unwanted heterogeneity in the resultant product. Therefore, based on these results, the PX 
biomaterial is the optimum choice for translating the transdifferentiation of B13 cells to 
HLCs to a HFB setting. 
 






The aim of the research in this Chapter was to investigate the biocompatibility of PX 
membranes. This was characterised initially through attachment capacity and viability of 
the rat pancreatic B13 and human osteosarcoma MG63 cells in comparison with TCPS and 
PLGA, two established biomaterials. PX membranes showed improved cell attachment of 
both cell lines compared to that of untreated PS membranes, suggesting that the oxygen 
plasma surface treatment developed in Chapter 4 was effective. Furthermore, PX 
membranes were able to support B13 and MG63 cell attachment with good viability after 
48 hr. Attachment and viability of B13 and MG63 cells on PX membranes were also found 
to be comparable to equivalent cultures on TCPS. 
PX membranes were also able to support transdifferentiation of the B13 cell line to HLCs 
with loss of the pancreatic phenotype, induction of hepatic markers and adoption of a 
flattened, enlarged HLC morphology after 14 days of treatment with Dex + OSM. In 
addition, the secretion capacity of serum albumin from transdifferentiated HLCs was also 
retained on PX membranes, although reduced when compared to cultures on TCPS. There 
was no observed change in PX membrane structure, unlike PLGA membranes which 
demonstrated distinct deformation.  
In conclusion, these results demonstrate that the PX biomaterial is biocompatible, with 
comparable cell attachment and viability to TCPS and ability to support 
transdifferentiation of pancreatic cells to HLCs. These results are very encouraging for 
eventually translating the PX biomaterial to a HFB setting. However, there is scope for 
further optimisation of PX membrane biocompatibility, such as modification of membrane 
surface roughness to improve cell attachment, viability and function, particularly with the 
requirement for a fully porous membrane to facilitate nutrient and waste transfer during 
cell culture. 
  






Conclusions and Future Work 
7.1 Conclusions 
The research in this thesis has focused on the design of a potential interim support therapy 
for liver failure – the bioartificial liver (BAL) device. The concept of the BAL device is to 
utilise hepatocytes or hepatocyte-like cells (HLCs) housed within a suitable bioreactor with 
the purpose of replicating normal liver functions. The purpose of this treatment is to bridge 
patients with liver failure to transplantation or to aid liver regeneration. Although some 
BAL device designs have reached clinical trials, none are currently in full clinical use as 
there is currently no significant difference in patient survival when comparing BAL device 
therapy with standard medical treatments. The two major challenges to producing a 
clinically viable BAL device are sourcing suitable hepatocytes or HLCs that can 
recapitulate in vivo hepatocyte functionality; and secondly, providing a suitable culture 
environment within the bioreactor for the cells to effectively function as hepatocytes or 
HLCs. 
This thesis focused on two main research areas integral to BAL device design – firstly, the 
development of novel polystyrene (PS) phase inversion membranes to be used as a cell 
culture scaffold in a hollow fibre bioreactor (HFB) – a bioreactor configuration that 
resembles the architecture of the physiological liver. Although PS is widely used as a 2D 
cell culture substrate, it has yet to be reported as a biomaterial for phase inversion hollow 
fibre membrane cell culture purposes. Secondly, HLCs generated from the 
transdifferentiation of pancreatic cells were considered as a potential cell source for BAL 
devices due to their wide hepatic functionality. The culture medium HepatoZYME+ was 
reported to improve the hepatic phenotype in human embryonic and induced pluripotent 
stem cell differentiation. However, the effect of this culture medium on the 
transdifferentiation of pancreatic cells to HLCs was not known, and was selected as a 
potential method of improving upon current transdifferentiation protocols. 
  





Therefore, the core research aims were as follows: 
1. To develop and characterise a system for fabricating phase inversion PS 
membranes suitable for HFB cell culture using a flat sheet membrane model. 
 
2. To improve upon the phenotype of transdifferentiated HLCs by characterising and 
comparing the HepatoZYME+ and “50:50” culture media against established Dex-
based transdifferentiation protocols. 
 
3. To characterise and compare the biocompatibility of the developed phase inversion 
polystyrene membranes with established biomaterials and investigate the utility of 
transdifferentiating pancreatic cells to HLCs on the developed biomaterial. 
Chapter 4 investigated the development of PS flat sheet membranes. Using a PS-NMP 
polymer-solvent casting dope, it was found that ternary systems utilising either deionised 
water or 70% (v/v) IMS as nonsolvents were able to cast PS flat sheet membranes, using 
the phase inversion immersion precipitation method. Both systems yielded asymmetrical 
membranes with a nonporous top skin layer over a highly porous substructure. This 
indicated that these ternary systems alone were unable to produce completely porous 
membranes. Oxygen plasma treatment was identified as a suitable method for increasing 
PS membrane hydrophilicity. Membranes treated with oxygen plasma were denoted as 
“PX”, to distinguish them from the more hydrophobic untreated PS membranes. 
Oxygen plasma treatment with the inductively coupled plasma chamber generated surface 
pores on 70% (v/v) IMS cast PS membranes only. This change in physical structure is in 
agreement with the literature where plasma treatment has been utilised to etch material 
surfaces. However, this observation was not replicated using the capacitively coupled 
plasma chamber, suggesting that further work may be required to optimise the oxygen 
plasma treatment method for generating surface pores, such as varying plasma power and 
exposure time. Additional work into examining the mechanical effects of the plasma 
treatment method upon the membrane structure and also substrate stiffness would also aid 
further characterisation of the suitability of the biomaterial as a culture substrate, 
particularly as substrate stiffness is a factor affecting cultured cell behaviour. 





The research in Chapter 5 examined the utility of the culture media HepatoZYME+ and a 
diluted variant, “50:50”, to induce transdifferentiation of pancreatic B13 cells to HLCs and 
furthermore maintain the hepatic phenotype. The work here determined that overall, 
HepatoZYME+ based media was no improvement over Dex-based transdifferentiation 
media as both an induction and maintenance treatment due to loss of viability. The 50:50 
variant similarly showed overall culture deterioration but was able to show some induction 
of hepatic markers and a change in morphology to a HLC phenotype. Furthermore, 50:50 
maintained expression of hepatic markers in cells that had already been induced to 
transdifferentiate using Dex + OSM at both early and later stages. Importantly, loss of the 
pancreatic phenotype was maintained after changing from Dex + OSM to HepatoZYME+ 
based cultures. In addition, secretion of the hepatic protein albumin appeared to be 
increased beyond that of Dex + OSM treated cells upon changing the culture medium to 
50:50. Culture with 50:50 was observed to generate multinucleate cells, although the 
stability of these cells long term is questionable. Overall, the Dex + OSM treatment was 
determined to be the optimum transdifferentiation medium for stable induction, 
maintenance and viability. 
The biocompatibility of PX membranes developed using the PS-NMP-water ternary 
system and treated with oxygen plasma was assessed in Chapter 6. Treatment with 1% 
(v/v) antibiotic-antimycotic was found to be suitable for sterilising PX membranes. The 
pancreatic B13 and human osteosarcoma MG63 cell lines displayed improved attachment 
to PX membranes over untreated PS, confirming that the oxygen plasma surface treatment 
had generated a surface more conducive to cell culture. B13 cell attachment on PX was 
comparable to that of TCPS and greater than that of PLGA. MG63 cell attachment on PX 
was comparable to TCPS. After 48 hr culture cell viability was high for both cell lines on 
TCPS, PX and PLGA. 
The B13 cell line retained a pancreatic phenotype when maintained in complete B13 
culture medium upon PX membranes. When treated with the Dex + OSM 
transdifferentiation culture medium, the cells converted to HLCs on PX. These cells 
demonstrated the utility to secrete serum albumin, although this utility was reduced relative 
to TCPS. B13 cells induced to transdifferentiate on PLGA membranes showed greatly 
reduced serum albumin secretion function and overall cell attachment. Furthermore, PLGA 





appeared to show signs of plasticising and deformation under transdifferentiation culture 
conditions, a feature not observed in PX membranes. 
In conclusion, the PX membranes developed in this thesis were determined to be the 
preferential biomaterial for translation to HFB cell culture compared to PLGA and also 
displayed some comparability with TCPS. Furthermore, as transdifferentiated HLCs 
showed hepatic functionality on PX membranes, they have the potential to be utilised as a 
cell source for a BAL device utilising PX hollow fibre membranes. 
 
7.2 Future work 
7.2.1 Short term aims 
 
Generation of a porous polystyrene membrane surface 
This work has established PX membranes as scaffolds able to support cell culture. For 
translation of this work to a HFB setting, further optimisation of the membrane structure 
should be performed to create a porous surface layer, allowing for the mass transfer of 
nutrients from medium flowing intraluminally to the cells cultured on the fibre surface. 
The research in Chapter 4 noted the potential of oxygen plasma as an etching agent. 
However, this was not found to be a universal effect as it was only observed when using 
the inductively coupled plasma chamber with the PS-NMP-70% (v/v) IMS ternary system. 
Therefore, further optimisation of the plasma treatment method as a physical surface 
modifier may be performed by comparing the effects of different plasma generation 
methods, power and time exposure with regards to their effects upon membrane structure, 
surface chemistry and wettability. One approach would be to investigate additional 
plasmas to treat the membrane surface. Argon and nitrogen plasmas have been utilised to 
etch polymer surfaces as well as modify the surface wettability for cell culture 
[184,201,209]. Further work would be required to assess whether differences in surface 
chemistry from utilising different plasmas or a combination of plasmas will affect overall 
biocompatibility due to addition of different functional groups compared to oxygen plasma 
treatment, such as C=N. From a process point of view, a single method that can affect 
surface wettability, chemistry and morphology would be ideal. However, with this 





approach, finding a balance between wettability, biocompatibility and issues with 
overexposure causing bulk weakening of the overall membrane structure will require 
careful optimisation. 
Another potential method of increasing membrane surface porosity would be to treat PS 
membrane surfaces prior to plasma treatment with sodium hypochlorite (NaClO). This is 
often used as a disinfection agent in tissue culture as well as for the removal of adsorbed 
proteins from haemodialysis membranes [272]. It has previously been shown to increase 
porosity of pure and blended polyethersulfone membranes [273,274] as well as poly(vinyl 
alcohol)-PLGA blended membranes [275]. However, as these increases in porosity are 
reported as coinciding with a weakening of membrane mechanical structure, development 
of an appropriate concentration of NaClO will be required. Furthermore, careful attention 
should also be given to changes in surface chemistry from this treatment which may affect 
overall wettability and biocompatibility, as NaClO is an oxidising agent. 
The incorporation of a porogen as part of the membrane manufacture process is a further 
approach that is independent of altering polymer chemistry. Here, a porogen such as 
sodium chloride could be incorporated into the dope solution [276,277]. The dope is then 
cast in a nonsolvent bath as per the immersion precipitation method. As the membrane 
precipitates, the porogen dissolves and is subsequently leached out to generate pores [278]. 
The pore sizes and overall porosity can be controlled by the size of the salt crystals as well 
as the weight percentage of salt contained within the casting dope. Therefore, this is an 
economical approach that can potentially be tailored to specific cell requirements, as well 
as allowing tight control over the MWCO at the surface for separating specific products 
within the culture medium. Again, further characterisation of membrane tensile strength, 
substrate stiffness and structure will be required to ensure that such an additive does not 
lead to a weak and unsuitable hollow fibre membrane structure. 
 
Improvement of the hepatic phenotype in transdifferentiated hepatocyte-like 
cells 
Although HepatoZYME+ was deemed an unsuitable culture medium for the 
transdifferentiation of B13 cells to HLCs, further work to confirm that the basal medium 





HepatoZYME-SFM as the causative agent could be performed by reducing the dilution of 
the basal medium in comparison with viability studies. If possible, quantitative ELISAs to 
examine hepatic function would also be useful in determining whether HepatoZYME-SFM 
in more dilute, nontoxic concentrations can benefit conversion to the hepatic phenotype. 
This can be combined with gene expression data to assess upregulation of hepatic genes. 
Another approach to transdifferentiating B13 cells to HLCs in serum-free medium would 
be to characterise its proliferation and transdifferentiation using Panserin 401 as a basal 
medium. Panserin 401 has previously shown to be successful in culturing the parent line 
AR42J, which encouraged increased zymogen formation under treatment with Dex, 
indicating a push towards a more exocrine phenotype [279]. Culture with the B13 subclone 
has yet to be characterised in the literature, and characterisation could be done using the 
methods already utilised in this thesis, such as immunofluorescent staining for protein 
expression. This could be further complemented with Western blotting. In addition, 
functional quantification of pancreatic and hepatic markers and gene expression through 
PCR would provide a comprehensive profile. Certainly, given the increased cell death 
observed in the HepatoZYME+ culture, further viability studies would also complement 
this work. 
 
Biocompatibility of surface treated polystyrene membranes with different cell 
types 
The flat sheet membrane model as developed could be utilised for further biocompatibility 
studies. As the research in Chapter 6 has shown that the adherent B13 and MG63 cell 
lines can be supported on the PX biomaterial, examining a range of other cell lines would 
expand their scope at being able to be translated to a HFB culture setting with this 
biomaterial. This is an attractive prospect due to the increased expansion capability of this 
culture method compared to traditional flask culture methods. Furthermore, assessment of 
other hepatocyte functions of transdifferentiated HLCs cultured on PX membranes, such as 
xenobiotic responsiveness, could be compared to other hepatocyte-like cell lines such as 
HepG2, C3A, HepaRG, and also primary hepatocytes. As the B13 cell line can also 
convert into insulin producing β-cells [217] and ductal cells [222], this utility on PX 
membranes could also be assessed. 





7.2.2 Long term aims 
 
Development and characterisation of porous polystyrene hollow fibre 
membranes 
As a flat sheet membrane model for fabricating PX membranes has been developed, this 
needs to be translated to a HFB system. Therefore, the initial long term aim would be to 
determine if the parameters for casting established in the flat sheet membrane model can be 
utilised for casting hollow fibre membranes. Furthermore, once an efficient method for 
generating fully porous membranes has been established, further characterisation of the 
hollow fibre membrane will be required with regards to the bioreactor design. 
Investigations such as water and gas permeability of the membrane will be important in 
determining how porous the membrane walls are with regards to optimisation of medium 
flow rate and nutrient diffusion across the membrane wall. 
 
Transdifferentiation of pancreatic cells to hepatocyte-like cells in a polystyrene 
hollow fibre bioreactor system 
Once PX hollow fibre membranes have been established, it will be necessary to establish 
whether B13 cell culture and transdifferentiation to HLCs can be translated from a 2D 
static system to the 3D flow configuration of the HFB. Initially, a suitable seeding density 
and method of seeding will need to be established, as an issue with static seeding upon 
hollow fibres is non-uniform distribution across the membrane and reduced attachment, 
thus requiring the use of rotational seeding or oscillating perfusion methods to gain better 
uniformity and attachment [280,281]. Furthermore, as too low or too high a density can 
influence the transdifferentiation efficacy and overall culture viability, characterisation of 
attachment, viability, proliferative capacity and transdifferentiation utility will be essential 
for determining the correct operating methods for this cell line. Comparison with other 
hepatocyte-like cell lines and also primary hepatocytes will be necessary to establish the 
quality of transdifferentiated HLCs in a BAL device setting. Responsiveness to xenobiotics 
and subsequent analysis of cytochrome P450 activity would be useful in use of this system 





as an in vitro drug toxicity model. As the B13 cell line is a rat pancreatic line, further work 
utilising a human pancreatic cell source would be more clinically relevant [134,135]. 
 
Determination of operating conditions for polystyrene hollow fibre bioreactor 
cell culture utilising different cell types 
As there is the possibility of expanding the scope of this biomaterial to different tissue 
types for large scale cell expansion, such as the use of MG63 cells to generate HGF and the 
differentiation of stem cells down different lineages for cell therapies [150,172,282–285], 
determination of ideal operating conditions for specific cell types is important for 
bioreactor design optimisation. In the case of the BAL device, this is necessary to ensure 
that the environment mimics normal physiological conditions as closely as possible. 
Mathematical models will be useful in tailoring the system to a specific cell type [164]. In 
particular, as some hepatic functionality within hepatocytes is zonated depending on 
oxygen and nutrient gradients down the porto-venous axis, replicating this as closely as 
possible will further optimise BAL device design to provide a more in vivo like response 
[53,83]. 
To conclude, the overarching goal of this thesis was to develop a novel biomaterial and 
utilise a novel cell source for BAL device design, based upon a HFB system, using tissue 
engineering techniques. This research has elucidated the development of a biocompatible 
phase inversion membrane (PX) that can support functional transdifferentiated HLCs and 
has potentially expanded the scope of the design to support different cell types for large 
scale expansion. The ultimate long term aim would now be to develop an optimised BAL 
device design in an in vivo setting utilising the developments contributed by the research in 
this thesis. 
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